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Introduction
Intellectual disability (ID) is present in 2-3 percent of the population and 
patients with ID show a significantly higher use of health care facilities compared 
to the general population1. The causes of intellectual disability are wide ranging 
and include genetic and environmental factors. ID can be caused by a myriad 
of factors including prenatal infections, prenatal uses of medicine and alcohol, 
brain malformation, monogenetic mutations in ID genes, chromosomal 
abnormalities and metabolic diseases. However, for 30-50% of diagnosed ID 
patients, the cause remains unknown1-3. 
The Ubiquitin proteasome pathway
Before the Ubiquitin proteasome pathway (UPP) was identified, proteins 
where thought to solely undergo lysosomal degradation. Research in the late 
1970’s showed that reticulocytes lacking lysosomes had ATP dependent protein 
degradation, suggesting a second kind of degradation system in place4-8. Shortly 
there after, Ciechanover and colleagues described a heat stable polypeptide 
(APF-1), and Goldstein and colleagues described a ubiquitin peptide (first named 
UBIP; ubiquitous immunopoietic polypeptide) linked to proteins that were later 
degraded9-12. APF-1 and ubiquitin where later identified to be the same protein6,13. 
The discovery of the UPP resulted in a shared Nobel prize for chemistry awarded 
to Aaron Ciechanover, Avram Hershko and Irwin Rose in 2004.
The Ubiquitin proteasome pathway functions in a two-step process. First 
the identification and tagging of proteins destined for degradation. Second, 
degradation of the protein by the 26S proteasome. Identification and tagging 
of proteins involves the addition of ubiquitin moieties which is a conserved 
76-residue long peptide that can be linked to a protein by the formation of a 
bond between the C- terminal glycine of ubiquitin and a lysine on the substrate 
protein5-9,14. The ubiquitination of a protein is a three-step process initiated with 
the E1 ubiquitin-activating enzyme forming a thiol ester bond with the carboxyl 
group of glycine at amino acid 76 of ubiquitin (G76), activating the ubiquitin 
C-terminus; this process requires ATP9,13. In the second step a trans-esterification 
reaction transfers the activated ubiquitin to the E2 conjugating enzyme on a 
cysteine residue in the active site of the E28,15. The E2 enzymes determine the 
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length and shape of the poly-ubiquitin chain and can thereby influence the fate 
of the ubiquitinated proteins14,16. Finally the E2 enzyme ubiquitin complex than 
transfers the activated ubiquitin to an E3 ligase-substrate complex9,17 (Figure 1). 
Figure 1: Schematic overview of ubiquitination. An ubiquitin activating enzyme (E1) activates an 
ubiquitin. The activated ubiquitin is than transferred to the ubiquitin conjugating protein (E2). 
Subsequently the activated ubiquitin is transferred to an E3 ligase-subunit complex, either directly from 
the E2 to the substrate (RING ligase) or indirectly via the E3 ligase (HECT). After the substrate is 
sufficiently ubiquitinated the protein is degraded by the 26S proteasome.  (Figure adapted from http://
www.bikaken.or.jp) 
There are three types of E3 protein ligases, classified on the presence of a 
HECT domain (Homologous to E6AP Carboxyl-Terminus), RING domain (Really 
Interesting New Gene) or Ring-in-between-Ring (RBR) domain. The RING 
ligases form multim eric complexes for its functioning, binding both the E2 and 
the target protein and catalyzing the direct transfer of the ubiquitin from the E2 
to the target protein15,18; The HECT ligases, on the other hand, accept the ubiquitin 
from the E2 conjugating enzymes and form an E3 thio-ester intermediate with 
the ubiquitin moiety prior to transferring the ubiquitin to the substrate16,19,20. 
Ring between ring ligases share features of both HECT and RING E3 ligases. 
Although there are two RING domains present and an in between ring domain 
(IBR), this E3 ligase was found to contain a catalytic cysine in the second RING 
that actually mediated ubiquiitnation in a HECT like manner21.
The fate of the ubiquitinated protein depends on the particular lysine 
involved in chain formation and the length of the chain. There are seven lysines 
on the ubiquitin where a second ubiquitin can bind. When substrate proteins 
have only a single ubiquitin group, this mono-ubiquitination is a signal for 
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endocytotic trafficking of plasma membrane proteins or initiation of DNA 
repair and may function as subsequent ubiquitin receptors in the endosome18,22. 
Lysine 63 (K63)-linked ubiquitin chains can actually make novel ubiquitin 
chains for signaling in DNA repair and control of endocytosis19,20,23.  There is 
a form of linear ubiquitination that activates nuclear-factor kB (NF-kB), an 
important transcription factor involved in immune responses21. Lysine 48 (K48) 
ubiquitination, however, is the most common modification and targets proteins 
for degradation22 (Figure 2). The high complexity of the ubiquitin chains and the 
possibility to build a ubiquitin chain on different lysine residues on the same 
protein can have many different consequences for different proteins23.
Figure 3: 3D representation of the 26S proteasome. On the left side the inner 20S core with the alpha en 
beta subunits. On the right side the two 19S regulatory subunits with the 20S subunit in the middle. 
(Figure adapted from Adams 200411)
The second step in the UPP is the degradation of the proteins by the 26S 
proteasome into peptides varying in size between 3 and 23 amino acids. The 
ubiquitinated proteins are transported to the proteasome by shuttle proteins24,25. 
The proteasome itself has two major units, the 20S core and two 19S regulatory 
domains on either end of the inner 20S cylinder, resembling two lids. The 19S 
unit recognizes the poly-ubiquitinated proteins and propels them towards the 
20S core in a ATP-dependent mechanism26. Degradation takes place in the 
inner rings of the 20S proteasome after removal of the ubiquitin peptides by 
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de-ubiquitinating enzymes (DUBs) and unfolding of the protein15. The 20S part 
consists of two outer rings and two inner rings; the outer rings contain 7 alpha 
subunits and the inner ring 7 beta subunits. The catalytic activity results from 
the activation of 3 of the 7 beta subunits (1,2 and 5). The inner core is very small, 
enabling the unfolded proteins to pass through27,28 (Figure 3). 
Figure 3: 3D representation of the 26S proteasome. On the left side the inner 20S core with the alpha en 
beta subunits. On the right side the two 19S regulatory subunits with the 20S subunit in the middle. 
(Figure adapted from Adams 200411)
In general the ubiquitin proteasome pathway (UPP) controls itself by 
specifically regulating the ubiquitination through the E3 ligases and the E2 
ligases. General up-regulation of the whole UPP pathway is seen in muscle 
wasting as discussed later in this introduction and in cases of extreme tissue 
breakdown as is encountered during larval metamorphosis29. 
There are a lot of specific regulation mechanisms in the UPP. For example 
some E3 ligases specialize in recognizing phosphorylated proteins30-34, 
destabilized residues of proteins or very specific sequences that are not always 
exposed35,36. Some E3 ligases bind only in trans when the target proteins need to 
bind first to ancillary proteins (like E6 mediated breakdown of p53 as described 
later). Another form of UPP regulation is seen in modification by ubiquitin-like 
proteins. These ubiquitin-like proteins conjugate to a protein in a ubiquitin like 
manner, locally changing the topography of a protein. Hereby these ubiquitin-
like proteins can mask or open the binding sites of E3 ligases (review see 
Glickman et all 2002)37.
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UPP in synaptic plasticity, learning and memory
That ubiquitination plays a role in neurodegenerative disorders like Alzheimer 
was already discovered in the late 1980s38-40. However, it took almost a decade 
before the first description of the physiological role of the UPP was described 
in the nervous system. The first description of the involvement of the UPP was 
of degradation of a subunit of cAMP-dependent Protein Kinase A (PKA) in Long 
Term Facilitation (LTF) in Aplysia41-43. Over the years the exact mechanism how 
the UPP controls synaptic plasticity remains unclear. One theory proposed by 
Dong et al (2008) suggests a potential mechanism starting with the protein 
Activating Transcription Factor 4 (ATF4) a known cAMP Response Element-
Binding protein (CREB) inhibitor, which was shown to be degraded upon 
chemically induced Long Term Potentation (LTP). This in turn promotes CREB 
activity and results in the expression of Brain Derived Neurotrophic Factor 
(BDNF) involved in the expression of LTP44. Further evidence proving that UPP-
mediated protein degradation is necessary for learning was shown by Banerjee 
et al (2009). They showed that the MOV10 (Moloney Leukemia Virus 10) helicase 
which is part of the RNA Induced Silencing Complex (RISC), is rapidly degraded 
when NMDA receptors are activated. Due to this degradation, a set of mRNA’s 
selectively enters the polysome compartment (e.g. CaMK2A; alpha-Calcium/
Calmodulin-dependent protein Kinase 2 and Limk1; Lysophospholipase 1). This 
takes place in dendrites, making MOV10 a potential pivotal control element in 
regulating local protein synthesis in dendrites45. Additionally Ehlers et al (2003) 
showed that the Post Synaptic Density (PSD) is altered upon synaptic activity, 
which is accompanied by altered protein turnover. This was proven to take 
place through proteasome mediated degradation, thus showing a direct link 
between protein turnover and the organization of synapses46. It was later shown 
that ubiquitination and degradation of PSD-associated proteins occurs during 
several learning paradigms 47. 
The UPP system is also involved in Long-Term Depression (LTD)48. LTD can 
be NMDA-dependent or mGLuR-dependent. For NMDA-dependent LTD, Post-
Synaptic Density protein 95 (PSD-95) is of major importance at the postsynaptic 
density where it tethers AMPA- and NMDA- glutamate receptors to signaling 
proteins and to the cytoskeleton. PD95 is recognized by the E3 ligase Mdm2. 
When the NMDA receptor is activated by an LTD-inducing stimulus, PSD-95 
is degraded. Preventing ubiquitination or inhibiting the proteasome prevents 
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NMDA-receptor induced AMPA internalization, suggesting that the UPP is 
involved in regulating AMPA receptor surface expression upon LTD induction49. 
Whether mGluR-dependent LTD also depends on the UPP is not clear: some 
studies claim to see reduction when inhibiting the proteasome while others 
claim to see an enhancement 49,50. 
Finally, the proteasome itself is effectively recruited to the synapse in 
response to synaptic activity where it can remodel the synapses51.  This could be 
mediated through NAC1, a proteasome-associated protein, because NAC1 knock 
out (KO) mice do not show activity dependent translocation. Alternately this 
could be through translocation of CaMK2A to the PSD52, since a Camk2a mutant, 
which cannot translocate to the PSD, results in less proteasome targeting in 
the PSD53. The increased activation of the proteasome upon NMDA receptor 
activation is thought to be dependent on CaMK2A that directly phosphorylates 
RPT6, a subunit of the before mentioned 19S complex of the 26S proteasome53.
Infusion with the proteasome inhibitor lactacystin of CA1 hippocampal region 
in rats causes retrograde amnesia of inhibitory avoidance learning54. This may be 
ascribed to increased ubiquitination and 26S proteasome proteolytic activity in 
hippocampus 4 hours after training54. Proteasome inhibitor administration also 
increased cell surface expression of the GluR1 subunit of the AMPA receptor, and 
augmented fear memory as measured by freezing after tone shock conditioning55. 
Fear extinction learning is also affected by proteasomal inhibition56. Moreover, 
infusion of proteasome inhibitor right after memory retrieval in CA1 region 
disrupts anisomysin-induced memory loss, suggesting that UPP underlies the 
destabilization process after fear memory retrieval47. Finally, blocking the entire 
proteasome increases synapse number and strength57. All these results indicate 
that proteasome activity is needed for long-term memory consolidation and 
the maintenance of late LTP (needed to retain memory) the UPP inhibits the 
induction of L-LTP, but enhanced the maintenance, by preventing degradation 
of transcription repressors and by stabilizing translation suppressors involved 
in the late stage of translation in both dendrites and the cell body 44,58.
Further involvement of the UPP in learning and memory is demonstrated 
by the mouse mutant lacking a specific DUB (UCH-L3 ubiquitin C-terminal 
hydrolase L3), which has deficits in working memory. However hippocampal 
LTP is not affected in these mice59, indicating that de-ubiquitination is essential 
for working memory but this particular DUB not for LTP.  
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To conclude, it is clear that ubiquitination and protein degradation is 
important for synaptic plasticity to occur and for learning and memory. The 
effect of proteasome inhibition is extensive, encompassing processes like LTD, 
LTP L-LTP, but the precise mechanism remain largely unknown. Besides its 
role in synaptic plasticity, the UPP has also been associated with postsynaptic 
density and stability, synapse formation, ubiquitination of AMPA and NMDA as 
reviewed by Mabb et al 201060.
Dysfunction of the Ubiquitin proteasome pathway in disease
The UPP described above is well regulated. Therefore a disruption in 
this process can severely affect an individual. Two types of disruptions in the 
system are possible, the first being a gain of function mutation, resulting in 
accelerated degradation of proteins. The second is a loss of function mutation 
where the proteins accumulate and are not degraded. Given the essential role 
of the UPP system in the cell, it is likely that mutations that severely affect UPP 
function might not be compatible with life and therefore will never present as a 
disease.
Malignancies have been associated with deregulation in the ubiquitin 
proteasome pathway. It can be easily hypothesized that if growth factors 
(polypeptides that stimulate cell proliferation) are not properly degraded or 
tumor suppressor proteins are too heavily degraded that this could be the start of 
a malignancy61. This is shown for human papilloma virus (HPV) known to cause 
cervical cancer. HPV expresses early and late proteins in its life cycle designated 
by either E1,2, 4-7 and L1-2. The E3 ligase linked to Angelman syndrome (AS) was 
first identified as a protein associated with the E6 oncoprotein (E6-AP) of the 
HPV virus62,63. E6-AP promotes degradation of the p53 tumor suppressor in the 
presence of HPV, promoting tumor growth63. Also the tumor suppressor protein 
p27 undergoes increased degradation in breast-, colorectal- and prostate tumors. 
The level of p27 determines the prognosis of these cancers, with low levels of 
this tumor suppressor having a bad prognosis64. A third example is Von Hippel-
Lindau (VHL) disease which is characterized by a wide range of malignancies 
caused by germ line mutations in the VHL gene. These tumors show a high 
vascularization due to high expression of Hypoxia inducible factor 1-α (HIF1- α) 
and vascular endothelial growth factor (VEGF). Much like the role E6AP plays in 
HPV induced cervical cancer, dysfunction of the E3 ligase VHL and promotes the 
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growth and the vascularization of the tumors65,66. Many more malignancies have 
been associated with the UPP but that is beyond the scope of this thesis. 
Besides malignancies, mutations in UPP genes can cause several other 
disorders like Liddle’s syndrome, a form of hereditary hypertension caused 
by deregulation of the endothelial Na+ channel (eNaC). The eNaC channel is 
normally short lived and targeted for degradation by NEDD4 (Neural precursor 
cell Expressed Developmentally Down-regulated protein 4) an E3 HECT ubiquitin 
ligase. The mutations that cause Liddle’s syndrome disrupt the E3 recognition of 
the eNaC thereby stabilizing the Na+ channel67. Another disruption of the UPP is 
seen in severe muscle wasting as a result of long immobilization, denervation 
and severe metabolic stress, which activates the ubiquitin proteasome pathway 
resulting in muscle degradation. Research into proteasome inhibitors might be 
of great benefit to reduce muscle wasting68,69. 
Neurodegenerative disorders have been associated with the UPP as well. 
In Alzheimer disease (AD), misregulation of the UPP probably results from 
accumulation of tau aggregates. These tau aggregates in AD patients are 
immuno-reactive to ubiquitin antibodies. In relation to this, there is decreased 
hydrolyzing activity of the proteasome70-72.  Parkinson disease (PD) and Lewy 
body dementia, both known for Lewy body inclusions containing a-synuclein 
(which is mutated in very rare forms of familiar PD), are ubiquitin-positive like 
the tau aggregates in AD73. Indeed a-Synuclein protein has been shown to be 
targeted by the UPP74. Additionally Parkin, a well-known gene causing a familiar 
form of PD is an E3 ligase. Surprisingly however this form of PD develops 
without the presentation of the Lewy body inclusions75. Mutations in Parkin 
result in loss of ubiquitation function76. Other rare mutations causing familiar 
PD are located in UCH isozyme UCH-L1, a de-ubiquitinating enzyme, again 
demonstrating the importance of the UPP regulation in Parkinson77. Huntington 
disease (HD) shows nuclear inclusions also reactive to ubiquitin much like the 
tau aggregates in AD and the Lewy body inclusions in PD. Like Huntington, 
both spinocereberal ataxia and spinobulbar muscular atrophy (Kennedey’s 
disease) are caused by expansions of polyglutamine tracts by different proteins: 
Huntingtin in HD; ataxins in spinocerebral ataxia and the androgen receptor in 
Kennedys disease78-80. All of these proteins have been shown to be ubiquitinated, 
although it remains unclear if al these inclusions seen in these diseases are toxic 
or just a secondary reaction of the body in response to proteins that cannot 
be eliminated81-83. Finally Amyloid lateral sclerosis (ALS) shows ubiquitin-
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immunoreactive intra-neural inclusions like the AD, PD and HD inclusions but 
in a different area84-86. These inclusions correspond with the progression of the 
disease, displaying clearly that ubiquitination and the lack of degradation by the 
proteasome of mayor importance87.
Neurodevelopmental disorders of the central nervous system associated 
with the UPP are rare and the focus of this thesis. Autism spectrum disorders 
show a number of candidate genes in the ubiquitin proteasome pathway like 
PARK, UBE3A, RFWD2 and FBXO4088,89. Kaufman syndrome was first described 
in 1971, subsequently many descriptions of patients with the same features 
followed90-93. Kaufman oculocerebrofacial syndrome (KOS) is characterized by 
reduced growth, hypotonia, facial dismorphia, microcephaly, ocular anomalies 
and intellectual disability90-95. In 2013 the syndrome was linked to los of function 
of UBE3B protein95. Very little is known about the precise function of this 
particular E3 ligase92,94. Additional developmental disorders caused by the UPP 
are discussed in more detail below.
UBE2A/HR6A
The prevalence of mental retardation is significantly higher in males where 
16% of male mental retardation is X-Linked Intellectual Disability. This is thought 
to be due to the sensitivity of gene defects on the X chromosome because of the 
lack of an alternate allele in males96,97. One example is HR6A/UBE2A, located on 
the X chromosome, encoding an E2 ubiquitin conjugating enzyme14. Males with 
a deletion or mutation in this gene suffer from a X-Linked Intellectual Disability 
disorder known as UBE2A deficiency syndrome. UBE2A deficiency syndrome is 
characterized by psychomotor retardation, severely impaired speech, synophrys, 
urogenital-, skin abnormalities and mild to severe intellectual disability98-101. 
HR6A (Human homologue to RAD6A) is a homologue of the Saccharomyces 
cervisiae RAD6 gene sharing about 70% sequence homology. It is also highly 
homologous (95%) to HR6B (Human homologue to RAD6B)102. The Drosophila 
homologue Dhr6 closely resembles HR6A and HR6B proteins (85-87%). Based on 
the degree of divergence among the different RAD6 homologues, the duplication 
event of this gene must have occurred 200 x 106 years ago in the Jurassic era103. 
The first evidence of the importance of this gene comes from yeast studies. 
RAD6 yeast mutants are very sensitive to DNA damage and lack the ability to 
repair DNA damaged sites. They do not undergo meiosis or sporulation and 
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grow poorly102-104. These activities are all regulated by the E2 activity of the 
RAD6 protein. When mutating Cys-88 to Val, the RAD6 protein no longer has 
E2 activity, causing a defect in DNA repair and sporulation105. Adding either 
HR6A or HR6B rescues the DNA repair defect seen in yeast102. RAD6 in yeast can 
poly-ubiquitinate histones H2A and H2B in an E3 independent manner. This is 
mediated by the highly acidic 23-residue carboxyl tail domain which is required 
for sporulation but not for DNA repair. Human HR6 does not contain this acidic 
tail and therefore by adding human HR6 to mutant RAD6 yeast, it can rescue the 
DNA repair deficit but only a small portion of the sporulation ability106,107. Rad6 
protein binds to one of 6 RING finger E3 ligases: Ubr1, Ubr2, Ubr3, Rad18, Rad5 
and Bre1108. Ubr1 and 2 are involved in the N-end rule degradation of proteins 
(proteolytic degradation based on N-terminal residues of short lived proteins) 
109. Ubr3 regulates sensory pathways via APE1 protein (Apurinic/apyrimidinic 
Endonuclease 1)110. Rad18 ubiquitinates PCNA (Proliferating Cell Nuclear 
Antigen) and is responsible for error prone replication of trans lesion synthesis. 
Rad5 is responsible for DNA repair processes 111 and Bre1 is involved in histone 
mono-ubiquitination108,112.  In 2013, a seventh E3 ligase was identified that 
binds to UBE2A being Parkin. Parkin has been implied in the ubiquitination of 
mitochondrial proteins and mitophagy. Mitophagy deficits were also observed 
in Drosophila dRad6 mutants and in cells derived form patients with UBE2A 
deficiency syndrome. Notably, The Drosophila dRad6 mutants showed impaired 
neuronal vesicle trafficking, providing the first causal link between UBE2A and 
neuronal function. To sum up, Rad6 is involved in many cellular functions. The 
interaction of E2 and E3 ligases determines what proteins get ubiquitinated, 
in the case of Rad6 the functions of the E3 ligases it interacts with explain the 
deficits seen in the Rad6 mutants. 
The involvement of the RAD6 protein in yeast sporulation sparked 
extensive studies of the human HR6A/B proteins for their involvement in 
gametogenesis. This resulted in the development of a HR6B mutant mouse; 
the first mutant in the UPP113. This mutant showed male infertility. This was 
followed by the development of the HR6A mutant mouse displaying female 
infertility in homozygous state114. This can be explained by the presence of the 
HR6A gene located on the X chromosome and the involvement in oogenesis. In 
spermatogenesis the X chromosome is silenced while in oocytes one active X 
chromosome is present. HR6B was shown to be important for X chromosome 
inactivation maintenance in spermatocytes113.  
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The intellectual disability as seen in UBE2A deficiency syndrome suggests an 
important role for HR6A in brain function, However, the Hr6a mouse mutant 
has only been studied in relation to reproduction. The role of this protein in 
brain function is part of this thesis. 
UBE3A
In 1965 Dr. Harry Angelman (Figure 4A) described three children with similar 
features naming them Happy puppet children, after an oil painting (a boy with 
a puppet by the renaissance artist Giovanni Francesco Caroto) he saw on a 
vacation in Italy115 (Figure 4B). The initial diagnosis was purely clinical. Over the 
years many more patients were described to have the Angelman (puppet like) 
syndrome116-122. Changing the name to Angelman syndrome was first suggested 
in 1982 by Charles Williams and Jaime L. Frias to avoid offending the family 
members117. Angelman syndrome is characterized by severe developmental delay, 
absence of speech, epilepsy, movement and balance deficits and inappropriate 
laughter123. The first clue to the underlying genetic defect came in 1987 when two 
articles described deletions on chromosome 15 that were not associated with 
Prader-Willi syndrome 124,125. Prader-Willi syndrome is characterized by failure 
to thrive in infancy and in a later stage by excessive eating and weight gain and 
developmental delay. Subsequent investigations showed that chromosome 15 is 
subjected to parent-of origin imprinting, paternal deletions leading to Prader-
Willi syndrome and maternal deletions causing Angelman syndrome126,127. These 
syndromes where descripted as sister syndromes128. 
Figure 4: A. Dr. Harry Angelman, B. A boy with a puppet by Giovanni Francesco Caroto
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Angelman syndrome has a birth incidence rate of 1:25.000129 and results 
from maternal de novo gene deletions (70%); a point mutation in the UBE3A 
gene (10%); imprinting defects (5%); UPD (UniParental Disomy) (5%). In 10% of 
the cases no mutation is found in the UBE3A gene130. The chromosomal region 
associated with Angelman syndrome is highly imprinted, where some genes are 
only expressed from the paternal allele and some only from the maternal allele 
as reviewed by Horsthemke et al 2008127 (Figure 5). A single large transcript that 
includes SNRPN and snoRNA’s is expressed from the paternal allele. This large 
transcript is an antisense transcript (UBE3A-ATS) of the UBE3A gene effectively 
silencing UBE3A131,132. Recent data shows that the UBE3A paternal allele is silenced 
in all mature neurons in all brain areas but remains bi-allelically expressed in 
astrocytes, mature myelinating oligodendrocytes and immature neurons in 
the postnatal stem cell niches although at very low levels133-135. This differential 
silencing is not due to different imprinting in different cell types but due to 
alternative splicing of the UBE3A-ATS in different tissues. This is illustrated 
by the SNURF/SNRPN gene which shows an ubiquitous pattern of expression 
unlike the distal part of the UBE3A-ATS which is only brain specific132.
UBE3A, also known as E6-associated protein (E6-AP) is an E3 ubiquitin ligase 
37. The targets of UBE3A could be misregulated by lack of ubiquitination and be 
causative for AS. Over the years many putative targets have been described (table 
1). However, although many targets have been identified it becomes clear that a 
distinction should be made between ubiquitinated targets and proteins that are 
deregulated in AS mice, but are not directly ubiquitinated by UBE3A, as shown 
recently with the ARC protein136. An additional distinction is necessary between 
ubiquitinated targets that are degraded and that are not137. The complicated 
nature of interactions and the lack of replication of published findings is a mayor 
drawback in the progression in the field of research on Angelman syndrome. 
Confirmation of targets in in-vivo assays are necessary and even more important, 
investigation of these targets in the Ube3a maternal deficient mouse is essential. 
In 1997 the first mouse model for Angelman was developed based on the 
uniparental disomy (UPD) seen in the Angelman patients131,132. This UPD 
mouse model displayed growth retardation, mild ataxia, hyperactivity, EEG 
abnormalities and gross obesity. This first UPD mouse model was soon followed 
in 1998 by a mouse model with a Ube3a deletion on the maternal chromosome, 
showing motor dysfunction, spatial learning deficit, inducible seizures and 
long-term potentiation (LTP) deficit138. To gain more insight into expression 
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patterns of the maternal versus the paternal Ube3a, Miura et al (2001) developed 
a LacZ reporter mouse139. All these mouse models have been an invaluable tool for 
research on Angelman syndrome. 
Figure 5: Ideogram of chromosome 15, displaying imprinted genes. Maternally expressed genes displayed 
in red, paternally expressed genes in blue. The location of two breakpoints depicted by BP1-3, displaying 
type I and type II deletion.  (Figure adapted from Cox 2015)
Electrophysiological studies of Ube3a mice indicated that the LTP deficits 
result from mechanisms downstream of calcium influx. This was confirmed 
by the finding of a change in phosphorylation state of CaMK2A in the AS 
mice. CaMK2A showed diminished activity while the total CaMK2A levels 
were not different. The phosphorylation levels on the T286 site (activating 
phosphorylation site) and the TT305/6 site (the inhibitory phosphorylation site) 
were increased and the phosphatase activity of PP1 was reduced, resulting in 
increased inhibition of CaMK2A in AS mice140. A subsequent study showed that 
by introducing a mutation which prevents phosphorylation on the TT305/6 
site of CaMK2A (CaMK2A-T305V/T306A) the watermaze-, fear conditioning-, 
rotarod- and bodyweight phenotype, CaMK2A activity and LTP deficits seen in 
AS mice could be rescued141.
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Putative targets of UBE3A and association with E6
Name E6? Function Protein Interaction
AIBI - Steroid co-activator oncogene142 Ubiquitination
Annexin A1 - Phospholipid binding ect143 Degredation
ARC - Internalization of AMPA144 Degredation
Rho-GEF pbl - Regulates cytokines145 Regulation
ASPM - Centrosomal related protien146 Binding
A synuclein - Unknown/ interacts with phospholipids147 Degredation
Bak + Pro-apoptotic protein148 Degredation
Be6 + Transcriptional activation149 Binding 
BLK - Regulates cellular processes like cytoskeleton organization150 Ubiquitination
BMAL + Core clock transcription factor151 Ubiquitination
C/EBPα - Transcription factor involved adipocyte differentiation152 Ubiquitination
CG8209 - Proteasome related protein137 Ubiquitination
Disc + Large tumor suppressor153 Degradation
DLG4/PSD95 + Tumor suppression154 Degradation
E6AP - Protein degradation155 Ubiquitination
Ephexin 5 - Positive regulator of excitatory synapse development156 Ubiquitination
ESR1 - Activating expression of ARC136 Inhibition
Grim-19 + Tumor suppressor157 Ubiquitination/ 
Degradation
hADA3 + Transcriptional co-activator158 Inhibition
HERC2 - HECT E3 ligase159 Binding
HCV - Viral pathogenesis and hepatocarcinogenesis160 Ubiquitination/ 
Degradation
hDLG + Large tumor suppressor161 Binding
HHR23A - Cell cycle progression and DNA repair162 Ubiquitination
HIF1AN - Hypoxia induced factor 163 Binding
Hsp70 - Molecular chapperones164 Binding
hTERT + Catalytic rate limiting unit of telomerase 165 Indirect by 
ubiquitination 
of NFX-91
MAPK6 - Mitogen-activated protein163 Binding
MCM7 - DNA replication initiation166 Ubiquitination
NEURL4 - Neurolized E3 protein ligase163 Binding
P27 - Kinase inhibitor167 Ubiquitination
P53 + Tumor suppressor168 Degradation
Pbl/ECT2 - Neuronal outgrowth in post mitotic cells145 Ubiquitination
PML - Regulation growth inhibition, senescence ect169 Ubiquitination
PRDX1 Antioxidant enzyme170 Ubiquitination/ 
Degradation
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Putative targets of UBE3A and association with E6 Continued
Name E6? Function Protein Interaction
PTPN3 + Regulating tyrosine phosphorylation of growth factor171 Degradation
Rhoa - Small GTPase involved in prostate cancer172 Indirect 
regulation
Ring 1B - Ubiquitin ligase that modifies nucleosome histone H2A173 Ubiquitination/ 
Degradation
RPN 10 - Proteasome shuttling agent137 Ubiquitination/ 
Degradation
Rps10b - Ribosomal subunit137 Ubiquitination
Sacsin - Unknown function in the nervous system144 Binding
SCR1B + Tumor suppressor174 Ubiquitination/ 
Degradation
SHR - Steroid hormone receptor175 Coactivator
SOD1 - Protein is linked to familial amyotrophic lateral sclerosis176 Ubiquitination
TH1 - Unclear/assembly functional negative elongation factor177 Ubiquitination
TSC - Tumor suppressor178 Ubiquitination
UchL5 - Proteasome related protein137 Ubiquitination
Vartul + Tumor suppressor179 Ubiquitination
Table 1: Putative targets of UBE3A, their association with E6 oncoprotein, main function of the protein 
and the nature of the interaction.   
Scope of this thesis
The general goal of this thesis is to understand the role of UPP in two different 
neurodevelopmental disorders, in particular in the role of UBE3A causing 
Angelman syndrome. In chapter 2 we characterize a potential mouse model for 
UBE2A deficiency syndrome. In chapter 3 we make use of established and novel 
AS mouse models to elucidate the origin of the motor deficits seen in Angelman 
syndrome. In chapter 4 we investigate PML, a potential target of UBE3A ligase, 
and the role of PML in learning and memory, together with its contribution 
to the phenotypes seen in AS mice. Finally in chapter 5 we investigate to what 
extend the phenotypes of AS mice can be rescued by reactivating the Ube3a gene 
in a temporal manner. 
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Abstract
UBE2A deficiency syndrome (also known as X-linked intellectual disability 
type Nascimento) is an intellectual disability syndrome characterized by 
prominent dysmorphic features, impaired speech and often epilepsy. The 
syndrome is caused by Xq24 deletions encompassing the UBE2A (HR6A) gene 
or by intragenic UBE2A mutations. UBE2A encodes an E2 ubiquitinconjugating 
enzyme involved in DNA repair and female fertility. A recent study in Drosophila 
showed that dUBE2A binds to the E3 ligase Parkin, which is required for 
mitochondrial function and responsible for juvenile Parkinson’s disease. 
In addition, these studies showed impairments in synaptic transmission in 
dUBE2A mutant flies. However, a causal role of UBE2A in of cognitive deficits 
has not yet been established. Here, we show that Ube2a knockout mice have 
a major deficit in spatial learning tasks, whereas other tested phenotypes, 
including epilepsy and motor coordination, were normal. Results from 
electrophysiological measurements in the hippocampus showed no deficits 
in synaptic transmission nor in the ability to induce long-term synaptic 
potentiation. However, a small but significant deficit was observed in mGLUR-
dependent long-term depression, a pathway previously implied in several other 
mouse models for neurodevelopmental disorders. Our results indicate a causal 
role of UBE2A in learning and mGLUR-dependent long-term depression, and 
further indicate that the Ube2a knockout mouse is a good model to study the 
molecular mechanisms underlying UBE2A deficiency syndrome.
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Introduction
 The prevalence of intellectual disability is significantly higher in males 
compared with females, which is largely due to mutations on the X chromosome 
(1,2). Of all the males with intellectual disability, ~16% suffer from X-linked 
intellectual disability (1,2). Recently, the UBE2A gene was identified as a cause of 
X-linked intellectual disability type Nascimento, also known as UBE2A deficiency 
syndrome, which is caused by mutations in the E2 ubiquitin-conjugating 
enzyme UBE2A/HR6A gene (3). Patients with UBE2A deficiency syndrome are 
characterized by mild to severe intellectual disability, prominent dysmorphic 
features, impaired speech, malformations of urinary systems, skin abnormalities 
and often epilepsy (3–9). Currently, 29 patients with UBE2A deficiency syndrome 
have been identified, of which 17 patients carried intragenic UBE2A gene 
mutations and 12 patients carried larger deletions encompassing the UBE2A gene 
(3–9).
 The UBE2A gene was originally identified as the homolog of RAD6 (HR6A) 
gene, which plays an important role in DNA damage-induced mutagenesis, 
mismatch repair and gene silencing (10–12). The HR6A gene shares 95% homology 
with HR6B, which is also a RAD6 homolog. Both genes belong to the family of E2 
ubiquitin-conjugating enzymes, which is involved in the ubiquitin proteasome 
pathway (UPP) required for protein degradation (13). E1 enzymes are responsible 
for activation of ubiquitin, E2 conjugating enzymes bind the activated ubiquitin 
and E3 ligases bind the substrates and transfer the conjugated ubiquitin from the 
E2 enzyme to the substrate. With 600 known members, E3s are the most studied 
proteins, since they are responsible for substrate recognition. At least 38 E2 
genes are known, and only two E1 activating enzymes have been identified (14). 
Different E2–E3 pairs are known to have very diverse functions (15). Recently, 
one of the E3 ligases that bind to UBE2A has been identified as Parkin (16). 
Mutations in Parkin cause juvenile Parkinson, and Parkin has been implied in 
the ubiquitination of mitochondrial proteins and mitophagy (17,18). Mitophagy 
deficits were also observed in Drosophila dRad6 mutants and in cells derived 
from patients with UBE2A deficiency syndrome. Notably, the Drosophila dRad6 
mutants showed impaired neuronal vesicle trafficking, providing the first causal 
link between UBE2A and neuronal function (16). Taken together, these studies 
implied that loss of UBE2A results in mitochondrial dysfunction, which leads to 
reduced ATP levels, thereby causing the synaptic deficits in dRad6mutants.
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 Previously, a Ube2a−/y knockout mouse has been generated to study 
the role of this gene in reproduction, since research on the paralogue 
Ube2b,showed that Ube2b knockout mice have severe spermatogenic deficits 
(19). Surprisingly, Ube2a−/y males showed normal fertility, whereas Ube2a−/− 
females were infertile, suggesting sex-specific roles in reproduction for 
both homologs (20). However, the presence of neurological deficits in these 
mice has not been investigated. Here, we used the Ube2a−/y knockout mouse 
to establish a causal link between Ube2a mutations and learning disability, 
and investigated whether these mice suffered from changes in synaptic 
transmission and synaptic plasticity.
Results
Ube2a−/y mice have no overt motor performance deficit
 Patients with the E2 deficiency syndrome display motor delay (3–9). 
Moreover, UBE2A has been shown to form a functional E2/E3 ubiquitination 
pair with Parkin, involved in juvenile Parkinson (7). To investigate whether 
loss of UBE2A causes motor deficits in mice, we made use of Ube2a−/y mutants 
(20). Motor performance was assessed by training the mice on an accelerating 
rotarod. There was no performance difference between the mutants and wild-
type (WT) littermates [F(1,25) = 0.8, P= 0.4) displayed by a repeated measures 
ANOVA], and both groups significantly improved their rotarod performance 
over the 5 days of training (Fig. 1A). To increase the difficulty of the test, we 
tested the mice on the reverse rotarod at which they have to learn to walk 
backward. Again, all mice improved in their performance over the 5 days of 
training, and even though there was a trend toward decreased performance 
of the mutants, no significant effect of genotype was observed [F(1,25) = 2.3, 
P= 0.1 using a repeated measures ANOVA; Fig. 1B]. 
 Hypotonia is also a common feature of UBE2A deficiency syndrome 
patients (3,5,7,9). To test whether Ube2a−/y mutants have reduced muscle 
strength, we measured their grip strength. No significant differences were 
observed between the WT mice and the Ube2a−/y mice, neither in the front 
paws [t(1,25) = 1.4, P = 0.2] nor in all four paws [t(1,25) = 1.4, P = 0.2] (Fig. 1C).
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Figure 1: Ube2a−/y mice do not show overt motor deficits. (A) Rotarod performance of WT mice (black 
circles) andUbe2a−/y mice (white circles) over 5 days. Y-axis represents the latency time to fall off the 
rotating rod. (B) Performance on the reversal rotarod also showed no difference in motor performance 
between WT and Ube2a−/y mice. (C)Ube2a−/y mice (white bars) do not show any muscle strength differences 
compared with WT mice (black bars) in front paws nor in all four paws (WT n = 14 and Ube2a−/y n = 13 for 
all experiments shown in A–C). Error bars indicate SEM.
Ube2a−/y mice do not show epilepsy
 Approximately half of the E2 deficiency syndrome patients have seizures. 
There is no clear relation between having an intragenetic mutation or a large 
deletion, with regard to possibility of developing epilepsy; even patients 
with the same mutation show difference in prevalence of epilepsy (3–9). 
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Spontaneous seizures where not observed in Ube2a−/y mice; therefore, we 
tested whether we could induce auditory evoked seizures in these mice, as 
mouse models for human seizure disorders often have a reduced seizure 
threshold in this assay (21–23). However, the Ube2a−/ymice (29 mice tested) 
showed no induced seizures, indicating that the loss of Ube2a is not sufficient 
for epileptogenesis in mice.
No social behavioral deficits in Ube2a−/y mice
Patients with UBE2A deficiency syndrome show behavioral abnormalities 
(not further specified), which might indicate social dysfunction (3–9). Moreover, 
autism spectrum disorder is a common comorbidity of syndromes associated 
with severe intellectual disability such as Fragile X, Rett and tuberous sclerosis 
complex (TSC) syndrome. Therefore, we tested social behavior in the Ube2a−/y 
mice. Nest building is a natural response behavior displayed by mice for heat 
preservation, reproduction and shelter and deficient in mouse models of Fragile 
X, Rett and TSC (23–25). Deficits in nest building were shown to be associated 
with a variety of brain areas and mainly seen as social dysfunction if the mice 
are unable to build a nest (26). Both WT mice and Ube2a−/y mice displayed 
a significant increase in nest size F(6,23) = 71.2, P < 0.001 (Fig. 2A), and no 
differences between genotypes were observed F(1,23) = 1.3, P = 0.3. Similarly, 
Ube2a−/y mice also showed no deficits in the Marble burying test, a test that has 
been used to assess autism-like repetitive movement phenotypes in mice such 
as Angelman syndrome and Fragile X syndrome (27–31) [t(1,25) = 0.6, P = 0.6; Fig. 
2B]. Taken together, these results indicate that loss of UBE2A does not result in 
phenotypes commonly seen in mouse models for associated with autism.
Ube2a−/y mice show impaired hippocampal learning
Intellectual disability is a common feature of all patients with UBE2A 
deficiency syndrome. To investigate if loss of UBE2A is sufficient to induce 
cognitive deficits in mice, we made use of the Morris water maze task, in which 
the animal has to learn the location of a hidden escape platform in a pool of opaque 
water (32). After 7 days of training, WT mice showed a significant reduction in
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Figure 2: Ube2a−/y mice do not show deficits in nest building and marble burying. (A) Nest-building task 
showed no difference in the ability to construct a nest between WT mice (black circles) and Ube2a−/y mice 
(white circles) over 7 days, and Y-axis represents weight of material left unused (WT n = 13 and Ube2a−/y 
mice n = 12). (B) Testing repetitive, autism-like behavior using the marble burying task showed no increase 
or decrease in buried marbles between WT mice (black bars) and Ube2a−/y mice (white bars) nor in the 
unburied marbles (WT n = 14 and Ube2a−/y n = 13). Error bars indicate SEM.
escape latency with no significant difference between the two genotypes F(1,25) 
= 0.28, P = 0.6 using a repeated measures ANOVA (Fig. 3A). To test whether the 
mice had learned the spatial location of the platform (hippocampus-dependent 
spatial learning) or just learned that the platform is at a fixed distance away 
from the rim (hippocampus-independent procedural learning), we removed the 
platform at a probe trial given at Day 8 (Fig. 3B). WT mice searched significantly 
more in the target quadrant when compared with the other quadrants t(1,25) = 
4.3, P < 0.05 (Fig. 3C) and showed significantly more crossings of the platform 
position compared with similar positions in the other quadrants t(1,25) = 4.9, P < 
0.001 (Fig. 3D), respectively. In contrast, Ube2a−/y mutants showed no preference 
for the target quadrant [t(1,25) = 0.9, P = 0.4] (Fig. 3C) nor did the mutants show 
an increased number of platform position crossings (Fig. 3D) compared with 
other positions [t(1,25) = 1.2, P = 0.2]. Swim speed in the probe trial was similar 
between the genotypes [t(1,25) = 1.1, P = 0.3) suggesting that the deficit was not 
caused by reduced ability to swim. To control for motivation and inability to 
perform the water maze test, we performed a visible water maze, in which the 
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location of the platform is marked. This test demonstrated again no differences 
between genotypes F(1,22) = 2.8, P = 0.1 (Fig. 3E). Taken together, these results 
suggest that the Ube2a−/ymutants are specifically impaired in the spatial learning 
component of the water maze test.
Figure 3: Water maze learning inUbe2a−/y mice is impaired. (A) Water maze training latencies to reach 
hidden platform over 7 training days are not different between WT mice (black circles) andUbe2a−/y mice 
(white circles). Y-axis indicates average time to reach hidden platform. (B) Heat-plot representation of all 
tracks combined of the probe trial at Day 8. The color represents time spent at a certain location (red is 
high and blue is low). (C) A probe trial at Day 8 shows a clear deficit in Ube2a−/y mice with respect to the 
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time spent searching in the target quadrant (black bar) compared with the average time in the other 
quadrants (white bar). (D) Quantification of the number of platform crosses at each of the four virtual 
platform positions also shows an impairment inUbe2a−/y mice (WT n = 14 and Ube2a−/y n = 13). (E) 
Training latencies in the visible water maze in which the platform is marked and moved every day to a 
new position. The time to reach visible platform over 6 training days is not different between WT mice 
(black circles) and Ube2a−/y mice (white circles). Y-axis represents average time to reach visible platform. 
Error bars indicate SEM, and asterisks indicate P < 0.05.
Hippocampus-dependent learning can also be tested using contextual fear 
conditioning, in which the animal has to associate a certain context (conditioned 
stimulus) with an aversive event (foot shock, unconditioned stimulus). There 
were no differences observed in baseline freezing [t(1,23) = 0.3, P = 0.8) before the 
0.75 mA shock was delivered. However, when context-dependent memory was 
tested 24 h after training, Ube2a−/y mice showed significantly less freezing than 
WT mice [t(1,23) = 2.6, P < 0.05). This deficit was still observed when the mice 
were tested again 7 days after training [t(1,23) = 3.7, P < 0.05) (Fig. 4A). This fear-
conditioning phenotype is not due to decreased sensitivity of the shock, inability 
to freeze or deficits in amygdala function, because when the shock was paired 
with a tone as conditioned stimulus, freezing was normal in Ube2a−/y mice 24 h 
after shock [t(1,23) = 1.0, P = 0.3] and during the long-term memory test [t(1,23) 
= 1.3, P = 0.20] (Fig. 4B). Taken together, these results suggest that the Ube2a−/y 
mutants are impaired in learning tests that depend on normal hippocampal 
function.
No long-term potentiation but a long-term depression 
deficit in Ube2a−/y mice
 A previous study showed that loss of the Drosophila Rad6 gene causes 
reduced ATP levels due to mitochondrial dysfunction, resulting in impaired 
vesicle release required for normal synaptic transmission. Given the large 
body of literature implicating the CA1 Schaffer–collateral pathway in spatial 
learning, we measured synaptic function and synaptic plasticity of this 
synapse by making use of extracellular field recordings in acute hippocampal 
slices. First, we investigated synaptic transmission in Ube2a−/y mice. Input–
output measures revealed no changes in synaptic transmission, since no 
differences were observed in the postsynaptic excitatory postsynaptic 
potentials (fEPSP) slope F(1,108) = 2.2, P = 0.1 nor in the presynaptic fiber 
volley amplitude F(1,108) = 2.3, P = 0.6 (Fig. 5A), nor in the ratio of these 
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two parameters. This suggests that there are no overt anatomical deficits 
in Ube2a−/y mice. To further investigate if there are changes in presynaptic 
vesicle release, we measured paired-pulse facilitation (PPF). However, also 
PPF did not indicate any anomalies in neurotransmitter release as mutant 
mice were not different from WT miceF(1,58) = 0.12, P = 0.73 (Fig. 5B).
Figure 4: Contextual fear-conditioning deficit in the absence of a cued fear-conditioning deficit in 
Ube2a−/y mice. (A) Freezing of the mice is shown at baseline (training before the shock) and during testing 
24 h or 7 days [long term memory (LTM)] after the shock.  Ube2a−/y mice (white bars) show significantly 
reduced freezing levels compared with WT (black bars). (B) Cued (tone) conditioning in which the mice 
learn to associate the tone (conditioned stimulus; CS) with the shock (unconditioned stimulus) showed 
no difference in freezing levels between WT and Ube2a−/y mice. Pre-CS indicates freezing before onset of 
the tone, whereas CS 24 h and CS LTM indicate the freezing levels during the tone, 24 h or 7 days after 
training, respectively. Error bars indicate SEM, and asterisks indicate P < 0.05.
 Synaptic plasticity, as measured by the ability to induce long-term 
potentiation (LTP), is thought to be the cellular correlate for learning 
and memory storage (33). This measure is both sensitive to changes in 
neurotransmitter release upon high-frequency firing, as well as postsynaptic 
changes. We measured the ability to induce LTP by using a high-frequency 
100 Hz/s stimulus protocol and a more physiological theta-burst stimulation 
protocol. Despite the profound deficits in spatial learning tasks, we observed 
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Figure 5: Ube2a−/y mice show reduced mGLUR-dependent LTD at the hippocampal CA3–CA1 synapse. (A) 
Synaptic transmission (WT n= 64, Ube2a−/y n = 46 slices) and (B) PPF (WT n = 27, Ube2a−/y n = 23 slices), a 
measure of presynaptic function, are unaffected inUbe2a−/y mice (white dots). (C) LTP induced by a 100 
Hz/1 s tetanus (WT n = 27, Ube2a−/y n = 23 slices) or by theta-burst stimulation (WT n = 18, Ube2a−/y n = 18 
slices) is not affected in Ube2a−/y mice. (E) mGLUR5-dependent LTD induced by DHPG application shows 
a mild but significant deficit in Ube2a−/y mice (WT n = 33, Ube2a−/y = 30). The dashed line shows baseline 
level before DHPG application. Error bars indicate SEM.
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no changes in the ability to induce LTP, as both 100 Hz LTP F(1.48) = 0.1, P = 
0.7 and two-theta LTP F(1,34) = 0.2, P= 0.6 were unaffected (Fig. 5C and D).
Many studies have shown that impairments in hippocampal long-term 
depression (LTD) while preserving LTP can also affect learning and memory 
formation (34,35). A particular form of LTD that depends on the Group I 
metabotropic glutamate receptors has gained considerable interest, since 
this form of plasticity is specifically impaired in a mouse model for Fragile X 
and believed to underlie the cognitive deficits in this mouse model (36–39). 
Recent studies have also implicated mGLUR signaling impairments in TSC, 
and convergence of the mTOR and FMRP signaling route (40–44). Moreover, 
mGLUR LTD deficits were recently observed in a mouse model for Angelman 
syndrome (45), suggesting that impairments in this pathway may be common 
to many neurodevelopmental disorders. Hippocampal slices from Ube2a−/y 
mice and their WT littermates were treated with Dihydroxyphenylglycine 
(DHPG) (50 μM, 5 min), a specific agonist of Group I mGluRs to induce 
LTD. As shown in Figure 5E, Ube2a−/y mice show a moderate but significant 
reduction in the ability to induce mGluR-dependent LTD F(1,61) = 5.7, P < 0.05.
Discussion
 UBE2A is an intellectual disability syndrome characterized by prominent 
dysmorphic features, impaired speech and half of the patients display epilepsy. 
In this study, we tested to what extend mice with mutations in the murine 
Ube2a gene paralleled the disorder and can serve as a model to investigate the 
underlying pathology.
UBE2A patients show motor delay (3–6), but we found no overt motor 
deficits in Ube2a−/y mice as assessed by rotarod learning and reversal rotarod 
learning, although it is notable that we consistently found a trend toward 
mild impairments. Since the patients suffer from motor delay rather than 
overt motor dysfunction, it could be that our adult mice have overcome such 
deficits. Hypotonia is a feature seen in around 38% patients (3,5–7,9), but 
no changes in muscle strength were observed in Ube2a−/ymice. Since only a 
quarter of the patients display hypotonia, it is possible that this phenotype is 
not directly related to the UBE2A mutation or that it requires modifier genes 
to become apparent.
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Likewise, penetrance of the epilepsy phenotype is ∼50% in the UBE2A patients, 
but there were neither spontaneous nor evoked audiogenic seizures observed 
in the Ube2a−/y mice. This result suggests that loss of UBE2A is not sufficient to 
develop epilepsy. Back-crossing the Ube2a−/ymice in the 129SVE background, 
which is more permissive to observe seizures (46,47), may potentially reveal 
an epileptic phenotype.
 Consistent with the intellectual disability observed in all UBE2A deficiency 
syndrome patients described so far, the Ube2a−/y mice display clear cognitive 
deficits as shown in the Morris water maze learning paradigm and the 
contextual fear-conditioning paradigm. The pronounced deficits in the 
Morris water maze probe trial, in the absence of a motor deficit or a deficit 
in the latency to find the platform, indicates the presence of a hippocampal 
deficit. This was confirmed with the fear-conditioning paradigm where the 
mice showed a clear context-conditioning deficit, in the absence of a cued-
conditioning deficit. Together with, the observation that intellectual disability 
is observed in all UBE2A deficiency syndrome patients so far implies an 
essential role of UBE2A in (hippocampus-dependent) learning.
In contrast to the Drosophila studies, we were unable to identify any deficits 
in presynaptic function, as measured by basal synaptic transmission and 
PPF. Moreover, mice showed no deficit in LTP induced by high-frequency 
stimulation, which is very sensitive to changes in neurotransmitter release 
upon high-frequency firing (48), arguing strongly against an essential role of 
mammalian UBE2A in vesicle release.
 Despite the absence of presynaptic deficits, we found mild changes in 
hippocampal synaptic plasticity, which is thought to be essential for normal 
learning. Plasticity deficits (LTP, LTD or both) of the Schafer collateral CA3–CA1 
pathway have been reported in most mouse models of intellectual disability 
disorders like TSC, NF1, Noonan, Rett syndrome, Angelman syndrome and 
Fragile X (46,49–51). However, the protocol needed to reveal such plasticity 
deficits varies widely and is likely reflecting the different signaling pathways 
underlying these plasticity induction protocols. Like the Fragile X mouse 
model, we found that the plasticity deficit in Ube2a−/y mice was specifically 
observed in the mGluR-dependent induction of LTD. However, unlike Fragile 
X mice (52), Ube2a−/y mice showed impaired LTD rather than enhanced LTD, 
similar to what has been found in Tsc1 mutant mice (40–44). Although the 
ubiquitination and the proteasome have previously been implied in mGluR-
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induced LTD, the precise role of this pathway in regulating this form of 
plasticity remains to be elucidated (45,53–55).
 Taken together, our results imply an essential role for UBE2A in hippocampal 
learning and synaptic plasticity, and provide an attractive mouse model to 
study the role of UBE2A and the role of protein ubiquitination in learning and 
memory.
Material and Methods
Subjects
Ube2a−/y male knockout mice (Ube2a−/y) were generated as described by Roest 
et al. (20). Mice were genotyped at 7–10 days, but the experimenter remained 
blind for the genotype during data collection and analysis. Genotypes were 
confirmed after all experiments were finalized, and the code was then broken 
to perform the final statistical analysis. Mice were housed in groups of 2–4 
mice per home cage. Genotype groups were age matched. The mice were kept 
on a 12 h light/dark cycle, with food and water available ad libitum. Behavioral 
experiments were performed during the light period of the cycle. All animal 
experiments were approved by the Dutch Ethical Committee and in accordance 
with Dutch animal care and use laws.
Rotarod
Motor coordination of 3–4 months old mutant and WT littermates was 
tested on an accelerating Rotarod (model 7650, Ugo Basile, Biological Research 
Apparatus, Varese, Italy). Mice were measured for 2 trials a day for 5 days with 
an inter-training interval of 1 h. The Rotarod has a cylinder with a diameter of 
3 cm that can accelerate from 4 to 40 rpm in 300 s. The latency to stay on the 
rotarod was recorded by determining the time taken for a mouse to drop off or 
stop running for three consecutive rotations. For the reverse rotarod, the same 
devise was used with added plastic dividers to prevent the mouse from turning 
around while walking backward.
Marble burying test
 Mice were placed in a clean plastic rat cage (Tecniplast 1290D Eurostandard 
Type 3). The cage contained a 5 cm thick layer of sawdust (Lignocel Hygienic 
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animal bedding), with 20 dark blue glass marbles (15 mm diameter). The 
marbles were placed equal distance apart in a grid-like pattern, and the 
animals were given 30 min to bury them. After 30 min, the number of buried 
marbles was assed (defined as two-thirds of the marble covered in bedding) 
by an observer blind to genotype.
Water maze
Prior to start of the water maze, mice were handled for 5 days. The water 
maze is a circular pool that measures 1.2 m in diameter with a circular platform 
submerged 1 cm bellow the water (26°C) surface. The light in the room was 
dimmed, and the water was made opaque using white paint. SMART version 
2.0 (Panlab, Barcelona, Spain) was used to track the mice. Mice received 2 trials 
a day with an inter-trial interval of 30 s. For each trial, the mice were placed on 
the platform for 30 s and then placed in the pool at pseudorandom positions and 
allowed to search for the platform for 60 s. If the mouse located the platform, 
it was allowed to stay on the platform for 30 s before the onset of a new trial. 
If the mouse was unable to locate the platform, the mouse was placed on the 
platform by the experimenter for 30 s. This training protocol was repeated for 7 
consecutive days. On Day 8, a probe trial was performed. The mouse was placed 
on the platform, and after 30 s, the platform was removed and the mouse was 
placed in the water on the opposite side in the bath. The mice were allowed to 
search for the platform for 60 s.
For the visible water maze test, we used the same paradigm as described for 
the training sessions in the hidden water maze; the only difference was that the 
platform was marked and the position of the platform changed with each trial.
Nest building
For measuring nest building, mice were single housed 1 week prior to onset 
of the experiment. Ten grams of nesting material was provided (thick blot paper 
biorad170–4085) at the start, and the untouched material was weighed every 24 
h for 7 days. This was used to calculate the amount of nest-building material 
utilized.
Grip strength
Using a force gauge (BIOSEB, Chaville, France) attached to a grid, grip strength 
was determined by placing the mice with their forepaws and subsequently all 
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four paws on the grid and steadily pulling the mice by the tail. The grip strength 
is defined as the maximum strength produced by a mouse before releasing the 
grid. An average of three trials was taken as an individual performance score for 
each mouse.
Seizures
 To assess seizure susceptibility, we tried to induce an audiogenic seizure 
by vigorously scraping scissors across the metal grating of a mouse cage lid 
(creating a high-pitched sound of the 95–105 DB) for 30 s or shorter if a seizure 
developed before that time.
Fear conditioning
 Fear conditioning was performed in a standard modular test chamber 
located in a standard medium-density fiberboard sound attenuating cubicle 
(Med Associates, Inc., Albans, VT). The box was equipped with a grid floor 
on which a 0.75 mA foot shock was delivered. For context conditioning, mice 
were placed inside the chamber for 180 s after which a foot shock of 2 s was 
administered after 148 s. After 24 h and after 7 days, the mice were placed 
back in the chamber and the freezing was measured for 3 min. Freezing was 
defined as cessation of all movement except for breathing, as quantified using 
the EthoVision automated video-based algorithm with detection parameters 
calibrated by independent manual scoring. After context conditioning in 
Context A, mice were trained again in a Context B, using a 10 kHz tone of 20 s 
co-terminating with a 2 s foot shock of 0.75 mA. Mice were tested in Context C 
for cue conditioning 24 h and 7 days later, when the tone was again presented 
to the mice.
Field recording
 Mice were anesthetized and decapitated. Sagittal slices (400 μm) 
were obtained and submerged in ice-cold artificial cerebrial spinal flued 
(ACSF) using a vibratome. The hippocampi were subsequently dissected 
out. The hippocampal slices were left to recover for at least 1.5 h at room 
temperature before experiments were initiated. After recovery, they were 
placed in a submerged recording chamber and perfused continuously with 
ACSF equilibrated with 95% O2, 5% CO2 at 31°C at a rate of 2 ml/min. ACSF 
consisted of (in mM) 120 NaCl, 3.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.25 NaH2PO4, 26 
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NaHCO3 and 10 D-glucose. Extracellular recordings of fEPSPs were made in 
CA1 stratum radiatum with platinum (Pt)/iridium (Ir) electrodes (Frederick 
Haer Company). A bipolar Pt/Ir was used to stimulate Schaffer collateral/
commissural afferents with a stimulus duration of 100 μs. Stimulus–response 
curves were obtained at the beginning of each experiment 30 min after placing 
the electrodes. LTP was evoked using the following two different tetani: (1) 
100 Hz (1 train of 1 s at 100 Hz) and (2) 4 theta (4 trains of 4 stimuli each at 100 
Hz, spaced by 200 ms). The 100 Hz protocol was performed at one-third of the 
maximum fEPSP and the 4 theta at two-thirds of the maximum fEPSP. LTD 
was induced after 20 min stable baseline recording with 100 μmol 3,5-DHPG 
(TOCRIS biosciences) applications for 5 min. LTD was measured at half of 
maximum fEPSP. During LTP and LTD experiment, slices were stimulated 
once per minute. Potentiation and de-potentiation were measured as the 
normalized increase or decrease in the mean fEPSP slope for the duration of 
the baseline. Only stable recordings were included, and judgment was made 
blind to genotype. Average LTP and LTD were defined as the mean last 10 min 
of the normalized fEPSP slope.
Statistical analysis
 We used SPSS software for statistical analysis. For rotarod, reversal 
rotarod, nest building and field recordings, a repeated measures ANOVA with 
genotype as between-subject factor and time as a within subject factor was 
used to asses differences. For all other tests, Student’s two-tailed t-test was 
used for group comparison on a single variable (e.g. grip strength, time spent 
in target quadrant, freezing and buried marbles).
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Abstract
Angelman syndrome (AS) is a severe neurological disorder that is associated 
with prominent movement and balance impairments that are widely considered 
to be due to defects of cerebellar origin. Here, using the cerebellar-specific 
vestibulo-ocular reflex (VOR) paradigm, we determined that cerebellar function 
is only mildly impaired in the Ube3am–/p+ mouse model of AS. VOR phase-reversal 
learning was singularly impaired in these animals and correlated with reduced 
tonic inhibition between Golgi cells and granule cells. Purkinje cell physiology, 
in contrast, was normal in AS mice as shown by synaptic plasticity and 
spontaneous firing properties that resembled those of controls. Accordingly, 
neither VOR phase-reversal learning nor locomotion was impaired following 
selective deletion of Ube3ain Purkinje cells. However, genetic normalization of 
αCaMKII inhibitory phosphorylation fully rescued locomotor deficits despite 
failing to improve cerebellar learning in AS mice, suggesting extracerebellar 
circuit involvement in locomotor learning. We confirmed this hypothesis 
through cerebellum-specific reinstatement of Ube3a, which ameliorated 
cerebellar learning deficits but did not rescue locomotor deficits. This double 
dissociation of locomotion and cerebellar phenotypes strongly suggests that 
the locomotor deficits of AS mice do not arise from impaired cerebellar cortex 
function. Our results provide important insights into the etiology of the motor 
deficits associated with AS.
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Introduction
Angelman syndrome (AS) is a neurological genetic imprinting disorder 
caused by mutations affecting the maternally inherited UBE3A gene, which 
encodes the E3A ubiquitin protein ligase (UBE3A or E6-AP). Individuals with 
AS suffer from severe developmental delay, cognitive deficits, epilepsy, and a 
lack of speech (1). Individuals with AS also experience problems with movement 
and balance, an important aspect of the diagnostic criteria described in the 
original description of the disorder (2). Even in the least severe cases, forward 
lurching, unsteadiness, jerky motions, and tremulous movement of limbs may 
manifest (1). The locus of these motor abnormalities is currently unknown, but 
it is possible that cerebellar dysfunction is a causal factor, given that ataxia and 
tremor are both common symptoms of cerebellar disorders. In support of this 
hypothesis, GABAA receptors have been shown to be reduced in the cerebellum of 
patients with AS and in postmortem AS material (3–5). Furthermore, movement 
studies in patients with AS showed abnormal electromyographic (EMG) 
rhythmic bursts when maintaining posture (6), which could be indicative of 
cerebellar dysfunction. However, there has yet to be a rigorous investigation of 
the putative cerebellar contributions to AS motor phenotypes.
Mice that maternally inherit Ube3a gene deletions (AS mice, referred to herein 
asUbe3am–/p+ mice) are a suitable model for studying the origin of motor deficits in 
AS, as they exhibit globally impaired motor coordination when performing tasks 
on the accelerating rotarod and balance beam and in bar cross and gait tests 
(7–12). AS mice exhibit deficits in cerebellar granule and Purkinje cell function 
that are suggestive of cerebellar dysfunction (13). However, similar to the human 
behavioral studies, none of these motor tests conducted with mice are specific 
for cerebellar dysfunction; genetic, anatomic, or pharmacologic lesions in other 
parts of the brain are known to also affect performance on these type of tasks 
(14). Moreover, UBE3A is not only highly expressed in the cerebellum, but also in 
other sensorimotor brain structures such as the cerebral cortex and striatum (7, 
8, 15–18). Hence, the observed motor deficits can just as easily arise from circuit 
dysfunction outside of the cerebellum as from within the cerebellum.
Here, we leveraged conditional Ube3a genetics and cerebellum-specific 
behavioral tasks to elucidate the extent to which cerebellar dysfunction is 
responsible for the motor deficits in AS. Despite normal Purkinje cell physiology 
in AS mice, we found mild cerebellar learning deficits that correlated with 
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reductions in tonic inhibition onto granule cells. However, cerebellar learning 
deficits proved to be clearly dissociable from locomotor deficits when we 
reinstated Ube3a expression specifically in the cerebellum or following genetic 
normalization of CaMKII signaling. We therefore conclude that locomotor 
deficits in AS are most likely not of cerebellar origin.
Results
The cerebellar cortex expresses high levels of UBE3A in Purkinje and Golgi 
cells.
Cell type–specific silencing of the paternal Ube3a allele dictates that UBE3A 
expression in neurons is solely provided by the maternal Ube3a allele (19–22). To 
determine whether cerebellar neurons are subject to similar imprinting rules, 
we performed Western blot analyses of UBE3A protein expression in cerebellar 
homogenates from WT and AS mice. Consistent with the expected effects of 
paternal Ube3a imprinting, UBE3A levels in AS cerebella were reduced to 6% ± 
5% of levels in WT controls (Figure 1A). To verify thatUBE3A is also imprinted 
in the human cerebellum, we extended our UBE3A Western analyses to samples 
obtained postmortem from individuals with AS and neurotypical controls. We 
found that UBE3A expression in the AS cerebellum was drastically reduced 
relative to that in controls, confirming that UBE3A expression in the human 
cerebellum is almost exclusively derived from the maternal allele (Figure 1A).
We next used immunohistochemistry (IHC) to spatially map maternal 
UBE3A protein expression within the cerebellum. Previous studies documented 
robust maternal UBE3A expression in Purkinje neurons (7, 8, 13, 15–18), which 
we also observed (Figure 1B). In addition, consistent with previous observations 
in maternal Ube3a-YFP reporter mice (17), we observed prominent UBE3A 
immunoreactivity in a subset of putative GABAergic interneurons within the 
granule cell layer of WT but not AS mice (Figure 1B). We subsequently confirmed 
their identity by colocalization with GlyT2-EGFP (Figure 1C), which specifically 
labels Golgi interneurons within the cerebellar granule cell layer (23). Hence, 
we conclude that maternal UBE3A expression in the adult cerebellar cortex is 
enriched in Purkinje and Golgi cells.
39681 Bruinsma.indd   56 28-03-16   20:30
Cerebellar function in Angelman syndrome
57
3
Figure 1: UBE3A is highly expressed in the cerebellum. (A) Western blot analysis revealed high UBE3A 
expression levels in the cerebellum of mice and humans. Cortical samples of the same protein 
concentration were used as a reference. UBE3A protein was greatly reduced in AS mice and in AS patients, 
indicating that UBE3A expression was almost exclusively derived from the maternal allele in cerebellar 
neurons. The Western blot shown is representative of samples run in duplicate. (B) UBE3A IHC in the 
cerebellum of WT mice revealed robust labeling of Purkinje cells (in the Purkinje cell layer [PCL]) and 
sparsely labeled cells within the molecular layer (ML). High expression levels were also observed in 
sparsely labeled cells in the granule cell layer (GCL) (white arrows), indicative of Golgi cell labeling. (C) 
UBE3A immunofluorescence (red, middle panel) colocalized with GlyT2-EGFP expression (green, top 
panel) in sparsely labeled cells in the granule cell layer, identifying them as Golgi cells. Each staining was 
performed using a minimum of 3 mice. Scale bars: 5 mm (B, top panels), 1 mm (B, bottom left panels), 0.05 
mm (B, bottom right panels, andC).
AS mice show only mild cerebellar learning deficits.
A large body of evidence has shown that cerebellar dysfunction commonly 
impairs the adaptation of compensatory eye movements (24–27). This adaptation 
is critically important to stabilize images on the retina and prevent retinal slip. 
The contribution of the visual and vestibular reflex pathways can be separately 
quantified by providing either visual stimulation (only the screen is rotating) to 
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trigger an optokinetic reflex (OKR) or vestibular stimulation (only the mouse is 
rotating) to elicit a vestibulo-ocular reflex (VOR) (for a visual explanation of 
these compensatory eye movement paradigms, see the cartoon in Figure 2 and 
ref. 28). To investigate whether AS mice showed abnormalities in gross cerebellar 
function, we first measured baseline OKR and VOR performance during 
sinusoidal visual or turntable stimulation. AS mice showed no deficits (OKR 
gain repeated-measures ANOVA F1,12 = 0.0,P = 1.0, phase F1,12 = 0.0, P = 0.9 and 
VOR gain F1,12 = 4.6, P = 0.05 and phase F1,12 = 4.1, P = 0.06) in the baseline 
amplitude (gain) or timing (phase) of either the optokinetic or vestibular reflex 
(Figure 2, A and B). In addition, we examined the visually enhanced VOR (VVOR), 
which uses a combination of visual and vestibular information to move the eye. 
Again, the response of the VVOR was unaffected (repeated-measures ANOVA 
F1,12 = 0.9,P = 0.6 gain and F1,12 = 0.0, P = 1.0 phase F1,12 = 0.0, P = 1.0) in AS mice 
(Figure 2C). These results indicate that cerebellar functions subserving basic eye 
movement performance are not altered by a lack of UBE3A protein. We further 
assessed cerebellum-dependent learning using the VOR gain-decrease 
adaptation test and phase-reversal paradigms. In the VOR gain-decrease test, 
the surrounding screen rotated in the same direction (in-phase) and with the 
same amplitude as the head of the animal, which was fixed to the turntable (27). 
There was no difference between genotypes in VOR gain-decrease learning, as 
neither the ability to reduce the gain (repeated-measures ANOVA F3,22 = 1.6, P = 
0.2) nor the ability to consolidate the learned response overnight was affected 
(ANOVA F3,22 = 2.2, P = 0.12) (Figure 2D). In contrast, AS mice showed 
prominent deficits (repeated-measures ANOVA F3,22 = 9.3, P < 0.0001; all P < 
0.05 by post-hoc test) in the VOR phase-reversal paradigm (Figure 2E), 
during which the visual stimulus also rotated in the same direction as the 
head but with greater amplitude, effectively reversing the direction of the 
VOR (29). Taken together, these results show that AS mice perform normally 
on cerebellar tests such as the OKR, VOR, VVOR, and VOR gain-decrease 
paradigms, but show a striking impairment in the more demanding phase-
reversal eye movement task. These results indicate the presence of mild 
cerebellar deficits in AS mice.
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same amplitude as the head of the animal, which was fixed to the turntable (27). 
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during which the visual stimulus also rotated in the same direction as the 
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on cerebellar tests such as the OKR, VOR, VVOR, and VOR gain-decrease 
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reversal eye movement task. These results indicate the presence of mild 
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Figure 2: AS mice show only mild specific cerebellar deficits. Baseline compensatory eye movements 
were evaluated by recording the OKR in the light (A), the VOR in the dark (B), and the VVOR in the light 
(C) (n = 7, for both WT and AS groups in all experiments). To test the OKR, the mice were subjected to 
visual stimulation by sinusoidally rotating the surrounding screen with the light on (A). VOR responses, 
driven by vestibular input, were induced by rotating the table in the dark (B). Combining both visual and 
vestibular stimulation by rotating the turntable while the light was on evoked the VVOR (C). No differences 
between genotypes were observed in OKR, VOR, or VVOR with respect to gain and phase. (D) The 
adaptability of the VOR was tested with a VOR gain-decrease protocol, in which the turntable with the 
mouse was rotated at the same amplitude (5°) and direction as the surrounding screen. No difference was 
observed in the VOR gain decrease or in the consolidation of learning the next day. (E) Following the VOR 
gain-decrease protocol shown in D, mice were subjected to a VOR phase-reversal protocol, in which the 
turntable with the mouse was rotated at a 5° amplitude and the surrounding screen at a 7.5° amplitude on 
day 2 and at a 10° amplitude on days 3 and 4, in the same direction. AS mice were significantly impaired 
in this more demanding cerebellar learning task. *P < 0.05, as determined by repeated-measures ANOVA. 
Error bars indicate the SEM.
Parallel fiber–to–Purkinje cell plasticity is not affected in AS mice.
Plasticity deficits at the parallel fiber (PF) to Purkinje cell synapse can 
result in cerebellar learning deficits (29). To investigate whether AS mice have 
impaired PF–Purkinje cell plasticity, we performed whole-cell recordings of 
Purkinje cells while inducing either long-term potentiation (LTP) via 1 Hz 
stimulation of PFs or long-term depression (LTD) via 1 Hz paired stimulation 
of PFs and climbing fibers (CFs). Both LTP and LTD could be readily induced 
to a similar degree in AS and WT mice (for LTP: AS 126% ± 6.4%, WT 125% 
± 5.4%, P = 0.77; for LTD: AS 57% ± 5.3%, WT 64% ± 2.9%, P = 0.26) (Figure 3, 
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A and B). In addition, paired-pulse facilitation (PPF) (with 50 ms between 
pulses), a measure of neurotransmitter release, was similar between AS and 
WT mice both before and after LTP/LTD induction (data not shown), making 
it unlikely that postsynaptic plasticity deficits were masked by presynaptic 
compensatory mechanisms. Taken together, these experiments suggest that 
UBE3A is not required for plasticity at the PF–Purkinje cell synapse.
Figure 3:  Normal PF–Purkinje cell plasticity and firing in AS mice. (A) Schematic representation of the 
placement of stimulus electrodes to induce LTP or LTD. PC, Purkinje cell. (B) LTP of the PF–Purkinje cell 
synapse was induced in Purkinje cells by PF stimulation at 1 Hz for 5 minutes. A repeated-measures 
ANOVA revealed no significant differences between the normalized EPSC amplitude in WT (n = 8) or AS 
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mutants (n = 7) 45–50 minutes after the induction of LTP. Insets show representative traces before (bold 
line) and after (thin line) induction of LTP. (C) LTD of the PF–Purkinje cell synapse was recorded in 
Purkinje cells after conjunctive PF-CF stimulation at 1 Hz for 5 minutes. No difference was observed 
between the normalized EPSC amplitude in WT (n = 8) and AS mutants (n = 7) 45–50 minutes after the 
induction of LTD (assessed by repeated-measures ANOVA). Error bars indicate the SEM. Scale bars: 10 pA 
and 10 ms (B and C). (D) Representative raw traces of extracellular single-unit recordings of spontaneous 
activity in Purkinje cells of WT and AS mice. Asterisks indicate complex spikes. (E) Purkinje cell–firing 
analysis showed no differences (Student’s 2-tailed t tests) in the complex spike (CS) firing rate, the CF 
pause, the simple spike (SS) firing rate, or in the CV and CV2 simple spikes (n = 22 for AS and n = 19 for 
WT). Error bars indicate the SEM. FF, firing frequency.
Spontaneous Purkinje cell activity is not altered in AS mice.
Purkinje cells form the sole output cells of the cerebellar cortex and are 
capable of modifying their intrinsic frequency and regularity of firing (30–32). As 
such, the spiking pattern of the Purkinje cell is likely to encode information that 
is processed in the cerebellum, including during compensatory eye movements 
(26, 27, 33, 34). We therefore recorded the spontaneous spiking activity of Purkinje 
cells in awake AS mice and in their WT littermates (Figure 3C). However, we 
detected no significant between-groups difference in the simple spike firing rate 
(t39 = 0.9, P = 0.3), the complex spike firing rate (t39 = 0.5, P = 0.6), or the CF pause 
(t39 = –1.6, P = 0.10) (Figure 3, D and E). The coefficients of variation for simple 
interspike intervals, CV (t39 = 0.47, P = 0.5) and CV
2 (t39 = 0.0, P = 1.0), were also 
unchanged. Thus, in contrast to a previous report on another AS mouse model 
(35), we observed normal spontaneous Purkinje cell firing in AS mice.
Tonic inhibition of granule cells is reduced in AS mice.
As shown in Figure 1, UBE3A is not only prominently expressed in cerebellar 
Purkinje cells, but also in cerebellar Golgi cells. Golgi cells provide tonic as well as 
phasic inhibition onto granule cells (36). Tonic and phasic inhibition are mediated 
by extrasynaptic, α-6–containing GABAA receptors and synaptic, β-2–containing 
GABAA receptors, respectively (for review see ref. 29). Tonic inhibition of granule 
cells in AS mice has been shown to be impaired, perhaps due to hyperfunctional 
GAT1-mediated reductions in available extrasynaptic GABA (37). To confirm 
these findings in our AS mice, we recorded both tonic and phasic inhibition in 
granule cells dialyzed with a high-chloride internal solution at –70 mV. Mean 
tonic inhibition of AS granule cells (–17.1 ± 2.6 pA) was significantly lower than 
that of WT controls (–33.1 ± 5.6 pA; t22 = –2.7, P < 0.01) (Figure 4A). In contrast, 
phasic inhibition was not affected, as the frequency, amplitude, and kinetics 
of spontaneously occurring inhibitory postsynaptic currents (sIPSCs) in AS 
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granule cells were comparable to that observed in WT mice (all P > 0.5) (Figure 
4B). These data confirm that tonic but not phasic inhibition between Golgi cells 
and granule cells is selectively impaired in AS mice. Since the current behavioral 
phenotype in AS mice closely resembles the deficits of mouse mutants in which 
granule cell inhibition is specifically manipulated (38), we hypothesize that tonic 
Golgi cell inhibition of cerebellar granule cells may contribute to the cerebellar 
phase-reversal learning deficit of AS mice.
Figure 4: Reduced tonic but not phasic inhibition at the Golgi-to-granule cell synapse in AS mice. (A) 
Left: representative traces of currents recorded from 4-week-old WT and AS mouse granule cells. The 
amplitude of tonic currents was measured by comparing the holding currents before and after the 
application of picrotoxin (PTX). Right: summary of tonic currents recorded in WT (n = 10) and AS (n = 15) 
granule cells. Student’s 2-tailed t tests showed a significant difference (*P < 0.05) in tonic currents. (B) 
Comparison of sIPSC amplitudes, rise times, and decay times between WT (n = 13) and AS (n = 19) mice 
using a 2-tailed Student’s t test. Granule cells showed no changes in phasic inhibition. Error bars indicate 
the SEM. Inset: representative traces of sIPSCs recorded in granule cells from a 4-week-old WT mouse 
(black) and an AS mouse (red).
UBE3A expression in Purkinje cells is dispensable for normal cerebellar 
learning and locomotion.
Given our collective observations in AS mice with normal Purkinje cell 
physiology (Figure 3) and mild cerebellar learning deficits (Figure 2), which 
may be linked to impaired tonic granule cell inhibition (38), we hypothesized 
that selective loss of UBE3A expression in Purkinje cells would contribute 
to neither cerebellar learning nor locomotor deficits. To investigate this, we 
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deleted the maternal Ube3a gene specifically in Purkinje cells by crossing 
female floxed Ube3a mice with male mice expressing Cre recombinase from 
the L7 promoter (39). The resultant Ube3afl/p+ L7-Cre mice exhibited a selective 
loss of UBE3A in Purkinje neurons relative to WT (Ube3am+/p+ L7-Cre) controls, 
whereas expression in cerebellar Golgi cells remained intact (Figure 5A). 
We then tested whether Purkinje cell–specific deletion of UBE3A affected 
normal VOR phase-reversal learning. Notably,Ube3afl/p+ L7-Cre mice showed 
normal VOR phase-reversal learning and retained the ability to consolidate 
the learned response overnight (all P > 0.05), indicating that Purkinje cell–
specific UBE3A loss does not affect cerebellar learning (Figure 5, C and D).
Figure 5: UBE3A expression in Purkinje cells is dispensable for normal cerebellar learning and 
locomotion. (A) IHC staining showing Purkinje cell–specific deletion of UBE3A expression in Ube3afl/p+ 
L7-Cre mice. Black arrows indicate granule cells, and white arrows indicate Purkinje cells (representative 
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image from 3 animals). Scale bars: 5 mm (top panels), 0.25 mm (WT, bottom left; Ube3afl/p+ L7-Cre, bottom 
left) 0.05 mm (WT, bottom right; Ube3afl/p+ L7-Cre, bottom right). (B) Rotarod learning for Ube3afl/p+ L7-Cre 
(n = 10) mice was not impaired compared with that for Ube3am  L7-Cre (WT) (n = 10) control mice (repeated-
measures ANOVA). The y axis indicates the time the mice stayed on the rotarod before falling off. (C) 
Ube3afl/p+ L7-Cre mice (n = 7) showed normal adaptation in the VOR gain-decrease paradigm compared 
with their WT littermates (n = 6). (D) Ube3afl/p+ L7-Cre mice (n = 7) showed no differences in subsequent 
VOR phase-reversal learning compared with control mice (n = 6). Statistical significance was tested using 
a repeated-measures ANOVA. Error bars indicate the SEM.
To test whether loss of UBE3A expression in Purkinje cells is responsible for 
the locomotor deficits, we tested Ube3afl/p+ L7-Cre mutant mice on the accelerating 
rotarod, which has reliably revealed gross motor coordination deficits in AS mice 
(7–12). Consistent with the observation that UBE3A expression in Purkinje cells 
is not required for normal cerebellar leaning, we observed no significant deficit 
in locomotor performance in the rotarod test (repeated-measures ANOVA F1,21 = 
0.7, P = 0.8; Figure 5B). Hence, loss of UBE3A expression in Purkinje cells is not 
sufficient to cause the cerebellar and locomotor deficits observed in AS mice.
Normalization of αCaMKII inhibition rescues locomotor but not cerebellar 
learning deficits in AS mice.
CaMKII activity is markedly reduced in AS mice, presumably due to 
increased inhibitory phosphorylation of αCaMKII at Thr305/Thr306 (40). 
Accordingly, normalizing CaMKII inhibition in AS mice by mutating the 
Thr305/Thr306 phosphorylation sites of the CaMK2Agene, thereby preventing 
autophosphorylation at αCaMKII Thr305 and Thr306 (41), fully restores certain 
capabilities, including locomotor performance (9). In the cerebellum, αCaMKII is 
exclusively expressed in Purkinje cells and is essential for Purkinje cell plasticity 
and cerebellar learning (42). Given our results showing that UBE3A expression 
in Purkinje cells is not required for normal cerebellar and locomotor learning, 
we hypothesized that introducing the αCaMKII-T305V/T306A mutation in 
AS mice would rescue the locomotor but not the cerebellar learning deficits. 
Hence, we crossed female AS (Ube3am–/p+) mutants with male heterozygous 
αCaMKII-TT305/6VA mutants (referred to hereafter as CaMKII-305/6VA mice). 
This crossing resulted in 4 genotypes (WT, AS mutants, heterozygous CaMKII-
305/6VA mutants, and AS/CaMKII-305/6VA double mutants). We replicated our 
previous findings (43) that the AS motor deficit seen on the accelerating rotarod 
is rescued in the AS/CaMKII-305/6VA double mutant (repeated-measures 
ANOVA on genotype F3,30 = 13; P < 0.0001), with only AS mice showing a 
significant deficit in rotarod performance compared with WT mice (Figure 6A). 
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Figure 6: Reduction of αCaMKII inhibition rescues motor performance on the rotarod but not cerebellar 
learning. (A) Rotarod learning in AS mice was impaired and could be rescued by reducing αCaMKII 
inhibition through the αCaMKII-305/6VA mutation. The y axis indicates the time the mice stayed on the 
rotarod before falling off (WT, n = 10; AS, n = 7; CaMKII-305/6VA, n = 10; AS/CaMKII-305/6VA, n = 8). (B) 
VOR gain decrease was normal in AS and AS/CaMKII-305/6VA double mutants. Graph shows the gain 
decrease during a 50-minute training period on day 1 as well as the consolidation of learning on day 2. (C) 
The impaired cerebellum-dependent learning in AS mice identified by the VOR phase-reversal task could 
not be rescued by normalization of αCaMKII inhibition. We used 6 αCaMKII-305/6VA mutants and 7 mice 
each for all other genotypes. *P < 0.05, as determined by a repeated-measures ANOVA, followed by a post-
hoc Bonferroni test. Error bars indicate the SEM.
To investigate whether reduction of αCaMKII inhibition also rescued cerebellar 
function, we measured baseline OKR, VOR, and VVOR performance in the 
AS/CaMKII-305/6VA double mutants and control mice. Like the AS mutation, 
neither the CaMKII-305/6VA nor the AS/CaMKII-305/6VA double mutation 
affected the baseline amplitude (gain) or timing (phase) of either the optokinetic 
or vestibular reflex. However, whereas the AS mice again showed a clear deficit 
in the VOR phase-reversal paradigm, this deficit was not rescued in the AS/
CaMKII-305/6VA double mutants (F3,22 = 9.314, P < 0.0001, by repeated-measures 
ANOVA), indicating that both AS mice as well as AS/CaMKII-305/6VA mice were 
significantly impaired compared with their littermate controls and CaMKII-
305/6VA single mutants (all P < 0.05 by post-hoc Bonferroni test) (Figure 6, B 
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and C). These results indicate that the molecular mechanism that underlies the 
VOR phase-reversal deficit is distinct from the mechanism that underlies the 
locomotor impairment.
Reinstatement of UBE3A expression in the cerebellum rescues cerebellar 
learning but not locomotor impairments.
Rescue of rotarod performance in AS/CaMKII-305/6VA double mutant 
mice could be due to normalization of function in extracerebellar motor 
circuits with enriched CaMKII expression, such as in the cortex or striatum. 
Alternatively, gain of function in Purkinje neurons could also conceivably 
explain the rescue, however, this is unlikely. To further challenge the 
assertion of cerebellar involvement in AS motor deficits, we used Ube3aStop/
p+ CreERT+mice (44), which, in the absence of the Cre-ERT–activating drug 
tamoxifen, express UBE3A at AS levels in the forebrain due to the presence of a 
floxed stop cassette that inhibits transcriptional read-through of the Ube3aStop 
allele. In the cerebellum, however, this inducible gene regulation system is 
less tightly controlled, resulting in region-specific Cre recombination and 
reinstatement of UBE3A; Ube3aStop/p+ CreERT+ mice express UBE3A at nearly 
35% of WT UBE3A levels in the cerebellum, presumably due to leaky, tamoxifen-
independent translocation of Cre-ERT to the nucleus in cerebellar neurons of 
this Cag-CreERT line (44). Locomotor deficits in Ube3aStop/p+ CreERT+ and AS 
mice were similar (F1,27 = 39.5, P < 0.0001) (Figure 7A and ref. 44), indicating 
a lack of rescue by cerebellar UBE3A reinstatement. In contrast, this level of 
UBE3A expression proved sufficient to support normal cerebellar learning, as 
Ube3aStop/p+ CreERT+ mice showed no deficits in the VOR phase-reversal learning 
paradigm compared with Ube3am+/p+ CreERT+ controls (all P> 0.05; Figure 7, B 
and C). These results suggest that cerebellar learning deficits and locomotor 
impairments in AS mice are dissociable, differentially resulting from UBE3A 
loss in cerebellar and extracerebellar circuits, respectively.
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Figure 7: Cerebellar reinstatement of UBE3A expression rescues cerebellar learning but not rotarod 
learning. (A) Rotarod learning for Ube3aStop/p+ CreERT+ mice was impaired compared with that of Ube3am+/
p+ CreERT+ control (WT) mice. The yaxis indicates the time the mice stayed on the rotarod before falling off. 
(B) VOR gain decrease for Ube3aStop/p+ CreERT+ and control (WT) mice during a 50-minute training period 
on day 1 as well as the consolidation test on day 2. No differences were observed between the genotypes. 
(C) Ube3aStop/p+ CreERT+ mice showed no differences in VOR phase-reversal learning compared with control 
(WT) mice. Following the VOR gain decrease shown in B, the mice were further trained by rotating them 
at a 5° amplitude while the surrounding screen was rotated at a 7.5° amplitude (day 2) and a 10° amplitude 
(days 3 and 4), in the same direction, to induce VOR phase reversal. For all experiments, 7 mice of each 
genotype were used. *P < 0.05, as determined by a repeated-measures ANOVA, followed by a post-hoc 
Bonferroni test. Error bars indicate the SEM.
Discussion
Patients with AS show various severities of motor deficits such as an ataxic-
like gait, forward lurching, unsteadiness, clumsiness, jerky motions, and/or 
tremulous movement of limbs (1). The AS mouse model appears to be a suitable 
model for studying the motor deficits in AS, as it exhibits globally impaired 
motor coordination in a variety of tasks such as accelerating rotarod, balance 
beam, bar cross, and gait tests (7–12).
The idea that cerebellar deficits underlie the movement deficits in individuals 
with AS has been dogmatic since the original publication describing AS (2). Given 
that Purkinje cells provide the sole output of the cerebellar cortex and that these 
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cells express high levels of UBE3A, it is also not surprising that deficient Purkinje 
cell function is generally believed to underlie the locomotor deficits in AS mice 
and in patients with AS (13). Our results in AS mice overturn both of these dogmas. 
First, although we show that the Ube3a gene is highly expressed in cerebellar 
Golgi and Purkinje cells and that this expression is almost exclusively derived 
from the maternal allele, we found that cerebellar deficits of AS mice were rather 
mild and were only observed with an extremely demanding cerebellar task. 
Second, we observed none of the changes in Purkinje cell physiology (synaptic 
plasticity, action potential firing) that typically correlate with cerebellar learning 
impairments (29). Third, we show that deletion of Ube3a from Purkinje cells does 
not affect cerebellar learning or locomotion. And last, we used several mouse 
models to demonstrate a double dissociation between locomotor function and 
cerebellar learning, which strongly argues against cerebellar dysfunction being 
the underlying reason for the locomotor deficits.
Consistent with previous findings (37) and the potent tonic inhibition of 
granule cell activity by Golgi cell inhibition, we observed impaired tonic inhibition 
of granule cells by Golgi cells in AS mice. The moderate behavioral cerebellar 
phenotype in AS mice is in line with impaired granule cell inhibition, as similar 
phenotypes have been observed in other mouse models in which the granule cell 
network is specifically disrupted (ref. 45 and for review see ref. 29). In particular, 
the deficits observed in AS mice are strikingly similar to those identified in 
a recently reported mouse mutant with a granule cell–specific mutation in 
theKCC2 KCl cotransporter gene; this genetic manipulation depolarizes granule 
cells by increasing their cytosolic chloride concentration. Like AS mice, these 
mutants also show severely impaired phase-reversal learning, while their 
OKR, VOR, and VVOR basic motor performance and gain-decrease learning 
are unaffected (38). Together, these findings suggest that defective Golgi cell 
functioning might contribute to the observed cerebellar phase-reversal learning 
deficits in AS mice. However, we also cannot rule out the possibility that the 
cerebellar cortex plays no role at all and that these deficits arise instead from 
deficits in the cerebellar nuclei.
It seems unlikely that the impaired tonic inhibition of Golgi cells onto granule 
cells underlies the locomotor deficits in AS mice, as ablation of cerebellar Golgi 
cells causes only a transient ataxia (46). Instead, the locomotor and cerebellar 
VOR phase-reversal deficits are likely regulated by distinct mechanisms, a 
hypothesis supported by our measurements of the AS/CaMKII-305/6VA–double-
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mutant mice. We took advantage of the fact that AS mice have reduced CaMKII 
activity, presumably due to increased inhibitory phosphorylation of αCaMKII 
T305/T306 (40), and that genetic normalization of CaMKII function in AS mice 
can restore rotarod motor performance (9). In the current study, we replicated 
this phenotype and further showed that, despite normal performance on the 
rotarod, AS/CaMKII-305/6VA double mutants still showed marked impairments 
in the VOR phase-reversal adaptation task. Notably, αCaMKII is not expressed in 
cerebellar nuclei nor in cerebellar Golgi cells, which excludes the possibility that 
the rescue of the locomotor phenotype arises from impaired αCaMKII signaling 
in these cells (42). In separate experiments, we showed that reinstatement of 
UBE3A in the cerebellum could rescue the cerebellar VOR phase-reversal learning 
deficit, but not the rotarod deficit. These results provide further evidence that 
the VOR phase-reversal learning and rotarod deficits in AS mice arise through 
distinct mechanisms.
Collectively, our findings suggest that the mild cerebellar deficits of AS mice 
are not responsible for their pronounced locomotor deficits. Other candidate 
brain areas that could contribute to these locomotor deficits are the motor cortex 
and the nigrostriatal pathway, in which both UBE3A and αCaMKII are highly 
expressed. Notably, a recent study showed that AS mice exhibited behavioral 
deficits that correlated with abnormal dopamine signaling (47). Specifically, 
AS mice exhibited changes in dopamine release in both the mesolimbic and 
nigrostriatal pathways (47), whereas another study reported increased dopamine 
levels in the striatum, midbrain, and frontal cortex of AS mice (48). AS mice were 
also shown to have a reduced number of tyrosine hydroxylase–positive neurons 
in the substantia nigra (10). Interestingly, CaMKII phosphorylation is increased 
in the striatum of AS mutant mice (10), and CaMKII has been shown to be a 
regulator of the dopamine transporter and the dopamine D3 receptor (49–51). 
Collectively, these findings could indicate that impaired CaMKII/dopamine 
signaling in the nigrostriatal pathway is a possible mechanism underlying the 
AS motor pathophysiology. This issue remains to be addressed in future studies.
In conclusion, we show here that AS mice have rather mild cerebellar deficits 
and that these deficits are likely caused by the impaired tonic inhibition of 
granule cells rather than by Purkinje cell dysfunction. Moreover, we show 
through genetic manipulations that there is a double dissociation between 
cerebellar deficits and locomotor deficits, such that we can correct locomotor 
learning without rescuing cerebellar learning, and vice versa. These results 
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strongly suggest that the cerebellar cortex plays a minor role at best in the 
pronounced motor performance deficits observed in AS mice.
Methods
Mice.
Mutant mice harboring the Ube3a-null mutation (referred to herein as 
AS mice) and mutants heterozygous for the targeted αCaMKII-T305V/T306A 
mutation, which prevents phosphorylation at these residues (referred to herein as 
CaMKII-305/6VA mice), were developed as described previously (7, 9, 41). Mutant 
Ube3aStop/p+ mice were developed as described previously (44). Ube3afl/p+ mice were 
generated at the University of North Carolina Animal Models Core facility by 
using the Ube3aKO1st targeting construct (CSD46841; clone PG00126_Z_3_B08 A1), 
generated by the trans-NIH Knockout Mouse Project (KOMP; www.komp.org). 
Targeted C57BL/6N-tac mouse embryonic stem cells (PRX-B6N 1; Primogenix) 
were used to derive chimeric Ube3aKO1st males, which were crossed with C57BL/6 
Rosa26-FLPe mice (009086; The Jackson Laboratory) to excise theFRT-flanked 
lacZ gene trap from the Ube3aKO1st allele, resulting in the conditional Ube3afloxed 
allele (Ube3afl/+). The FLPe allele was eliminated by further crossing the mice on 
a congenic C57BL/6 background (000664; The Jackson Laboratory), on which 
the line was maintained. The GlyT2-EGFP was generated and provided by J.M. 
Fritschy (University of Erlangen-Nuremberg, Erlangen, Germany) (23). With the 
exception of the experiments using the Ube3afl/p+ mice, all experiments described 
in this article were carried out using hybrid mice on a F1 129/Sv-C57BL/6 
background, with the mutant Ube3a allele coming from the female mice on a 129/
Sv background. Experiments using the Ube3afl/p+ mice were performed on the 
C57BL/6 background. Mouse pups were genotyped at P5 to P7 and then coded 
to facilitate blinded analyses. Animals were re-genotyped after the completion 
of all experiments, and the code was broken only prior to performing the final 
statistical analyses.
IHC.
Mice were anesthetized by i.p. injection of pentobarbital and perfused 
with saline, followed by 4% paraformaldehyde. Mice were dissected and the 
brains removed and treated for another 2 hours in 4% paraformaldehyde at 
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4°C. Subsequently, the brains were transferred into 30% sucrose solution and 
kept overnight at 4°C. Using a freezing microtome (SM 2000R; Leica), 40-μm 
sagittal sections were collected in 0.1 M phosphate buffer (PB). Sections were 
preincubated in sodium citrate (10 mM) at 80°C for 1 hour, rinsed with TBS (pH 
7.6), and treated with 0.4% Triton X-100 and 10% normal horse serum (Invitrogen) 
in TBS buffer for 1 hour at room temperature. Sections were incubated with 
monoclonal E6AP antibody (clone 330; Sigma-Aldrich) and diluted 1:500 in TBS 
buffer with 0.4% Triton X-100 and 2% normal horse serum for 72 hours at 4°C. 
Postincubation sections were washed using TBS and incubated with secondary 
Cy3 antibody (Jackson ImmunoResearch; ALG 715-165-150) and diluted 1:200 
in TBS buffer with 0.4% Triton X-100 and 2% normal horse serum for 2 hours 
at room temperature. Sections were then washed with 0.1 M PB and mounted 
and covered using VECTASHIELD H1000 (Vector Laboratories). Images were 
captured using a Zeiss LSM 700 confocal microscope (Carl Zeiss) equipped with 
Zeiss Plan-Apochromat ×10/0.45, ×20/0.8 (both air), and ×40/1.3 (oil immersion) 
objectives. GFP and Cy3 were imaged using excitation wavelengths of 488 and 
550 nm, respectively.
For DAB staining, brains were fixed with 4% paraformaldehyde by 
transcardial perfusion, as described above. Immunocytochemistry was 
performed on free-floating 40-μm frozen sections using a standard avidin-
biotin-immunoperoxidase complex (ABC) method (Vector Laboratories) with 
anti-E6AP (1:1,000; clone E6AP-330; Sigma-Aldrich) as the primary antibody and 
rabbit anti-mouse HRP as the secondary antibody (1:200; ALG P0260; Dako), 
followed by DAB staining.
Western blot analysis.
For measurement of UBE3A protein expression, mice were sacrificed by 
cervical dislocation, and the cerebellum was snap-frozen in liquid nitrogen. 
Human temporal cortex tissue was obtained from the National Institute of 
Child Health and Human Development (NICHD) Brain and Tissue Bank for 
Developmental Disorders. The tissues were homogenized in a lysis buffer 
containing 10 mM Tris-HCl (pH 6.8), 2.5% SDS, 2 mM EDTA, and a protease and 
phosphatase inhibitor cocktail (Sigma-Aldrich). Fifteen micrograms of protein 
was used for Western blot analyses. The Western blots were probed with an 
antibody against UBE3A (1:5,000; BD Transduction Laboratories) and actin 
(1:10,000; Chemicon). The bands were visualized using ECL (Pierce, Thermo 
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Fisher Scientific). For quantification of protein levels, gray scale values of pixels 
of the UBE3A bands were calculated and corrected for the actin levels using 
ImageJ software (NIH).
Behavioral analysis.
Mice were housed in groups of 2 to 4 mice per home cage. Genotype groups 
were age and sex matched. The mice were kept on a 12-hour light/12-hour dark 
cycle, with ad libitum access to food and water. Behavioral experiments were 
performed during the light period of the cycle by a person who was blinded to 
the genotype.
Rotarod.
Motor coordination of 3- to 4-month-old mutant mice and their WT 
littermates was tested on an accelerating rotarod (model 7650, Ugo Basile; 
Biological Research Apparatus). Performance was determined as the average 
of 2 trials with an inter-training interval of 1 hour. This was repeated for 2 to 
5 days. The rotarod has a cylinder with a diameter of 3 cm that can accelerate 
from 4 to 40 rpm in 300 seconds. The latency to stay on the rotarod was recorded 
by determining the time taken for a mouse to drop off or stop running for 3 
consecutive rotations.
Eye movement recordings.
Compensatory eye movements were recorded as described before (28). In 
short, mice were anesthetized, and an immobilizing construction containing 2 
attached nuts (3 mm each) was placed on the frontal and parietal bones using 
OptiBond primer and adhesive (Kerr) and Charisma (Heraeus Kulzer). After 5 
days of recovery, mice were head fixed and placed in a restrainer in the middle of 
a turntable surrounded by a cylindrical screen (with a diameter of 60 and 63 cm, 
respectively). After a habituation session, baseline OKR, VOR, and VVOR were 
evoked by rotating the screen and/or table (5° amplitude, 0.1–1.0 Hz frequency). 
The next day, mice were subjected to five 10-minute periods of sinusoidal in-phase 
screen and table rotations (both at 5° amplitude, 0.6 Hz) aimed at decreasing the 
gain of the VOR. On the subsequent days, the VOR was phase reversed by five 
10-minute periods of in-phase table and screen rotations at 0.6 Hz, with screen 
amplitudes varying from 7.5° (day 2) to 10° (days 3 and 4). Mice were kept in the 
dark between training days to prevent active extinction. Before, between, and 
at the end of each training session, the VOR was measured. Mice used for eye 
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movement recordings were littermates between 3 and 6 months of age (average 
age of 21 weeks for WT mice, 22 weeks for AS mice, 24 weeks for CaMKII-305/6VA 
mice, and 23 weeks for CaMKII-305/6VA AS mutants; not statistically different; 
1-way ANOVA F3,22= 9.2, P = 0.6). The eye movements were recorded at 240 Hz 
using a CCD camera fixed to the table, and pupil position was obtained using an 
eye-tracking system (ISCAN). Video calibrations and subsequent eye movement 
computations were performed with custom-made MATLAB (MathWorks) 
routines, as described previously (33). To analyze compensatory eye movements, 
phase and gain were calculated by fitting a sine function to the averaged eye 
and stimulus velocity traces. Gain was calculated as the ratio of eye-to-stimulus 
velocity traces. Phase was computed as the difference in degrees between the eye 
and the stimulus velocity.
In vitro electrophysiology.
For in vitro recordings of Purkinje cells, cerebellar slices were prepared 
according to a standardized protocol to allow recordings of long-term synaptic 
plasticity at the PF–Purkinje cell synapse (43). Slices of the cerebellar vermis 
(250 μm) from 10- to 30-week-old mice were obtained by decapitation after 
isoflurane anesthesia. Slices were cut in ice-cold oxygenated (with 95% O2 and 
5% CO2) solution containing 240 mM sucrose, 5 mM KCl, 1.25 mM Na2HPO4, 2 
mM MgSO4, 1 mM CaCl2, 26 mM NaHCO3, and 10 mM D-glucose. Next, slices 
were transferred to a submerged room-temperature holding chamber with 
artificial cerebral spinal fluid (ACSF) containing 124 mM NaCl, 5 mM KCl, 1.25 
mM Na2HPO4, 2 mM MgSO4, 2 mM CaCl2, 26 mM NaHCO3, and 15 mM D-glucose 
oxygenated with 95% O2 and 5% CO2. Purkinje cells were visualized using a 
standard upright microscope (Zeiss) and recorded using an EPC-9 amplifier 
(HEKA). The resistances of the pipettes ranged from 3 to 4 MΩ when filled with 
intracellular solution containing 120 mM K-gluconate, 9 mM KCl, 10 mM KOH, 
3.48 mM MgCl2, 4 mM NaCl, 10 mM HEPES, 4 mM Na2ATP, 0.4 mM Na3GTP, 
and 17.5 mM sucrose (pH 7.25). The holding potentials ranged from –65 to –70 
mV by somatic current injections between 0 and –300 pA. Throughout the 
recordings, series and input resistances were monitored in voltage clamp mode 
by a –10 mV voltage step 1 second after each stimulus, which was presented 
at 0.1 Hz. Recordings that showed a deviation of greater than 15 % in holding 
current, series, or input resistances or in paired-pulse ratios were discarded (43). 
Following the recording of a stable baseline of more than 10 minutes, long-term 
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plasticity at the PF–Purkinje cell synapse was induced in current clamp mode 
by either pairing PF and CF stimulation at 1 Hz for 5 minutes (PF-LTD protocol) 
at a near-physiological temperature (34°C ± 1°C) or by PF stimulation at 1 Hz for 
5 minutes at room temperature (PF-LTP protocol). For PF stimulation, ACSF-
filled patch pipettes were placed in the outer third of the molecular layer laterally 
to the presumed position of the Purkinje cell dendritic tree to avoid direct 
depolarization. For CF stimulation, similar pipettes were placed in the top part of 
the granule cell layer near the patched Purkinje cell. Great care was taken to avoid 
direct depolarization of the Purkinje cell axon, which would inevitably result in 
a noticeable back-propagating action potential. For both stimuli, 500- to 700-μs 
block pulses of 1 to 10 μA were used. The stimulus strength for PF stimulation 
was adapted to evoke excitatory postsynaptic currents (EPSCs) of approximately 
200 to 300 μA during baseline; for CF stimulation, we aimed to evoke a single CF 
stimulus. All patch experiments were performed in the presence of bath-applied 
picrotoxin (10 mM) to block inhibitory transmission, unless stated otherwise. All 
chemicals were purchased from Sigma-Aldrich. For statistical analysis, the last 5 
minutes of the traces were used.
Granule cell recordings were done as described above, but we used P30–P32 
animals and kept the slices in ACSF for more than 1 hour at 34°C ± 1°C before 
the experiments started. In addition, granule cells were recorded using patch 
pipettes of 5 to 7 MΩ filled with intracellular solution containing 150 mM CsCl, 15 
mM CsOH, 1.5 mM MgCl2, 0.5 mM EGTA, 10 mM HEPES, 4 mM Na2ATP, and 0.4 
mM Na3GTP (pH 7.3). Recordings were performed at 34°C using standard ACSF 
supplemented with 10 μM NBQX and 10 μM D-AP5. Granule cells were held at 
–70 mV (without junction potential correction) in voltage clamp configuration. 
Recordings during which the initial holding current increased over –100 pA 
and/or the series resistance increased over 25 MΩ were excluded from analysis. 
The tonic GABAA receptor–mediated current was measured by comparing the 
difference in holding current recorded in the presence and absence of 10 mM 
picrotoxin. sIPSCs were detected using the Mini Analysis program (Synaptosoft). 
Cutoff amplitudes for IPSC detection were set at 6 to 8 pA. All selected IPSCs 
were visually inspected. Averaged IPSC waveforms were constructed exclusively 
from nonoverlapping events. The decay time was calculated as the time from the 
peak to 37% of the peak amplitude.
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In vivo electrophysiology.
A craniotomy of 2 mm was made in the left occipital bone, and a recording 
chamber was placed around it, allowing chronic in vivo electrophysiological 
recordings (52). Mice were head fixed, and extracellular Purkinje cell activity 
was recorded and analyzed as previously described (53). Purkinje cells were 
identified by the firing of complex spikes and were confirmed to be from a 
single unit by the presence of a pause of at least 5 ms in simple spike firing after 
each complex spike. The recordings were processed by a custom-made MATLAB 
routine based on principal component analysis. For each cell, the mean firing 
rate and coefficients of variation (CV and CV2) were determined for simple and 
complex spikes. CV is a measure of the regularity of spiking during the entire 
recording period and is calculated by dividing the standard deviation by the 
mean of all interspike intervals in a given recording; CV2 is a measure of the 
regularity on a spike-to-spike basis and is calculated as the mean of 2 times the 
difference between 2 consecutive interspike intervals (ISIs) divided by the sum 
of the 2 intervals, i.e., [(2 | ISI (ISI)n+1 – ISIn |)/(ISIn+1 + ISIn)].
Statistics.
For the consolidation measurement, a 1-way ANOVA test was used, followed, 
when significant, by a post-hoc Bonferroni test. Student’s 2-tailed t tests were 
used for group comparisons of a single variable (e.g., protein levels, LTP, and 
LTD). A repeated-measures ANOVA with genotype as the between-subjects 
factor and frequency or time as the within-subjects factor was used to assess 
group differences in the eye movement recordings. Genotypic differences were 
probed with post-hoc Bonferroni comparisons. For all analyses, a P value of less 
than 0.05 was considered significant.
Study approval.
All animal experiments were approved by the Dutch Dierexperimenten 
commissie (DEC) ethics committee and were performed in accordance with 
Dutch animal care and use laws.
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Abstract
Promyelocytic Leukemia (PML) is a tumor suppressor gene associated with 
PML nuclear bodies, which can be found in almost all tissues, and is deregulated 
in many cancer types. In addition, PML has been shown to be important for 
normal development of the neocortex. Since we have recently identified PML 
as a target of the ubiquitin ligase E6AP, a protein known to be critical for the 
pathophysiology underlying Angelman syndrome (AS), we hypothesized that 
either reduced or increased expression of PML may result in cognitive deficits. 
To test this directly, we assessed spatial learning and memory, reversal learning 
and context discrimination in heterozygous and homozygous Pml mouse 
mutants. In addition we tested the role of PML in synaptic plasticity. We found 
that homozygous or heterozygous loss of PML does not result in spatial learning 
or synaptic plasticity deficits. To test whether PML levels are increased in the 
brain of a mouse model of AS, and whether reducing PML expression in AS mice 
can rescue the behavioral phenotype of AS mice, we crossed heterozygous Pml 
mice with Ube3a mice. However, we did not find increased levels of PML in AS 
mouse brains. Moreover, reducing PML levels did not affect the AS phenotype. 
In conclusion, our results suggest that PML is not essential for normal spatial 
learning or hippocampal synaptic function in mice, and does not play a 
significant role in the pathophysiological mechanism underlying AS.
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Introduction
Promyelocytic Leukemia (PML) is a tumor suppressor gene associated with 
PML nuclear bodies, which can be found in almost all tissues. These nuclear 
bodies are thought to be involved in many cellular processes such as genome 
stabilization, transcriptional control, DNA repair, apoptosis, senescence and 
recruitment of signaling molecules as reviewed by Zhou et al (1). Additionally, 
PML has been shown to be important for the development of the neocortex. A 
decrease in PML can cause an increase in the number of proliferating neural 
progenitor cells, resulting in a skewed composition of neuronal subtypes in the 
developing cortex and a decrease in cortical thickness (2, 3). Cortical thickness 
is highly associated with cognitive performance, where lower cortical thickness 
usually indicates lower performance (4, 5). Nevertheless, PML has not yet been 
identified as a gene involved in intellectual disability (ID) disorders, (6), but it 
should be noted that for the majority of ID patients the genetic cause has not 
been identified. Besides the proposed role of PML in developing cortex, there 
are a number of links between PML and ID disorders. For instance, PML is up-
regulated by oncogenic RAS (7), and also interacts with the PTEN/AKT/mTOR 
pathway (7-10). All these genes are associated with ID (11). Finally, PML has 
recently been suggested to play a role in Alzheimer’s disease (12). 
Recently it has been shown that PML ubiquitination is regulated directly 
by E6-AP, an E3 protein ligase encoded by the UBE3A gene, and both proteins 
have been found to co-localize in nuclear bodies (13). E6-AP null mice have 
increased levels of PML in several tissues throughout the body, indicating 
that PML may indeed be a direct target of E6-AP (13). We have recently found 
an inverse correlation between E6-AP and PML in B-cell lymphoma, in mouse 
and human, and one allelic loss of E6-AP was sufficient to attenuate tumor 
development by the promotion of PML-dependent cellular senescence (14). 
Mutations in the maternal allele UBE3A gene cause Angelman syndrome (AS), a 
neurodevelopmental disorder characterized by severe intellectual disability and 
seizures (15-18). How the loss of neuronal E6-AP causes such a severe disorder is 
unknown, but we hypothesized that the link with PML and cortical development 
as well as with Ras/mTOR signaling, may provide an important clue. Moreover, 
since PML regulates the number of PML nuclear bodies (19) as well as the 
localization of phosphatases to these bodies (2), increased levels of PML in AS 
could affect cellular phosphatase activity. Since Ube3a mice show decreased 
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phosphatase activity (20) and increased levels of inhibitory phosphorylated 
Calcium/Calmodulin-dependent protein Kinase 2 (CaMKII) which contributes 
to the AS phenotype (21), this could well be another mechanism in which PML 
contributes to AS pathology.
Here we studied the role of PML in synaptic plasticity and learning, as well 
as its possible role in the pathophysiology of AS.  Despite the presumed role of 
PML in cortical development and its link with the Ras-mTOR pathway, with 
Alzheimer’s disease and with AS, we find no evidence that PML is important for 
normal synaptic plasticity and spatial learning, and PML deregulation does not 
seem to contribute to the AS phenotype.
Results
Reduction in PML has no effect on spatial learning
Since Pml−/− mice have previously been shown to have reduced cortical 
thickness and defects in neuronal differentiation we tested if lack or a reduction 
of PML is accompanied by deficits in learning.  We used the Morris Watermaze 
task, a spatial learning test known to be dependent on hippocampal function 
(22), but also on cortical functions when used to test long-term memory 
and behavioral flexibility learning. (23-25). Pml–/– mutant mice and wild-type 
littermate controls were trained for 7 days to learn the position of the submerged 
platform. A probe trial on day 8 (Fig. 1A/B), demonstrated that all mice learned 
to locate the platform (p<0.05 paired sample t-test for quadrant and platform 
crosses within genotypes). Moreover, time spent in the target quadrant did not 
differ between the genotypes (F(2,50)=0.5, p=0.6) nor did the number of platform 
crosses (F(2,50)=0.9, p=0.4), indicating that Pml–/– mice show no clear spatial 
learning deficits. In order to make the test more sensitive to cortical deficits, we 
performed a long-term memory test performed 7 after the last training session. 
Again, no deficits between genotypes was observed with respect to time spent 
searching in the target quadrant (F(2,50)=0.2, p=0.9) as well as the number of 
target crossings (F(2,50)=0.6, p=0.6) (Fig. C/D). In addition, Pml–/– mice showed 
normal behavioral flexibility when tested in the reversal learning watermaze 
test, in which the platform was moved to the opposite location in the pool. 
(F(2,50)=1.8, p=0.2, F(2,50)=1.0, p= 0.4)  (Fig. 1 E/F) Taken together, we conclude 
that the loss of PML does not result in significant learning and memory deficits 
in the Morris watermaze test. 
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4Figure 1: Watermaze learning in Pml
–/– mice is not impaired. (A) A probe trial at day 8 shows that all 
groups spent more time searching in the target quadrant (black bar) compared to the average time in the 
other quadrants (white bar). (B) All groups show that the target platform position (black bar) is crossed 
significantly more than a similar position in the other quadrants, represented by the white bar. (C, D) 
Long term memory in Pml–/– mice is not impaired. (E, F) Pml–/– show no deficits in reversal learning. White 
bar displays time spent in quadrant where the platform used to be (before switching), whereas black bar 
displays the time spent in the new target quadrant position (E). Number of crosses over old platform 
position (white bars) compared to new position (black bars) (F)  (Pml–/– n=18, Pml+/– n=18 and Pml–/– n=17). 
Error bars represent SEM and asterisks indicate p<0.05.
Figure 2: Context conditioning and context 
discrimination is not affected by the Pml mutation (A) 
Freezing of the mice is shown before the shock 
(baseline) and after the shock when the mice are placed 
back in the conditioning chamber either 24 hours (24hr 
cx A) after the shock or 7 days (LTM cx A) after the 
shock. (B) Much lower freezing levels are observed 
when the mice are placed after 48 hours (48h cx B) or 8 
days (LTM cx B) in context B which is the same box as 
chamber A but has a different shape, texture of the 
floor, lighting and smell que. Black bars depict freezing 
levels of  Pml+/+ (wild-type) mice, gray bars Pml+/– mice, 
and white bars depict the Pml–/– mice. (Pml–/– n=11, Pml+/– 
n=11 and Pml–/– n=11). Error bars represent SEM and 
asterisks indicate p<0.05.
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Figure 3: Hippocampal transmission 
and plasticity in Pml–/– mice (black dots) 
is unaffected (A) Pml–/– (white dots) show 
normal basal synaptic transmission (Pml–
/– n=18, Pml+/+ n=22) and (B) normal paired 
pulse facilitation (Pml–/– n=24, Pml+/+ 
n=24). (C) LTP induced by a 100 Hz/1s 
tetanus is not affected in Pml–/– mice (Pml–
/– n=12, Pml+/+ n=12) (D) LTP induced by 2 
bursts of 4 stimuli at 100 Hz (with 200 ms 
inter-burst interval) is not affected in 
Pml–/– mice. The dashed line shows 
baseline level before potentiation (Pml–/– 
n=25, Pml+/+ n=31). Error bars indicate 
SEM.
 To further probe for cognitive deficits in Pml–/– mice we used the context 
dependent fear conditioning test (26). In this task, mice are trained to associate 
a specific context (Conditioned Stimulus (CS)) to an unpleasant experience, 
namely a mild footshock (Unconditioned Stimulus (US)). When placed back 
in this context, mice will show freezing, which is a measure of how well the 
animal associates the context with the shock. This test was followed by a more 
sensitive context discrimination test, where the mice are placed in a different 
environment than where they received US, to test the ability to discriminate 
between the conditioned environment and an unconditioned environment. 
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However, neither Pml+/– nor Pml–/– mice displayed any problem in either the 
context learning or the context discrimination task (F(2,30)<0.3, p values above 
>0.7) (Fig. 2A/B). Taken together, our behavioral analysis indicates that reduction 
or total absence of PML does not have a significant effect on spatial learning 
paradigms.
Pml mutants show no LTP deficits
 Synaptic plasticity, as measured by the ability to induce long-term 
potentiation (LTP), is thought to be the neural correlate for learning and 
memory storage (27, 28).  Using extracellular recordings in acute hippocampal 
slices, we focused on the Schaffer–collateral pathway given the large 
literature implicating this synapse in many forms of spatial learning. We first 
investigated baseline transmission in Pml+/+ and Pml–/– mice. Input-output 
measures showed no differences in fEPSP slope F(1,38)=0.8, p=0.4 nor in the 
fiber folly amplitude F(1,38)=0.8, p=0.4 (Fig. 3A). To investigate if there were 
changes in presynaptic function, we measured paired pulse facilitation (PPF). 
We found no deficits in PPF F(1,46)=0.8, p=0.4 (Fig. 3B). Next, we measured 
the ability to induce LTP by using a 100Hz and the more physiological theta-
burst stimulation protocol (Fig. 3C/D). We observed no deficit in 100Hz LTP 
F(1,22)=0.1, p=0.7 nor was there a difference in the 2 Theta LTP F(1,54)=0.2, 
p=0.6, indicating that the PML is not required for normal synaptic plasticity 
in the hippocampal CA1 area. 
PML levels are not different in AS mice
It has been shown previously, that E6-AP promotes degradation of PML and 
that PML protein levels are increased in different organs (kidney, prostate, lung, 
colon and liver) of Ube3am–/p– null-mutants (13). Further, an inverse correlation 
has been found in B-cell lymphoma (14). However, Angelman syndrome, which 
is caused by loss of the maternal UBE3A gene, is primarily a neurological disorder 
because the paternal copy of the UBE3A gene is silenced in the brain, whereas 
there is still paternal expression in other organs. Therefore, we assessed the 
levels of PML in the brain of Ube3am–/p+ mice using Western blot analyses. As a 
control for the antibody specificity, we ran brain lysates of Pml–/– mice, which 
showed complete absence of the protein (0 +/– 1.3% of WT levels (Fig. 4B). 
However, when comparing PML protein levels in hippocampal lysates of Ube3am–/
p+ mice with their wild-type littermates, we found no difference (wild-type 100% 
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± 7.4, Ube3am–/p+ mice 100.8% ± 18.2 (Fig. 4A, Supplemental Fig. 2). Since Louria-
Hayon and coworkers, determined PML levels in Ube3am–/p– null-mice rather than 
Ube3am–/p+ mice, we also looked at PML levels in these homozygous knock-out 
mice. However, also Ube3am–/p– null-mice showed normal PML levels in the 
hippocampus (wild-type 100% ± 7.4, Ube3am–/p– null-mice 91.2% ± 5.3). These 
results indicate that there is no significant accumulation of PML protein in the 
hippocampus of Ube3am–/p+ mice, Ube3am–/p– mice with AS. 
Figure 4: PML protein level is not increased in Ube3am–/p+ mice and increased weight phenotype of 
Ube3am–/p+ mice is not rescued. (A) Representative Western-blot of hippocampal lysates (left) of WT, 
Ube3am–/p+ and Ube3am–/p– mice. Probed with the PML antibody.  Pml–/– lysates are loaded as control. The 
right blot shows a Western-blot of kidney samples from WT and Ube3am–/p+ mice. (B) Quantification of 
PML levels reveals no significant difference in expression between WT (black bar), Ube3am–/p+ (dark gray 
bar) and Ube3am–/p–  (light gray bar) mice (WT n=16, Ube3am–/p+ n=13 , Ube3am–/p– n=5 and Pml–/– n=5).  (C) 
Ube3am–/p+ mutants show increased body weight, which is not reduced in the Ube3am–/p+/Pml+/– mice (white 
bar) (WT n=9, Ube3am–/p+ n=13, Pml+/– n=20 and Ube3am–/p+/Pml+/–n=10). Error bars indicate SEM and asterisk 
indicates p<0.05.
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Reduction of PML does not affect the weight and motor phenotype of AS 
mice.
Although PML protein level is not significantly increased in brains of AS mice, 
we cannot exclude that PML is a target of E6-AP. For instance, its degradation 
through E6-AP mediated ubiquitination could be regulated in a more subtle 
way (e.g. activity dependent regulation in synapses). Hence, we decided to 
take a genetic approach to test whether decreasing PML levels in AS mice can 
rescue the AS phenotype, similar to what has been shown for reducing inhibited 
aCaMKII and the a1 subunit of Na/K ATPase in AS mice (21, 29). For that purpose 
we crossed male heterozygous Pml+/– mutants with female Ube3am–/p+ mutants to 
obtain the following four genotypes: wild-type, Ube3am–/p+, Pml+/– and Ube3am–/p+/
Pml+/– double mutants. 
Figure 5: Rotarod deficits seen in Ube3am–/p+ mice are not alleviated by the Pml+/– mutation (A) Rotarod 
performance of wild-type (WT) mice (black circle) Pml+/– mutants (black square) Ube3am–/p+ mice (white 
circles) and Ube3am–/p+/Pml+/– mice (white squares) over 4 days. Y-axis represents the latency time to fall off 
the rotating rod.   (WT n=11, Ube3am–/p+ n=13, Pml+/– n=20 and Ube3am–/p+/Pml+/–n=10), (B) mice carrying the 
Pml–/– (white circles) or Pml –/+ mutation (gray circles) show no rotarod deficit when compared to control 
littermates (Pml+/+ mice black circles) (Pml+/+ n=17, Pml+/– n=18 and Pml–/– n=17). Error bars indicate SEM 
and asterisk indicate p< 0.05.
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Obesity is reported in 15% of the AS patients, and in the majority of AS 
patients that carry an Ube3a mutation (16). Previously it has been shown that 
Ube3am–/p+ mice also have increased body weight, which could be rescued by 
reducing CaMKII inhibitory phosphorylation (21). As shown previously, all mice 
carrying Ube3am–/p+ mutation were 25% heavier than their wild-type littermates 
(30.5 g. versus 24.9 g F(1,47)=10.5, p<0.05), whereas mice carrying the Pml+/– 
mutation were not significantly different in weight compared to their wild-type 
littermates F(1,47)=0.3, p=0.6). However, the Ube3am–/p+/Pml+/– double mutants 
were similar in weight to the Ube3am–/p+ mice (no significant interaction between 
Pml+/– and Ube3am–/p+ genotypes; F(1,47)=1.4, p=0.2, Fig. 4C). These results indicate 
that reducing PML levels does not affect the obesity phenotype as seen in Ube3am–/
p+ mice.
Figure 6:  Intact context conditioning but impaired context discrimination in Ube3am–/p+ crossed with 
Pml+/– mice.  (A) Freezing of the mice is shown before the shock (baseline) and after the shock when the 
mice are placed back in the conditioning chamber (context A) either 24 hours (24hr cx A) after the shock 
or 7 days (LTM cx A) after the shock. (B) Ube3am–/p+ mice show increased freezing (reduced discrimination) 
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when the mice are placed in context chamber B which is the same box as chamber A but has a different 
shape, texture of the floor, lighting and odor. This discrimination deficit is only observed 8 days after 
training  (LTM cx B) but not present 48 hours (48h cx B) after training. Black bars represent WT, dark gray 
bars Pml+/– mice, light gray bars Ube3am–/p+ mice and white bars the Ube3am–/p+/Pml+/-. The context 
discrimination was affected in mice carrying Ube3am–/p+ mutation not after 24 hours (24hr Cx B) but in the 
long-term memory test (LTM Cx B) (B). (WT n=11, Ube3am–/p+ n=11, Pml+/– n=18 and Ube3am–/p+/Pml+/–n=10) 
Error bars indicate SEM and asterisk indicate p<0.05.
Patients with AS suffer from motor coordination problems (18, 30), which is 
also a robust phenotype in Ube3am–/p+ mice (15, 21, 31-35). To assess the involvement 
of PML in the motor performance deficit in Ube3am–/p+ mice, the four different 
groups of mice were trained to run on the accelerating rotarod. As was shown 
previously, mice carrying the Ube3am–/p+ mutation performed significantly 
worse than wild-type littermates. Mice carrying the Pml+/– mutation did not 
show a difference when compared to the wild-type littermates (F(1,50)=26.2, 
p<0.001), and reduction of PML levels in the Ube3am–/p+ mice  also did not affect 
motor performance  (Ube3am–/p+/Pml+/– double mutants versus Ube3am–/p+ mice: 
F(1,50)=0.9, p=0.3) (Fig. 5A). Because of the reported role of PML in cortical 
development, and the contribution of the motor cortex in rotarod performance 
(36), we also tested Pml–/– null mice in a separate experiment. Both Pml+/– and Pml–
/– mice showed no motor deficit when compared to their wild-type littermates 
(F(2,50)=0.2, p=0.8 repeated measures ANOVA) (Fig. 5B). Taken together, these 
results suggests that PML does not play a role in motor performance as assessed 
with the rotarod, and that the deficit in motor performance seen in Ube3am–/p+ 
mice cannot be rescued by reducing PML levels.
Hippocampus dependent learning deficit in AS mice is not rescued 
The most prominent feature of AS is the severe cognitive disability (30). 
Cognitive deficits were also found in Ube3a mice (21, 32-34, 37), however, 
the expression of this phenotype is variable and dependent on the genetic 
background of the strain in which the mice are kept (32). Unfortunately, a probe 
trial on day 8 revealed that all mice learned the task significantly (paired t-tests 
for either quadrant preference or platform crosses p<0.05 (Supplementary 
Material, Fig. 1A/B), and there was no significant interaction between genotypes 
for time spent in target quadrant F(1,46)=2.0, p=0.1 (Supplementary Material, 
Fig. 1A), nor for the platform crosses F(1,46)=0.2, p=0.7 (Supplementary Material, 
Fig. 1B). Hence, Ube3am–/p+ mice do not display Watermaze learning deficits in 
this genetic background. To test the effect of PML levels in Ube3am–/p+ mice in 
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a different hippocampus dependent task, we assessed context discrimination 
fear conditioning in the four different genotypes. When examining freezing 
behavior in Ube3am–/p+ mutants, we observed no deficit in context conditioning 
(63% versus 64% freezing F(1,50)=0.008, p=0.9) either 24 h or 1 week (73% versus 
69% F(1,50)=0.7, p=0.4) after training (Fig. 6A). We then tested the ability of 
AS mice to discriminate between the conditioned context and a modified 
(unconditioned) context.  Ube3am–/p+ mutants displayed increased generalization 
of the fear memory, showing significantly more freezing when placed in a novel 
context compared to littermate control mice (45% versus 23% F(1,50)=20.2, 
p<0.001) 1 week but not 48 h after training (23% versus 16% F(1,50)=2.3, p=0.1) 
(Fig. 6B). This deficit was also present in the Ube3am–/p+/Pml+/– double mutants 
F(1,50)=0.3, p=0.6) (Fig. 6B). Taken together, these results indicate that after one 
week of training, Ube3am–/p+ mutants perform poorly on a context discrimination 
test, and that reducing PML levels does not rescue this phenotype of Ube3am–/p+ 
mice.
Discussion
In this study we assessed the importance of the PML gene in synaptic 
plasticity and spatial learning. PML has previously been shown to regulate the 
fate of neuroprogenitor cells by affecting their differentiation leading to cortical 
developmental problems ultimately leading to the observed decreased cortical 
thickness in the absence of PML in Pml–/– mice (2). Since recent studies suggest 
that cortical thickness is highly associated with individual performance (4, 5) 
we would expected a clear phenotype on the Morris watermaze test, specifically 
on the long-term memory and reversal learning task, as well in the contextual 
conditioning learning and discrimination paradigms. However, we found no 
evidence of any learning deficit in the Pml mutants, nor in the ability to induce 
LTP in the hippocampus. Since, the difference in cortical thickness between wild 
type and Pml–/– mice reduces upon aging (2) we speculate that the adult mice may 
use compensatory mechanisms to overcome the loss of PML. 
PML has been shown to be a target for ubiquitination and proteasomal 
degradation by E6-AP (13). Hence, we hypothesized that PML might be involved in 
the mechanisms underlying the neurological phenotype of Angelman syndrome. 
We addressed this by testing behavioral phenotypes that were shown to be 
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affected in Ube3am–/p+ mice. In several studies (including ours) Ube3am–/p+ mice 
were shown to have deficits in context conditioning and watermaze learning 
(21, 29, 38). However, in the mixed F2 background of our Ube3a mice crossed with 
Pml mutants, the Ube3am–/p+ mice did not show a watermaze learning phenotype, 
nor was there a context conditioning phenotype. Recently it was shown that 
background differences clearly affect some of the phenotypes seen in Ube3am–/p+ 
mice, indicating that these phenotypes in mice may be dependent on modifier 
genes (21, 32).  Our results provide additional evidence for this notion. Hence 
the watermaze and context conditioning deficits of Ube3am–/p+ mice cannot be 
considered robust phenotypes associated with the Ube3am–/p+ mutation and 
should be used with caution. 
Like many previous reports, we observed a robust Ube3am–/p+ phenotype in 
the rotarod test and body weight. In addition we observed a phenotype in the 
(delayed) context discrimination test. However, reducing the levels of PML 
in Ube3am–/p+ mice by crossing them with the Pml–/– mice, did not rescue any of 
these phenotypes. Moreover, even though PML was shown to be up-regulated 
in different tissue types in Ube3a null-mutants, we were unable to find any 
significant up-regulation of PML levels in the brain of the Ube3am–/p+ or in 
the Ube3a null-mutants. Therefore we conclude that it is unlikely that PML is 
critically involved in the mechanism underlying the neurological phenotype of 
Angelman Syndrome. 
In conclusion, despite the role of PML in cortical development, we find that 
PML is not critically important for hippocampal synaptic plasticity, nor for 
spatial learning, memory, reversal and discrimination tests. In addition we 
conclude that PML is not critically involved in the neurological phenotypes seen 
in Ube3am–/p+ mice. 
Material and methods
Mice
Mutants heterozygous for Pml and mutant mice harboring the Ube3a null 
mutation (designated as Ube3am–/p+ mice) and were developed as described 
previously (2, 33).  To obtain homozygous Pml mice, Pml+/– mutants in a Sv-
C57BL/6 background were crossed with each other. All experiments with 
Ube3am–/p+ mutants described in this paper were carried out using hybrid mice in 
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a F1 and F2 129/Sv-C57BL/6 background. To that end, male heterozygous Pml+/– 
mutants in a C57BL/6 background were crossed with female Ube3am–/p+ mutants 
in a 129/Sv background. Mice were genotyped at 7-10 days, but the experimenter 
remained blind for the genotype during data collection and analysis. Genotypes 
were retested after all experiments were finalized, and the code was then broken 
to perform the final statistical analysis. Mice were housed in groups of 2-4 mice 
per home cage. Genotype groups were age and sex matched. The mice were kept 
on a 12h light/dark cycle, with food and water available ad libitum. Behavioral 
experiments were performed during the light period of the cycle. All animal 
experiments were approved by the Dutch Ethical Committee and in accordance 
with Dutch animal care and use laws.
Western blot analysis
For protein expression measurements of PML, mice were sacrificed by 
cervical dislocation and hippocampus was immediately frozen using liquid 
nitrogen. Human temporal cortex tissue was obtained from the NICHD Brain 
and Tissue Bank for Developmental Disorders. The tissues were homogenized 
in a lysis buffer containing 10 mM Tris-HCl pH 6.8, 2.5% SDS, 2 mM EDTA, 
protease and phosphatase inhibitor cocktail (Sigma, Saint Louis, MO). 15 μg was 
used for Western blot analyses. The Western blots were probed with an antibody 
against PML (1:500, Millipore) and actin (1:10000, Chemicon). The bands were 
visualized using Enhanced Chemo Luminescence (Pierce). For quantification of 
protein levels, gray scale value of pixels of the E6-AP bands were calculated and 
corrected for the actin levels using ImageJ.
Rotarod
Motor coordination of 3-4 months old, mutant and wild-type littermates was 
tested on an accelerating Rotarod (model 7650, Ugo Basile, Biological Research 
Apparatus, Varese, Italy). Mice where measured for 5 trials with an inter-training 
interval of 1 hour. The Rotarod has a cylinder with a diameter of 3 cm that can 
accelerate from 4-40 rpm in 300 seconds. The latency to stay on the rotarod was 
measured as the time for a mouse to fall off or to stop running for 3 consecutive 
rotations. 
Weight
Mouse weight was assed using a standard lab scale at 3-4 months of age.  
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Watermaze
Prior to start of the water maze mice where handled for 5 days. The water 
maze has a circular pool that measures 1.2m in diameter, the pool has a water 
level of 12 cm deep and the circular platform, is submerged 1 cm bellow the water 
(26°C) surface. The light in the room was dimmed and the water was colored 
white. SMART version 2.0 (Panlab, Barcelona, Spain) was used to track the mice. 
Mice received 2 trials a day with an inter-trial interval of 30 seconds. In each trial 
the mice where placed on the platform for 30 seconds and than put in the pool at 
pseudorandom positions and allowed to search for the platform for 60 second. 
If the mouse located the platform, it was allowed to stay on the platform for 30 
seconds before the new trial. If the mouse was unable to locate the platform the 
mice was put on the platform, by the experimenter for 30 seconds. This was 
repeated for 7 consecutive days. On the day 8 a probe trial was done, the mouse 
was put on the opposite side in the bath after 30 seconds on the platform after 
which the platform was removed.  The mice where allowed to search for the 
platform for 60 seconds.
Fear Conditioning
Fear condition was preformed in a standard modular test chamber located in 
a standard MDF sound attenuating cubicle (Med Associates Inc., Albans, VT) The 
box was equipped with a grid floor in which a 0.75mA footshock was delivered. 
For context conditioning mice where placed inside the chamber for 180 seconds, 
a foot shock of 2 seconds was administered after 148 seconds. After 24 hours and 
after 14 days the mice where placed back in the chamber and the freezing was 
measured for 3 min. For context discrimination mice where placed in a different 
looking and smelling environment and the freezing was assessed for 3 min 48 
hours and 15 days after training.
Field recordings
Mice where anesthetized and decapitated. Sagittal slices (400 μm) were 
obtained and submerged in ice-cold artificial CSF (ACSF) using a vibratome. 
The hippocampi were subsequently dissected out. The hippocampal slices were 
left to recover for at least 1.5h at room temperature before experiments were 
initiated. After recovery they were placed in a submerged recording chamber 
and perfused continuously with ACSF equilibrated with 95% O2, 5% CO2 at 31°C 
at a rate of 2 ml/min. ACSF consisted of (in mM) 120 NaCl, 3.5 KCl, 2.5 CaCl2, 1.3 
39681 Bruinsma.indd   95 28-03-16   20:31
Chapter 4
96
MgSO4, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. Extracellular recordings of 
field EPSPs (fEPSPs) were made in CA1 stratum radiatum with platinum (Pt)/
iridium (Ir) electrodes (Frederick Haer Company). A bipolar Pt/Ir was used to 
stimulate Schaffer collateral/commissural afferents with a stimulus duration 
of 100 μs. Stimulus–response curves were obtained at the beginning of each 
experiment, 20 min after placing the electrodes. Long-term potentiation (LTP) 
was evoked using the following two different tetani: (1) 100 Hz (1 train of 1 s at 
100 Hz); and (2) 2 Theta (2 trains of 4 stimuli at 100Hz, spaced by 200ms). The 
100Hz protocols was performed at one-third of the maximum fEPSP and the 
2 theta at two-third of the maximum fEPSP. fEPSP measurements were done 
once per minute. Potentiation was measured as the normalized increase of the 
mean fEPSP slope for the duration of the baseline. Only stable recordings were 
included, and this judgment was made blind to genotype. Average LTP was 
defined as the mean last 10 min of the normalized fEPSP slope.
Statistics
For the Pml group we used a simple repeated measure ANOVA for the rotarod 
where days were taken as the factor and the genotype as the independent 
variable. For the Fear Conditioning data we used a simple two-tailed student’s 
T test. To test the learning within a group for the water maze we used a simple 
tow-tailed paired sample T test. The LTP data was assessed using a repeated 
measure ANOVA where the within subject variable where the LTP levels in the 
last 10 minutes and the between subject variable was the genotype. In the Ube3a 
x Pml group for freezing and the weight a two-way analysis of variance (ANOVA) 
test was done. The dependent variable was either freezing time or weight. 
The independent variables were having the Ube3a mutation and/or having the 
Pml mutation. This determined the effect of each independent variable on the 
dependent variables and identified if there is a significant interaction effect 
on the dependent variable. The rotarod was analyzed using a 2 way repeated 
measures ANOVA where the average time spend on the rotarod each day was 
taken as the factor and the independent variables where the same as in the two 
way ANOVA. 
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Supplementary Material
Supplementary Material Figure 1: Ube3a mice crossed with PML mice show no deficit in the Morris 
watermaze. A) A probe trial on day 8 shows that all mice learned the location of platform. Black bars 
represent the time spent in the target quadrant where the platform used to be during training, White bars 
represent average time spent in the three other quadrants (B) Quantification of number of times the 
platform position was crossed (black bar; target position, white bars; similar positions in other quadrants. 
(WT n=11, Ube3am–/p+ n=11, Pml+/– n=18 and Ube3am–/p+/Pml+/–n=10) Error bars indicate SEM and asterisk 
indicate p<0.05.
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Supplementary  Figure 2: Representative full size Western-blot of hippocampal lysates of WT, Ube3am–/p+– 
mice. Probed with the PML antibody.  Pml–/– lysates are loaded as control.
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Abstract
Angelman syndrome (AS) is a severe neurodevelopmental disorder that results 
from loss of function of the maternal ubiquitin protein ligase E3A () allele. Due 
to neuron-specific imprinting, the paternalcopy is silenced. Previous studies in 
murine models have demonstrated that strategies to activate the paternalallele 
are feasible; however, a recent study showed that pharmacologicalgene 
reactivation in adulthood failed to rescue the majority of neurocognitive 
phenotypes in a murine AS model. Here, we performed a systematic study 
to investigate the possibility that neurocognitive rescue can be achieved by 
reinstatingduring earlier neurodevelopmental windows. We developed an AS 
model that allows for temporally controlled Cre-dependent induction of the 
maternalallele and determined that there are distinct neurodevelopmental 
windows during whichrestoration can rescue AS-relevant phenotypes. Motor 
deficits were rescued byreinstatement in adolescent mice, whereas anxiety, 
repetitive behavior, and epilepsy were only rescued whenwas reinstated during 
early development. In contrast, hippocampal synaptic plasticity could be 
restored at any age. Together, these findings suggest thatreinstatement early 
in development may be necessary to prevent or rescue most AS-associated 
phenotypes and should be considered in future clinical trial design.
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Introduction
Children with AS are typically diagnosed within the first year of life, 
due to developmental delay. The most prominent symptoms include motor 
impairments, epilepsy, intellectual disability, and absence of speech (1). AS is 
caused by loss of function of the maternally inherited UBE3A allele. In neurons, 
the maternally inherited UBE3A allele is the only active allele, since the paternally 
inherited UBE3A allele is silenced through cell type–specific imprinting. This 
imprinting results in the allele-specific and neuronally restricted expression of 
a large antisense RNA transcript (UBE3A-ATS), which selectively interferes with 
paternalUBE3A transcription through a cis-acting mechanism (2–6).
There is currently no effective treatment for AS, but the unique silencing 
mechanism of the paternal UBE3A allele holds great promise for developing 
novel therapeutic strategies. Two recent studies have shown that the paternal 
UBE3A allele can be pharmacologically reactivated (7, 8), which offers a unique 
molecular target with high clinical potential for the treatment of AS.
Notably, however, activation of the paternal Ube3a gene in adulthood appears 
insufficient to rescue the majority of neurocognitive phenotypes in the AS mouse 
model. The failure of phenotypic rescue in adult AS mice might have resulted 
from the incomplete reinstatement of UBE3A expression (35%–47% of WT levels) 
or, alternatively, because a neurocognitive rescue by UBE3A reinstatement 
requires early therapeutic intervention (8). Hence, for such a treatment strategy 
to be successful in the clinic, it is imperative to know whether there is a critical 
time window during which a disease-modifying therapy would be effective. This 
is particularly relevant for early-onset disorders, such as AS, whose causative 
gene is highly expressed in developing neural circuits.
Despite extensive knowledge of critical periods for the development of 
sensorimotor networks, much less is known about the critical periods for 
complex behaviors in neuro developmental disorders (9, 10). An inducible mouse 
model for Rett syndrome showed that adult activation of the Mecp2 gene could 
rescue behavioral alterations and synaptic plasticity deficits, suggesting a 
broad window of therapeutic opportunity (11). In contrast, adult reactivation 
of the Syngap1 gene in a mouse model of intellectual disability and autism did 
not reverse any of the core behavioral deficits related to anxiety and behavioral 
flexibility (12). However, to our knowledge, no previous study has been performed 
to systematically investigate the influence of critical developmental periods on 
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the ability to rescue disease-relevant behavioral phenotypes. Here, we explore 
the effect of gene reactivation across multiple developmental windows in a 
novel mouse model for AS. Our results demonstrate an essential role for Ube3a 
in neurodevelopment and define a critical period for therapeutic intervention 
during which Ube3a gene reactivation ameliorates the neurocognitive 
impairments of AS model mice
Results
Generation and characterization of a conditional Ube3a mutant.
To examine whether the therapeutic benefit of Ube3a gene reactivation 
is dependent upon the developmental stage at which gene expression is 
restored, we generated a conditional AS mouse model to allow temporally 
controlled reactivation of the Ube3a gene upon Cre-mediated deletion of a 
floxed transcriptional stop cassette inserted within intron 3 by homologous 
recombination (Ube3aStop/p+) (Supplemental Methods and Supplemental Figure 1)
We first investigated the efficiency of the transcriptional stop cassette in 
blocking Ube3aexpression. Female Ube3aStop/p+ mice were crossed to a constitutive 
Cre-expressing line with an early embryonic onset of recombination (ref. 13 
and Figure 1A). Because the paternal Ube3a allele is epigenetically silenced, mice 
with a maternally inherited stop cassette without Cre expression (Ube3aStop/
p+;Cre– mice) showed a severe loss of UBE3A protein (also known as E6-associated 
protein [E6AP]), comparable to the reduction in UBE3A expression observed 
in the traditional AS mouse model with a maternally inherited deletion of 
Ube3a (Ube3am–/p+) (Figure 1B; see also Figure 2D for a comparison toUbe3am–/
p+ mice). Immunohistochemical staining of Ube3aStop/p+;Cre– brain slices was 
indistinguishable from that of Ube3am–/p+ mouse samples (Supplemental Figure 
1B). These results confirm that the floxed stop cassette is highly effective in 
blocking transcription of the maternal Ube3a allele, while preserving the normal 
epigenetic silencing of the paternal allele.
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Figure 1: Embryonic reactivation of Ube3a expression rescues AS-like behavioral phenotypes. (A) 
Schematic representation of Ube3a reactivation (indicated by the gray arrow) during mouse embryonic 
development and time point of behavioral testing. (B) Western blot analysis of hippocampus (n = 4 per 
genotype), cortex (n = 5), and cerebellum (n = 5) from Ube3aStop/p+and WT littermates crossed with an 
embryonically active Cre line. (C–H) Ube3aStop/p+;Cre– mice show robust behavioral AS-relevant phenotypes, 
which can be fully rescued by embryonic reactivation of the Ube3a gene in the Ube3aStop/p+;Cre+ mice. 
Number of mice (WT;Cre+/Ube3aStop/p+;Cre–/Ube3aStop/p+;Cre+): accelerating rotarod, n = 14/8/17; marble 
burying test, n = 24/18/28; open field test, n = 14/8/17; nest building test, n = 7/7/7; forced swim test, n = 
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14/8/17; epilepsy test, n = 7/10/8. All data represent mean ± SEM. ANOVA with genotype as independent 
variable was used for statistical comparisons. A significant effect of genotype was identified in all 
behavioral tests (see Supplemental Table 1). *P < 0.05, **P < 0.01; Bonferroni’s post hoc analysis.
Embryonic reactivation of Ube3a expression rescues AS-like behavioral 
phenotypes.
 Next, we investigated the efficiency of Ube3a reactivation upon Cre-mediated 
deletion of the floxed stop cassette. UBE3A protein levels were reinstated in 
Ube3aStop/p+;Cre+ mice to 89% of WT levels in the hippocampus, 82% in the cerebral 
cortex, and 99% in the cerebellum. Furthermore, the subcellular distribution of 
UBE3A was indistinguishable between Ube3aStop/p+;Cre+ and WT;Cre+ mice, validating 
the functionality of the Ube3areactivation method (Figure 1B and Supplemental 
Figure 1B).
Figure 2: Molecular analysis of Ube3aStop/p+;CreERT+ mice reveals successful reactivation of the maternal 
Ube3a gene upon tamoxifen induction. (A) Schematics representing Ube3a reactivation achieved by 
tamoxifen treatment (gray arrows) in each experimental group. (B–D)Ube3aStop/p+;CreERT+ mice with 
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postnatally induced gene reactivation express UBE3A at levels comparable to those achieved with early 
embryonic gene reactivation in hippocampus (juvenile, n = 3 per genotype; adolescent, n = 4 per genotype; 
adult, n = 4 per genotype), cortex (juvenile, n = 3 per genotype; adolescent, n = 4 per genotype; adult, n = 3–4 
per genotype), and cerebellum (juvenile, n = 3 per genotype; adolescent, n = 4 per genotype; adult, n = 5 per 
genotype). Data represent mean ± SEM.
Early embryonic gene reactivation prevents the manifestation of AS 
phenotypes.
Impaired motor coordination, autistic traits, anxiety, and epilepsy are 
hallmarks of AS patients, for which analogous phenotypes are well established 
in AS model mice (3, 14–16). As expected based on the loss of Ube3a expression, 
Ube3aStop/p+;Cre– mice exhibited significant alterations in rotarod performance 
(Figure 1C), marble burying (Figure 1D), open field exploration (Figure 1E), nest 
building (Figure 1F), and audiogenic seizure threshold (Figure 1H), all of which 
are also present in the classical Ube3am–/p+ mouse model of AS (3,14). In addition, 
we identified a highly robust phenotype in the forced swim test present in both 
the classical Ube3am–/p+ mutant (data not shown) and the conditional Ube3aStop/p+ 
AS mouse model (Figure 1G).
Consistent with the therapeutic potential of Ube3a gene reactivation, 
Ube3aStop/p+;Cre+mice exhibited a full rescue of all of these neurological and 
behavioral abnormalities, confirming that embryonic reactivation of UBE3A 
protein expression is sufficient to prevent the manifestation of AS phenotypes 
across multiple domains (Figure 1 and Supplemental Table 1).
Gene reactivation in juvenile, adolescent, and adult animals reveals the 
presence of distinct critical periods.
We next crossed the Ube3aStop/p+ mice with a tamoxifen-inducible CreERT+ 
mouse line (17) to determine the efficacy of Ube3a reactivation at later stages 
of postnatal development. In particular, we induced Ube3a gene reactivation 
at 3 weeks (“juvenile mice”), 6 weeks (“adolescent mice”), and 14 weeks of age 
(“adult mice”), with behavioral testing performed at a mean age of 16 weeks, 
22 weeks, and 28 weeks, respectively (Figure 2A). Across these developmental 
time points, UBE3A protein levels in tamoxifen-treatedUbe3aStop/p+;CreERT+ mice 
were reinstated to 70%–100% of wild-type levels, which is comparable to 
those achieved by early embryonic reactivation (Figure 2, B–D, Supplemental 
Figure 2, and Figure 1B). Importantly, UBE3A expression in vehicle-
treatedUbe3aStop/p+;CreERT+ mice was also similar to that observed in Ube3aStop/p+;Cre– 
andUbe3am–/p+ mice (Figure 2D and Supplemental Figure 3), demonstrating 
the tight control of gene reactivation.
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Figure 3: Postnatal reactivation of Ube3a expression reveals a critical period for behavioral rescue. (A–
E) Behavioral testing of Ube3aStop/p+ and WT littermates treated with either vehicle (Veh.) or tamoxifen 
(Tamox.) shows distinct critical periods for recovery of the behavioral deficits. Numbers of mice 
(WT;CreERT+ Veh./ WT;CreERT+ Tamox./Ube3aStop/p+;CreERT+Veh./Ube3aStop/p+;CreERT+ Tamox.): (A) Accelerating 
rotarod after juvenile (n = 22/20/22/22), adolescent (n = 11/11/10/11), and adult (n = 11/9/12/13) gene 
reactivation. (B) Marble burying test after juvenile (n = 21/20/20/20), adolescent (n = 20/20/21/23), and 
adult (n = 13/11/14/15) gene reactivation. (C) Open field test after juvenile (n = 21/21/22/22), adolescent (n = 
11/11/10/11), and adult (n = 10/8/9/10) gene reactivation. (D) Nest building test after juvenile (n = 12/13/14/13), 
adolescent (n = 14/13/16/17), and adult (n = 9/8/9/8) gene reactivation. (E) Forced swim test after juvenile (n 
= 17/19/18/19), adolescent (n = 11/11/10/11), and adult (n = 11/8/9/9) gene reactivation. All data represent 
mean ± SEM. Two-way ANOVA or repeated-measures 2-way ANOVA with genotype and treatment as 
independent variables was used for statistical comparisons. A significant effect of genotype was identified 
in all behavioral tests (see Supplemental Table 2). **P < 0.01 for genotype significance.
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 Juvenile reactivation of Ube3a resulted in a full rescue of the motor 
coordination deficit. In contrast, adolescent reactivation only partially rescued 
motor coordination, while no improvement was observed with adult reactivation 
(Figure 3A). Together, these findings identify a critical period for Ube3a-dependent 
motor development, which closes between 3 and 6 weeks postnatally.
Postnatal reactivation of Ube3a expression reveals a critical period for 
behavioral rescue.
Figure 4: Ube3a reactivation in juvenile animals does not recover epilepsy susceptibility, but Schaffer 
collateral–CA1 LTP is fully recovered. (A) Epilepsy susceptibility in Ube3aStop/p+;CreERT+ mice persists after 
Ube3a gene reactivation at a juvenile age (n = 8 mice/group). (B) The induction of tonic-clonic seizures 
induced by audiogenic stimulation (indicated by the red arrows) is efficiently treated by administration 
of AEDs (blue rectangle illustrates treatment administration and wash-out period) in adult Ube3aStop/p+;Cre– 
(n = 2) and Ube3am–/p+ (n = 12) mice. Seizures reappeared 3 days after cessation of treatment. Percentages 
indicate the amount of mutant mice that developed seizures upon audiogenic stimulation (see also 
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Supplemental Methods for more experimental details). Hippocampal plasticity deficit as measured by 
LTP in mutant mice is ameliorated upon gene reactivation at both (C) juvenile and (D) adult ages. Data 
represent mean ± SEM. Two-way ANOVA with genotype and treatment as independent variables was 
used for statistical testing. All tests showed a significant effect of genotype (see alsoSupplemental Table 2 
for statistical comparisons). Number of slices/mouse used: juvenile reactivation: WT;CreERT+ Veh. (n = 
16/4),WT;CreERT+ Tamox. (n = 25/4), Ube3aStop/p+;CreERT+ Veh. (n = 22/4), Ube3aStop/p+;CreERT+ Tamox. (n = 22/5); 
adult reactivation:WT;CreERT+ Veh. (n = 18/6), WT;CreERT+ Tamox. (n = 37/8), Ube3aStop/p+;CreERT+ Veh. (n = 
23/4), Ube3aStop/p+;CreERT+ Tamox. (n = 15/4). **P < 0.01.
The critical window for rescuing motor coordination deficits was distinct 
from the window for rescuing autism- and anxiety-related phenotypes such 
as the marble burying task, open field test, nest building test, and forced swim 
test, which could be rescued by embryonic reactivation (Figure 1, D–G, and 
Supplemental Table 1) but not upon juvenile, adolescent, or adult reactivation 
(Figure 3, B–E, and Supplemental Table 2).
 The epilepsy phenotype was also refractory to postnatal Ube3a 
reactivation, as seizures persisted despite gene reactivation at a juvenile age 
(Figure 4A). Next, we sought to confirm whether the epilepsy phenotype in AS 
mice is differentially responsive to treatment with antiepileptic drugs (AEDs) 
in mice with Ube3a reactivation. Adult (>8 weeks) Ube3am–/p+and Ube3aStop/
p+;CreERT– mice were treated for 5 days with either valproate or clonazepam using 
a within-subjects design. Prior to treatment, every AS mouse examined showed 
audiogenic seizures (Figure 4B). However, after 5 days of treatment with either 
of these AEDs, seizures were completely prevented in all mice. Moreover, 3 
days after the cessation of AED treatment (wash-out period), all AS mice again 
showed audiogenic seizures (Figure 4B). These data confirm that seizures can be 
successfully treated in adult AS mice using conventional AEDs, but that they are 
nevertheless insensitive to postnatal Ube3areactivation.
Ube3a reactivation in juvenile animals does not recover epilepsy 
susceptibility, but Schaffer collateral–CA1 LTP is fully recovered.
To investigate the extent to which postnatal Ube3a reactivation is able 
to rescue electrophysiological phenotypes, we measured hippocampal 
long-term potentiation (LTP), a form of synaptic plasticity required for 
experience-dependent neurodevelopment. Intriguingly, we observed full 
recovery of hippocampal LTP following Ube3a gene reactivation at all time 
points examined (Figure 4, C and D, and Supplemental Table 2), indicating 
the absence of a critical period window for rescue of this important cellular 
phenotype.
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Figure 5: Partial reactivation of Ube3a expression during the first postnatal week attenuates the motor 
coordination and open field deficits. (A) Schematics representing Ube3a reactivation achieved by 
tamoxifen administration (gray arrows) to the lactating dams starting on the day of delivery. (B) Western 
blot analysis of UBE3A expression in hippocampal (n = 4 per genotype), cortical (n = 5), and cerebellar (n = 
5) tissues of mutant mice and their WT littermates. The thin black lines on the hippocampus blot indicate 
noncontiguous samples run on the same gel. (C) Rescue of the accelerating rotarod and open field 
impairments. Number of mice used (WT;CreERT+ Veh./WT;CreERT+Tamox./Ube3aStop/p+;CreERT+ Veh./Ube3aStop/
p+;CreERT+ Tamox.) for accelerating rotarod, marble burying test, open field test, and forced swim test: n = 
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14/12/14/11; for nest building, n = 12/12/12/11. All data represent mean ± SEM. Two-way ANOVA or repeated-
measures 2-way ANOVA with genotype and treatment as independent variables was used for statistical 
comparisons. A significant effect of genotype was identified in all behavioral tests (see Supplemental 
Table 2 for statistical comparisons). *P < 0.05; **P < 0.01.
Partial gene reactivation in newborn animals rescues the motor 
coordination and open field phenotype.
 Our data suggest that UBE3A is required during a critical period between 
early embryogenesis and the third postnatal week in order to prevent a wide 
spectrum of AS-like deficits, with the notable exception of defects in motor 
coordination and hippocampal LTP. To further refine the critical period window, 
we next induced gene reactivation immediately following birth by administering 
tamoxifen to lactating dams (Figure 5A). The efficacy of this method of tamoxifen 
administration was reduced compared with direct treatment of offspring, 
yielding 44%, 34%, and 63% of WT UBE3A levels, respectively, in the hippocampus, 
cortex, and cerebellum (Figure 5B). Notably, however, even with a reduced level of 
UBE3A reactivation, motor coordination was entirely rescued and performance 
in the open field test was significantly improved (Figure 5C). However, AS-like 
deficits persisted in the other behavioral paradigms, suggesting that the Ube3a-
dependent neurodevelopmental critical period for autism-related phenotypes 
in AS might not extend significantly beyond birth. Alternatively, given that we 
achieved only partial reactivation during the neonatal period, it remains distinctly 
possible that functional plasticity may extend beyond 3 weeks of age but is only 
evident with a higher efficiency of Ube3a reactivation.
Discussion
Our results demonstrate an essential role for Ube3a in neuro development and 
define critical periods during which Ube3a gene reactivation can ameliorate AS-
like phenotypes. In particular, the window for improving motor coordination 
extends furthest into postnatal development, whereas the autism- and anxiety-
related phenotypes appear to be established much earlier. In contrast, at the 
cellular level, there appears to be no critical window for reversing plasticity 
deficits. The finding that LTP could be fully recovered at all ages is consistent 
with previous findings showing that the hippocampal LTP deficit in adult AS 
mice is reversible upon acute pharmacological treatment with an ErbB inhibitor 
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or with ampakine cognitive enhancers (18, 19). However, expression of UBE3A 
in adult Ube3am–/p+ mice through a viral-mediated approach only partially 
recovered synaptic plasticity (20). This apparent discrepancy likely reflects the 
limited efficiency of in vivo virally mediated neuronal transduction, compared 
with the more homogeneous biodistribution of systemically administered 
pharmacological compounds.
Importantly, and consistent with our findings, to our knowledge no 
studies in AS mice have demonstrated the successful rescue of the behavioral 
phenotypes related to anxiety and repetitive behavior upon adult treatment, 
despite multiple efforts using a variety of different interventions. In addition, it 
is notable that the behavioral deficits related to anxiety and behavioral flexibility 
in the Syngap1 mutant mouse model for intellectual disability were also not 
rescued by adult reactivation of Syngap1 gene expression (12). These findings 
could suggest that the window during which gene activation can ameliorate 
autism-related phenotypes closes early in neurodevelopment. Importantly, 
however, these observations do not exclude the possibility that directly targeting 
downstream signaling pathways could have a broader window for therapeutic 
intervention (21). In fact, this possibility is very well demonstrated by the highly 
effective intervention of AEDs in preventing audiogenic seizures, in contrast to 
the failure of postnatal gene reactivation to alter the susceptibility to audiogenic 
seizures. Therefore, at least for seizure susceptibility, the therapeutic benefit of 
restoring the etiological loss of UBE3A was inferior to that achieved by targeting 
downstream mechanisms, in this case with AEDs. This finding strongly supports 
investigation of the targets of UBE3A and their downstream signaling pathways 
in order to develop drugs that can be applied as part of a complementary 
therapeutic strategy.
We believe that our results will be important for informing future AS clinical 
trials regarding the critical period for therapeutic intervention. However, there 
are two important limitations of our study. First, although our behavioral 
experiments were performed in an isogenic F1hybrid background of 129/Sv and 
C57BL/6 mice, we cannot exclude an effect of the many heterozygous mutations 
that are contributed by each of these inbred strains, such as the Disc1mutation, 
which is common to all 129/Sv substrains (22, 23). Such mutations may interact 
with the Ube3a mutation and interfere with the ability to obtain a behavioral 
rescue. To minimize such confounding effects, we included matched littermate 
control groups for all experiments performed. Moreover, we selected only 
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those behaviors that consistently exhibited a robust and reliably reproducible 
phenotype across all experiments and for which we have demonstrated that a 
full rescue could be obtained upon early embryonic gene reactivation. A second 
translational limitation of our study is the obviously profound difference in 
brain development and systems-level functioning between mice and humans. 
Whereas a 3-week-old mouse can take care for itself and adult maturity is 
complete by 6–8 weeks of age, humans have a very extended childhood even 
compared with other primates. Therefore, it remains highly uncertain how 
and to what extent the precise critical period windows we have identified can 
be translated to humans. A recent comprehensive comparative study of early 
brain maturation across multiple mammalian species estimated that the extent 
of brain maturation observed in a 3-week-old mouse pup is comparable to that 
in a 2-year-old human infant (24). Regarding critical period windows, among 
the most well-studied examples is ocular dominance plasticity. In mice, the 
critical period for acquiring binocular vision closes by 4 weeks of age. However, 
in humans this extends until approximately 7 years of age (25). Therefore, the 
window of therapeutic opportunity in human AS patients is likely to be much 
longer than in mice, and this may offer some reason for optimism that gene 
reactivation could be more effective in humans than we have observed in mice. 
However, regardless of the precise conversion of the developmental time scales, 
our studies suggest that early intervention is very likely to determine the extent 
to which gene reactivation is therapeutically effective.
In addition to demonstrating an important developmental role for UBE3A, 
our study provides a notable contrast to a similar study of gene reactivation 
therapy in Rett syndrome (11), another neurodevelopmental imprinting 
disorder that is clinically reminiscent of AS. Whereas we demonstrate that adult 
reactivation of Ube3a is only minimally efficacious as a therapeutic intervention 
in AS, adult reactivation of Mecp2 appears to be highly effective for the treatment 
of Rett syndrome (11). This distinction not only emphasizes the unique 
neurodevelopmental requirements for Ube3a and Mecp2, but also illustrates the 
importance of systematically investigating disease-specific preclinical models, 
no matter how phenotypically similar, when the goal is to accurately inform 
therapeutic discovery and human clinical trials.
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Methods
Mice
For all behavioral experiments except the epilepsy test, we crossed female Ube3aStop/
p+mice (in the 129S2/SvPasCrl background; Charles River) with either TgCAG-Cre 
mice (13) (herein referred as Cre+ mice) or with Tg(CAG-cre/Esr1*)5Amc/J (The 
Jackson Laboratory) (17) (herein referred as CreERT+), both kept in the C57BL/6J 
background (Charles River), to generate heterozygous Ube3aStop/p+;Cre+ and 
Ube3aStop/p+;CreERT+ mutants and littermate controls in the F1 hybrid 129S2-C57BL/6 
background.
Tamoxifen treatment
One-day to 8-month-old Ube3aStop/p+ mice and their WT littermates (both 
sexes) were used in this study. Ube3aStop/p+;CreERT+ mutants and WT mice were 
given tamoxifen to induce Cre-mediated deletion of the stop cassette. 
Tamoxifen (Sigma-Aldrich) was diluted in sunflower oil at a concentration of 
20 mg/ml. Each mouse received 0.10 mg tamoxifen per gram body weight, by 
daily i.p. injection. The control groups were treated with daily i.p. injections 
of sunflower oil (vehicle). The newborn group received tamoxifen through 
the milk of the mother, who received daily i.p. injections of tamoxifen for 
5 consecutive days starting at the day of delivery. Juvenile, adolescent, and 
adult groups received 7 daily i.p. injections of tamoxifen.
Behavioral analysis
All behavioral experiments were performed during the light period of the 
cycle. The experimenter remained blind to the genotype and treatment until 
final statistical analysis. For the accelerating rotarod test, mice were given 
two trials per day with a 45- to 60-minute inter-trial interval for 5 consecutive 
days. The maximum duration of a trial was 5 minutes. For the marble burying 
test, clean Makrolon cages (50 × 26 × 18 cm) were filled with bedding material 
at 4 cm thickness and 20 glass marbles, which were arranged in an equidistant 
5 × 4 grid. Animals were given access to the marbles for 30 minutes. Marbles 
covered for more than 50% by bedding were scored as buried. For the open 
field test, mice were placed in a brightly lit 120-cm-diameter circular open 
field for 10 minutes. For the nest building test, mice were singly housed for a 
period of 5–7 days before the start of the experiment. Subsequently, 12 g extra-
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thick filter paper (Bio-Rad) was added to the cage, and the unused nesting 
material was weighed for 5 consecutive days. From this, the percentage of 
used nesting material was determined. For the forced swim test, mice were 
placed for 6 minutes in a cylindrical transparent tank (18 cm diameter) with 
water (at 26°C ± 1°C). The duration of immobility was assessed during the 
last 4 minutes of the test. For the epilepsy test, we used mice in the 129/Sv 
background, since epilepsy susceptibility in AS mice is dependent on the 
genetic background (16). Audiogenic seizures were induced by vigorously 
scraping scissors across the metal grating of the cage lid. This was done for 
20 seconds or less if a tonic-clonic seizure developed before that time.
Electrophysiology.
After the behavioral tests, animals were sacrificed, and hippocampal 
sagittal slices (400 μm) were obtained using a vibratome. Extracellular field 
recordings were obtained in a submerged recording chamber and perfused 
continuously with artificial cerebrospinal fluid (ACSF). LTP was evoked using 
the 10 theta burst protocol (10 trains of 4 stimuli at 100 Hz, 200 ms apart), 
performed at two-thirds of the maximum field excitatory postsynaptic 
potential (fEPSP).
Western blot analysis.
Blotted nitrocellulose membranes were probed with antibodies directed 
against E6AP (E8655 Sigma-Aldrich; 1:1,000) and actin (MAB1501R, Millipore; 
1:20,000). A fluorophore-conjugated goat anti-mouse antibody (IRDye 
800CW, Westburg; 1:15,000) was used as secondary antibody, and protein 
was quantified using a LI-COR Odyssey Scanner and Odyssey 3.0 software.
Immunohistochemistry.
Forty-micrometer-thick frozen sections were subjected to hydrogen 
peroxidase (H2O2) treatment, placed in blocking solution (10% normal horse 
serum [NHS], 0.5% Triton X-100) for 1 hour and incubated overnight with 
the primary antibody (mouse α-E6AP [E8655 Sigma-Aldrich, 1:2,000] in 2% 
NHS, 0.5% Triton X-100). The next day the slices were incubated with the 
secondary antibody (α–mouse HRP; Dako; 1:200), which was detected by 
DAB as the chromogen.
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Statistics.
All data were statistically analyzed using IBM SPSS software, and P 
values less than 0.05 were considered significant. Statistical analysis was 
performed using 1-way ANOVA or 2-way ANOVA with Bonferroni’s post hoc 
comparison.
Study approval.
All animal experiments were approved by the Dutch Animal Experiment 
Committee (Dierexperimenten commissie [DEC]) and in accordance with 
Dutch animal care and use laws.
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Supplementary Material
Supplemental Methods 
Generation and breeding of the Ube3astop/+ line. 
The Ube3astop/p+ mouse was generated as follows: the Ube3a genomic 
sequence (ENSMUSG00000025326) was obtained from Ensembl and 
used to design the primers for the targeting constructs. PCR fragments 
encompassing exon 3 using 5' primer: 5'-CCGCGGGCTCCACTAGTCAATTTC-3' 
and 3' primer: 5'- GCGGCCGCACCACAGTCCCTGGAGTTC-3' (4.9 kb; exon 
denotation according to ENSMUSG00000025326) and exon 4 using 5' 
primer: 5'- GGCCGGCCGGAACTACCATATCCTGTTTTAC-3' and 3' primer: 
5'- GCGGCCGCAGCCGATCTAGGTATTC' (4.6 kb) were amplified using High 
Fidelity Taq Polymerase (Roche) on ES cell genomic DNA and cloned on either 
side of a Neomycin-stop cassette flanked by loxP sites (1). Exon 3 and 4 were 
sequenced to verify that no other mutations were introduced. For counter 
selection, the diphtheria toxin chain A (DTA) gene was inserted at the 5' of the 
targeting construct. The targeting construct was linearized and electroporated 
into embryonic day 14 (E14) ES cells (derived from 129P2 mice). Cells were 
cultured in BRL cellconditioned medium in the presence of leukemia inhibitory 
factor. After selection with G418 (200 μg/ml), targeted clones were identified by 
PCR (long-range PCR from neomycin resistance gene to the region flanking the 
targeted sequence). A clone with verified karyotype was injected into blastocysts 
of C57BL/6 mice. Male chimeras were crossed with female 129S2/SvPasCrl mice. 
The resulting heterozygous offspring was used for subsequent breedings. The 
Ube3astop/p+ was maintained by breeding heterozygous males with wild-type 
129S2/SvPasCrl mice (Charles River). For all behavioural experiments except 
epilepsy tests, we crossed female Ube3astop/p+ with either TgCAG-cre mice (2) 
(hereafter referred as Cre+ mice) or with Tg(CAGcre/Esr1*)5Amc/J (Jackson) (3) 
(here after referred as CreERT+ ) kept in the in C57BL/6J background (Charles 
River) to generate F1 heterozygous Ube3astop/p+ ;Cre+ and Ube3astop/p+ 
:CreERT+ mutants and littermate controls in the F1 hybrid 129S2-C57BL/6 
background. For the epilepsy test, both Cre lines were crossed 5 times into 129S2/
SvPasCrl and subsequently crossed with Ube3astop/p+ mice to obtain Ube3astop/
p+ ;Cre+ and Ube3astop/p+ ;CreERT+ mutants and littermate controls in the 
129S2 background. Mice were genotyped when they were 7-10 days, and re-
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genotyped at the moment the mice were sacrificed. Genotyping records were 
obtained and kept by a technician not involved in the 2 experimental design, 
performance and analysis. All animals were kept at 22±2⁰C with 12 hours dark 
and light cycle and were provided with food and water ad libitum. Mice were 
preferably group-housed (2-4) cage, unless when fighting between males was 
observed. 
Tamoxifen treatment and randomization. 
Cages were semi-randomly (alternatingly) assigned to either treat all mice 
within the cage with vehicle or with tamoxifen. Both male and female mice were 
used. The alternating randomization was adjusted if there was an imbalance 
of genotype or sex. One day to eight-month-old Ube3aStop/p+ mice and their 
WT littermates (both males and females) were used in this study. The group 
of Ube3aStop/p+ and WT mice crossed with CreERT+ transgenic mice were 
divided into 4 different experimental groups (classified as Newborn, Juvenile, 
Adolescent and Adult) based on the age of Tamoxifen administration to induce 
Cre-mediated deletion of the Stop-cassette. Tamoxifen (Sigma-Aldrich) was 
diluted in sunflower oil at a concentration of 20mg/ml. Each mouse received 0.10 
mg Tamoxifen per gram body weight, by daily intraperitoneal (i.p.) injection. The 
control groups were treated with daily i.p. injections of sunflower oil (vehicle). 
The Newborn group received Tamoxifen through the milk of the mother, who 
received daily intraperitoneal (i.p.) injections of Tamoxifen for 5 consecutive 
days starting at the day of delivery. Tamoxifen treatment was initiated between 
21-23 days of age in the Juvenile group; at 6 weeks of age in the Adolescent 
group; and at 14 weeks in the Adult group. These last 3 groups received 7 daily 
i.p. injections of Tamoxifen. The group of Ube3aStop/p+ and WT mice crossed 
with the embryonic active Cre+ transgenic mice (‘Embryonic’) received 3 vehicle 
injections when they were 6-8 weeks old. 
Behavioral analysis. All behavioral experiments were performed during 
the light period of the cycle. All animal experiments were approved by the Dutch 
Ethical Committee and in accordance with Dutch animal care and use laws. 
The experimenter remained blind to the genotype and treatment until final 
statistical analysis. Both male and female mice were used for the experiments. 
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Behavioural assays
All behavioural assays and scoring were done by an experimenter blind to 
genotype and treatment. Behavioral tests were typically run in the order as 
presented below. However the 3 marble burying and nest building test were 
added later to the battery, and a new cohort of adolescent and adult mice were 
used for these tests. Since the mice for the epilepsy test required a different 
genetic background (see above) we used a separate cohort for this test. 
Accelerating Rotarod. 
Motor function was tested using the accelerating rotarod (4-40 rpm, in 5 
minutes; model 7650, Ugo Basile Biological Research Apparatus, Varese, Italy). 
Mice were given two trials per day with a 45-60 min inter-trial interval for 5 
consecutive days. For each day we calculated the average of the time spent on 
the rotarod, or the time until the mouse made 3 consecutive rotations on the 
rotarod. Maximum duration of a trial was 5 min. Number of mice used in this 
task: Number of mice used: Embryonic: Wt;Cre+ (n=14), Ube3aStop/p+;Cre– 
(n=8), Ube3aStop/p+;Cre+ (n=17), Inducible: Adult – WT;CreERT+ Veh. (n=11), 
WT;CreERT+ Tamox. (n=9), Ube3aStop/p+ ;CreERT+ Veh. (n=12), Ube3aStop/p+ 
;CreERT+ Tamox. (n=13); Adolescent – WT;CreERT+ Veh. (n=11), WT;CreERT+ 
Tamox. (n=11), Ube3aStop/p+ ;CreERT+ Veh. (n=10), Ube3aStop/p+ ;CreERT+ 
Tamox. (n=11); Juvenile – WT;CreERT+ Veh. (n=22), WT;CreERT+ Tamox. (n=20), 
Ube3aStop/p+ ;CreERT+ Veh. (n=22), Ube3aStop/p+ ;CreERT+ Tamox. (n=22); 
Newborn – WT;CreERT+ Veh. (n=14), WT;CreERT+ Tamox. (n=12), Ube3aStop/
p+ ;CreERT+ Veh. (n=14), Ube3aStop/p+ ;CreERT+ Tamox. (n=11). 
Marble burying test. 
Clean open makrolon (polycarbonate) cages (50x26x18 cm) were filled with 
4 cm of bedding material. On top of the bedding material 20 blue glass marbles 
were arranged in an equidistant 5 x 4 grid and the animals were given access to 
the marbles for 30 minutes. After the test the mice were gently removed from 
the cage. Marbles which were covered for more than 50% by bedding were scored 
as buried. Occasionally, a mouse managed to escape out of the cage during the 
test, and was excluded. Number of mice used in this task: Embryonic: Wt;Cre+ 
(n=24), Ube3aStop/p+;Cre– (n=18), Ube3aStop/p+;Cre+ (n=28), Inducible: Adult – 
WT;CreERT+ Veh. (n=13), WT;CreERT+ Tamox. (n=11), Ube3aStop/p+ ;CreERT+ 
Veh. (n=14), Ube3aStop/p+ ;CreERT+ Tamox. (n=15); Adolescent – WT;CreERT+ 
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Veh. (n=20), WT;CreERT+ Tamox. (n=20), Ube3aStop/p+ ;CreERT+ Veh. (n=21), 
Ube3aStop/p+ ;CreERT+ Tamox. (n=23); Juvenile – WT;CreERT+ Veh. (n=21), 
WT;CreERT+ Tamox. (n=20), Ube3aStop/p+ ;CreERT+ Veh. (n=20), Ube3aStop/
p+ ;CreERT+ Tamox. (n=20); Newborn – WT;CreERT+ Veh. (n=14), WT;CreERT+ 
Tamox. (n=12), Ube3aStop/p+ ;CreERT+ Veh. (n=14), Ube3aStop/p+ ;CreERT+ 
Tamox. (n=11). 
Open Field test. 
To test locomotor activity and anxiety, the mice were individually placed in 
a brightly lit 120 cm diameter circular open field. The total distance travelled 
was recorded for 10 minutes (SMART software, Panlab, Barcelona). Number 
of mice used in this task: Embryonic: Wt;Cre+ (n=14), Ube3aStop/p+;Cre– 
(n=8), Ube3aStop/p+;Cre+ (n=17), Inducible: Adult – WT;CreERT+ Veh. (n=10), 
WT;CreERT+ Tamox. (n=8), Ube3aStop/p+ ;CreERT+ Veh. (n=9), Ube3aStop/p+ 
;CreERT+ Tamox. (n=10); Adolescent – WT;CreERT+ Veh. (n=11), WT;CreERT+ 
Tamox. (n=11), Ube3aStop/p+ ;CreERT+ Veh. (n=10), Ube3aStop/p+ ;CreERT+ 
Tamox. (n=11); Juvenile – WT;CreERT+ Veh. (n=21), WT;CreERT+ Tamox. (n=21), 
Ube3aStop/p+ ;CreERT+ Veh. (n=22), Ube3aStop/p+ ;CreERT+ Tamox. (n=22); 
Newborn – WT;CreERT+ Veh. (n=14), WT;CreERT+ Tamox. (n=12), Ube3aStop/
p+ ;CreERT+ Veh. (n=14), Ube3aStop/p+ ;CreERT+ Tamox. (n=11). 
Nest Building test. 
To measure nest building, mice were single housed for a period of 5 to 
7 days before the starting the experiment. Subsequently 12 grams (12±1) of 
compressed extra-thick blot filter paper (Bio-rad©) was added to the cage and 
cages were put back in the rack and undisturbed for 24h. For 5 consecutive 
days and approximately at the same time of the day, the unused nesting 
material was carefully cleaned, dried and weighed to determine the amount 
used for nestbuilding. Number of mice used in this task: Embryonic: Wt;Cre+ 
(n=7), Ube3aStop/p+;Cre– (n=7), Ube3aStop/p+;Cre+ (n=7), Inducible: Adult – 
WT;CreERT+ Veh. (n=9), WT;CreERT+ Tamox. (n=8), Ube3aStop/p+ ;CreERT+ 
Veh. (n=9), Ube3aStop/p+ ;CreERT+ Tamox. (n=8); Adolescent – WT;CreERT+ 
Veh. (n=14), WT;CreERT+ Tamox. (n=13), Ube3aStop/p+ ;CreERT+ Veh. (n=16), 
Ube3aStop/p+ ;CreERT+ Tamox. (n=17); Juvenile – WT;CreERT+ Veh. (n=12), 
WT;CreERT+ Tamox. (n=13), Ube3aStop/p+ ;CreERT+ Veh. (n=14), Ube3aStop/
p+ ;CreERT+ Tamox. (n=13); Newborn – WT;CreERT+ Veh. (n=12), WT;CreERT+ 
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Tamox. (n=12), Ube3aStop/p+ ;CreERT+ Veh. (n=12), Ube3aStop/p+ ;CreERT+ 
Tamox. (n=11). 
Forced swim test. 
Mice were placed for 6 min in a cylindrical transparent tank (27cm high and 
18cm diameter), filled with water (kept at 26±1 degrees Celsius) 15 cm deep. 
Since little or no immobility is observed during the first 2 min after the mouse 
has been placed in the water, the duration of immobility was only assessed 
during the last 4 min of the test. The mouse was considered to be immobile 
when he ceased to move altogether, making only movements necessary to keep 
its head above water. Number of mice used in this task: Embryonic: Wt;Cre+ 
(n=14), Ube3aStop/p+;Cre– (n=8), Ube3aStop/p+;Cre+ (n=17), Inducible: Adult – 
WT;CreERT+ Veh. 5 (n=11), WT;CreERT+ Tamox. (n=8), Ube3aStop/p+ ;CreERT+ 
Veh. (n=9), Ube3aStop/p+ ;CreERT+ Tamox. (n=9); Adolescent – WT;CreERT+ 
Veh. (n=11), WT;CreERT+ Tamox. (n=11), Ube3aStop/p+ ;CreERT+ Veh. (n=10), 
Ube3aStop/p+ ;CreERT+ Tamox. (n=11); Juvenile – WT;CreERT+ Veh. (n=17), 
WT;CreERT+ Tamox. (n=19), Ube3aStop/p+ ;CreERT+ Veh. (n=18), Ube3aStop/
p+ ;CreERT+ Tamox. (n=19); Newborn – WT;CreERT+ Veh. (n=14), WT;CreERT+ 
Tamox. (n=12), Ube3aStop/p+ ;CreERT+ Veh. (n=14), Ube3aStop/p+ ;CreERT+ 
Tamox. (n=11). 
Epilepsy test. 
Since epilepsy susceptibility in AS mice is dependent on the genetic 
background, these experiments were performed in a 129/sv background. For 
this test, mice were taken from their home cage and placed in a clean cage. To 
assess seizure susceptibility, audiogenic seizures were induced by producing a 
loud and continuous noise, achieved by vigorously screeching scissors across the 
metal grating of the cage lid. This was done for 20s or shorter if a tonic-clonic 
seizure developed before that time. Number of mice used in this task: Embryonic: 
Wt;Cre+ (n=7), Ube3aStop/p+;Cre– (n=10), Ube3aStop/p+;Cre+ (n=8), Inducible: 
Juvenile – WT;CreERT+ Veh. (n=8), WT;CreERT+ Tamox. (n=8), Ube3aStop/p+ 
;CreERT+ Veh. (n=8), Ube3aStop/p+ ;CreERT+ Tamox. (n=8). Mean age of the 
mice used in the epilepsy susceptibility test was the following: Embryonic, 10 
weeks; Juvenile, 9 weeks. 
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Antiepileptic drug (AED) treatment. 
Mutant Ube3aStop/p+;Cre– (n=2), Ube3am-/p+ (n=12) and WT littermates 
(n=3) in the 129sv background were used for these experiments. Tonic-clonic 
seizures were verified in all mutant mice upon audiogenic stimulation. No 
seizues were observed in WT mice. Mutant mice were randomized into two 
treatment groups (sodium valproate and clonazepam), and drug administration 
started 24hrs after the first epilepsy test. 1 Ube3aStop/p+;Cre– , 7 Ube3am–/
p+ and 2 WT mice were treated with 5 daily i.p. injections of sodium valproate 
(Alliance Healthcare™) at a concentration of 200mg/kg. The valproate was 
dispensed in sterilized water through agitation and syringes were filled while 
stirring. Valproate was freshly prepared daily. 6 The second treatment group 
composed of 1 Ube3aStop/p+;Cre–, 5 Ube3am–/p+ and 1 WT mouse, which were 
treated with 5 daily i.p. injections of 0.05mg/kg Clonazepam (Roche) dispensed 
in PBS-methylcellulose. Clonazepam was prepared fresh every two days. Two 
re-tests experiments were performed in both treatment groups; the first re-test 
was performed 30 min. after the last injection, on the fifth day of treatment, and 
the second re-test was done 3 days after treatment cessation. 
Electrophysiology. 
After the behavioural tests, animals were been sacrificed, sagittal slices 
(400 μm) were made and submerged in ice-cold artificial CSF (ACSF) using a 
vibratome, and hippocampi were dissected out. These sagittal hippocampal 
slices were maintained at room temperature for at least 1.5 h to recover before 
experiments were initiated. Then they were placed in a submerged recording 
chamber and perfused continuously at a rate of 2 ml/min with ACSF equilibrated 
with 95% O2, 5% CO2 at 31°C. ACSF contained the following (in mM): 120 NaCl, 
3.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. 
Extracellular recording of field EPSP (fEPSPs) were made in CA1 stratum 
radiatum with platinum/iridium electrodes (Frederick Haer). A bipolar Pt/Ir 
was used to stimulate Schaffercollateral/commissural afferents with a stimulus 
duration of 100 μs. LTP was evoked using the 10 Theta burst protocol (10 trains 
of 4 stimuli at 100Hz, 200ms apart), performed at two-third of the maximum 
fEPSP. fEPSP measurements were done once per minute. Potentiation was 
measured as the normalized increase of the mean fEPSP slope for the duration 
of the baseline. Only stable recordings were included, and this judgment 
was made blind to genotype. Average LTP was defined as the mean last 10 
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min of each protocol. Recordings showing unstable baselines were excluded 
from the experiment. Number of slices/mice used: Juvenile- WT;CreERT+ 
Veh. (n=16/4), WT;CreERT+ Tamox. (n=25/4), Ube3aStop/p+ ;CreERT+ Veh. 
(n=22/4), Ube3aStop/p+ ;CreERT+ Tamox. (n=22/5); Adult - WT;CreERT+ Veh. 
(n=18/6), WT;CreERT+ Tamox. (n=37/8), Ube3aStop/p+ ;CreERT+ Veh. (n=23/4), 
Ube3aStop/p+ ;CreERT+ Tamox. (n=15/4). 
Western Blots. 
To collect tissue for Western blot analysis, hippocampus, cortex and 
cerebellum were dissected and immediately frozen in liquid nitrogen. The 
lysates were prepared by adding lysis buffer (10mM Tris-HCL pH 6.8, 2.5% SDS) 
supplemented with protease inhibitor cocktail (Sigma-Aldrich®) to the tissue 
and homogenization was achieved by sonication. After centrifugation (6000 
rpm for 5min.) supernatants were collected. The protein concentration of the 
supernatants was determined using a BCA kit (Pierce, Thermo Scientific). A total 
of 20μg of each sample was loaded on the gel and a wet transfer was performed. 
The blotted nitrocellulose membrane was probed with antibodies directed 
against E6AP (E8655 Sigma-Aldrich®; 1:1,000) and Actin (MAB1501R Millipore©; 
1:20,000). A fluorophore-conjugated secondary Goat antimouse antibody 
(Westburg©, IRDye 800CW 1:15,000) was used and the protein was detected 
using Li-cor® Odyssey Scanner system. Quantification was done using Odyssey 
3.0 software (Li-cor® Biosciences). Number of samples used for immunoblot 
analysis range from 2 to 5 per genotype/brain area. 
Immunohistochemistry. 
Brains from adult mice were fixed by transcardial perfusion with 4% 
paraformaldehyde. Immunocytochemistry was performed on 40μm thick 
frozen sections. The sections were subjected to a hydrogen peroxidase (H2O2) 
treatment, placed in blocking solution (10% normal horse serum (NHS), 0.5% 
Triton X-100) for 1h and incubated overnight with the primary antibody (mouse 
α-E6AP (E8655 Sigma-Aldrich, 1:2000) in 2% of NHS, 0.5% Triton X-100). The 
next day the slices were incubated with the secondary antibody (α-mouse HRP 
(Dako©; 1:200), which was detected by 3,3’-diaminobenzidine (DAB) as the 
chromogen. DAB sections were analysed and photographed using a Leica© DM-
RB microscope and a Leica DFC450 digital camera. For overview pictures of the 
slices a Zeiss Stemi SV6 was used. 
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Data analysis and statistics. 
 Values are represented as means ± S.E.M. All the data was statistically 
analyzed using the IBM® SPSS software and P-values of 
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Supplementary Figure 1:
Supplemental Figure 1. Generation and histological validation of Ube3aStop/p+ knock-in mice. (A) 
Schematics depicting the generation of the inducible mouse model by the insertion of a floxed stop 
cassette into intron 3 of Ube3a, for which cre-mediated recombination leads to reinstatement of Ube3a 
gene expression. Black boxes correspond to Ube3a coding exons and green triangles represent the LoxP 
sites. (B) Immunohistochemical UBE3A stainings from Ube3am–/p+ knock-out mice and Ube3aStop/p+ and 
WT littermates crossed with a embryonically active cre-line. Brain overviews magnification = 1.6x (upper); 
zoomed-in pictures magnification = 5x (lower).
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Supplementary Figure 2:
Supplemental Figure 2. High level of recombination is achieved by embryonically expressed cre (‘Cre’) 
and tamoxifen inducible cre expression (‘CreERT’). (A) Polymerase chain reaction (PCR) of hippocampal 
tissue reveals successful recombination in mutant mice expressing Cag-Cre and in Ube3aStop/p+;CreERT+ 
mutant mice injected 7 times with tamoxifen (Tam.). (B) Representative Western blot and corresponding 
quantification illustrates hippocampal UBE3A reinstatement achieved by successive tamoxifen injections 
in the Ube3aStop/p+;CreERT+ mutant mice. (C) Time-course of UBE3A expression following gene reinstatement 
(days following the last seventh injection of tamoxifen). All data arerepresented as mean ± S.E.M.
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Supplememtary Figure 3:
Supplemental Figure 3. Histological analysis of Ube3aStop/p+;CreERT+ mice reveals successful reactivation 
of the maternal Ube3a gene upon tamoxifen induction. (A-B) Hippocampal, cortical, and cerebellar 
sections demonstrate brain-wide reactivation of Ube3a expression in tamoxifen-treated Ube3aStop/
p+;CreERT+ mice. Brain overviews magnification = 1.6x; zoomed-in pictures magnification = 5x.
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Supplementary Table 1:
Supplemental Table S2 Summary of the statistical tests applied for each behavioral paradigm 
performed on the postnatal reactivation groups. Statistical significance (P < 0.05) is indicated by green 
shading.
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Discussion
As discussed in Chapter 1, ubiquitination identifies and tags a protein for 
degradation. Ubiquitination is also involved in endocytotic trafficking and is 
associated with the initiation of DNA repair1. Proteins must be ubiquitinated 
in an orderly fashion during development and for the normal homeostasis of 
the body2.  Disruption of the ubiquitin proteasome pathway (UPP) has been 
implicated in the pathogenesis of many disorders including Huntington 
disease, Alzheimer’s disease, Parkinson’s disease, prion-like disorders, cystic 
fibrosis, Liddle syndrome and many kinds of cancers3-7. The research in this 
thesis focused on two neurological developmental disorders in which the UPP is 
pathogenically associated, namely UBE2A deficiency syndrome and Angelman 
syndrome (AS)8-12. The aim of this thesis is to expand our knowledge on these 
UPP related disorders. In Chapter 2 we identified new research options for the 
UBE2A deficiency syndrome. In Chapter 3, we have focused on the involvement 
of the cerebellum in underlying the motor deficits in AS.   We investigated one 
of the possible targets of UBE3A in Chapter 4.  In Chapter 5 we investigated if 
there is a critical time window in which AS symptoms can be reversed.
The importance of the UPP in neuronal functioning
The UPP seems to be involved in almost all cellular functions such as cellular 
stress, apoptosis and cell cycle control 13-15. Even slight disruptions of the UPP 
have severe consequences, as shown by the many diseases associated with 
dysfunction in the UPP7,16,17. It is thus no surprise that ubiquitination is of great 
importance to the development and functioning of the nervous system18-20. Most 
of the diseases known to be associated with the UPP result in dysfunction of 
neurons later in life, as is illustrated by diseases such as Alzheimer’s disease, 
Lewy body dementia and Parkinson disease4,6,7,21-23. In this thesis we looked at two 
developmental disorders related to the UPP.  
Since UBE2A deficiency syndrome is X-linked, men display signs of the 
syndrome24,25. Females carrying the mutation are not affected because of the 
inactivation of the X chromosome carrying the faulty gene26. The skewing of 
the X-inactivation in females most likely represents a survival/proliferation 
advantage of lymphocytes26
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The need for strict control for the UPP is also demonstrated in Angelman 
syndrome. The UBE3A gene (encoding an E3 ligase) is only expressed from 
the maternal alleles in neurons; all other tissues and cell types in the body 
express both alleles. Mutations affecting the maternal allele causes loss of 
or nonfunctional UBE3A protein in the neurons of the brain27-29. The lack of 
paternal UBE3A expression in neurons is due to a long antisense transcript 
(UBE3A-ATS)30. The difference between cell types expressing UBE3A is 
hypothetically caused by alternate splicing of the IC-UBE3A-ATS transcripts30. 
Why these splice difference exist and why the UBE3A gene is silenced might be 
linked to the finding that multiple active copies of the UBE3A gene are the most 
common genetic cause of autism31. Sno RNAs are believed to play a role in the 
splicing of the UBE3A gene32,33 and their absence is believed to play a role in the 
pathogenesis of the Prader Willi Syndrome34. The presence of a functional but 
silenced copy of the UBE3A gene creates a potential therapeutic opportunity as 
explored by Meng and colleagues. They showed that genetically truncating the 
UBE3A-ATS by inserting a poly-A cassette in the paternal allele resulted in the 
amelioration of some behavioral deficits in the AS mice35. Huang and colleagues 
were also successful in activating the silent paternal Ube3a allele in neurons by 
down-regulating the UBE3A-ATS with Topotecan36. In 2015, the use of anti-sense 
oligonucleotides (ASOs) to reduce the UBE3A-ATS and subsequently unsilence 
the UBE3A gene was reported. Injecting ASO’s into mature AS mice thus relieved 
some of the phenotypes displayed by these mice37. These studies highlight a 
possible treatment for AS. 
Notably, the distribution of UBE3A undergoes a cytoplasmic to nuclear 
shift in postnatal development of neurons, suggesting that it may have several 
distinct functions in the neuron29. UBE3A was shown to regulate dendritic 
arbor growth in fruit flies38. Overexpression also reduced dendritic complexity. 
A similar finding using AS mice showed that UBE3A ligase helps in specifying 
the polarization and asymmetric outgrowth of pyramidal neurons dendritic 
arbors and also influencing the distribution Golgi apparatus39. Using the fear-
conditioning paradigm an up-regulation of maternal UBE3A was demonstrated 
using the Ube3a-YFP reporter mice. The absence of UBE3A in AS mice led to 
deficits in activity- dependent ERK1/2 phosphorylation40, an enzyme which is 
well known for its role in memory formation and neuronal plasticity41-43. The 
ERK-dependent increase of AMPA receptor insertion was shown to be Ca2+/
calmodulin-dependent protein kinase II (CaMK2A) dependent44. A previous 
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study from our own lab showed that AS mice have an increased amount of 
T305/306-phosphorylated CaMK2A protein45. Hence, UBE3A might regulate 
synaptic plasticity by controlling the amount of inhibited CaMK2A.  Increased 
CaMK2A inhibition leads to deficits in ERK phosphorylation40, explaining the 
effects on the synapse in AS syndrome. 
Both UBE2A and UBE3A have clear effects on neuronal functioning, however 
many questions remain. The exact function of these proteins in the synapse 
remains to be elucidated and how exactly the proteasome is recruited and 
translocated to specific neuronal compartments is also still unclear46. 
Behavior of mice and men
Research using model organisms is extremely valuable where human 
experimentation is impossible due to ethical or practical reasons. Research 
using Mus musculus as an animal model is of great importance to further our 
knowledge of human physiology of all cell (tissue) types including neurons47-50. 
Animal models allow us to study gene defects seen in humans and generate 
large experimental groups. Scientists try to relate behaviors observed in human 
patients to the behavioral deficits seen in mouse models of a specific disease. 
Sometimes this behavior corresponds perfectly to behaviors seen in humans, as 
exemplified in the tuberous sclerosis complex syndrome (TSC) mouse model51,52. 
However caution is advised when extrapolating the observations made in mouse 
models to humans, and in particular when such an extrapolation relates to the 
potential for therapy.  This is clearly illustrated by the Neurofibromatosis mouse 
model research, where the use of statins showed a huge improvement in spatial 
learning deficits and attention impairments53. When testing statins in human 
trials it did not show any improvement in learning or attention54. Likewise a 
promising drug for treating fragile X syndrome called AFQ056, a new mGluR5 
antagonist reduced spine abnormalities and rescued sociability behavior in 
mice55-57. However in humans no improvement in behavior was observed58.
In Chapter 2 we tested a novel mouse model for UBE2A deficiency syndrome 
and we showed it to be a good model for learning deficits demonstrated by the 
patients. The mice, however, did not display an epilepsy phenotype in contrast 
to what is seen in 80% of the patients9,10,59. There are many mouse models that 
display spontaneous seizures, and these models have been extensively studied to 
identify and test anti-epileptic drugs 60 61. These studies are of great importance 
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for developing new treatments, as 40% of manifest epilepsy in humans is 
defined as intractable epilepsy and it does not respond to any anti-epileptic 
drug treatment62. Epilepsy is a key symptom in syndromes like AS and Dravet 
syndrome and is displayed in the corresponding mouse models, but only in 
specific background strains.63,64. Likewise our findings of lack of epilepsy in the 
UBE2A deficiency syndrome could very well be a matter of choosing the wrong 
background for our experiments. Given that the prevalence of epilepsy in the 
human UBE2A and AS patients is not 100%, there could be modifier genes in 
certain individuals and mouse strains that make them resistant to epilepsy. 
More research into these modifier genes could help with new possible treatment 
avenues for syndrome related epilepsy and intractable epilepsy.
Water maze and fear conditioning (FC) deficits in AS mice have been 
repeatedly reported64-68. As shown in Chapter 5, we did not find such deficits. 
The Ube3a mice used in Chapter 5 are a mix of the 129S1/SvImJ strain and the 
C57BL/6J strain from the cross with PML mice (P. Pandolf) 69. The water maze 
test has been widely criticized as a stressful task 48,49,70. The differences in stress 
levels in mice could result in increased water maze learning as seen in the post 
earthquake water maze in the study of Yanai et al. 2011 71. Interestingly Huang 
2013 et al. showed that water maze deficits in AS mice are also strain dependent 
64.  The genetic background of the mice used in Chapter 3 are different from the 
mice described in our water maze study.68 The same arguments about strain 
differences hold true for FC where this background difference could explain the 
specific FC generalization phenotype instead of the previous described context 
deficit 64. 
Marble burying behavior is decreased in AS mice as we show in Chapter 5. 
What impaired marble burying behavior means in terms of clinical relevance 
is unclear. In literature it is used to test neophobia, anxiety and obsessive 
compulsive disorder (OCD)72-74. The behavior is probably a type of defensive 
burying, demonstrated by coating the marbles with Tabasco making them 
more averse increased the marble burying75. Brain areas responsible for marble 
burying have not been extensively studied but lesions in hippocampus and 
septum decrease marble burying49. Huang et al. 2013 suggested that it is just a 
way to measure motor impairment like the rotarod and the rearing, which is 
also deficient in these mice64. In light of the evidence that we were able to fully 
rescue the rotarod phenotype but not marble burying phenotype, it appears that 
the Marble burying deficit in AS mice does not just reflect a motor impairment. 
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Similarly, the forced swim test outcome where AS mice spend more time 
floating than WT mice and the lack of a recue with gene reactivation also 
suggests this task does not reflect a motor impairment. The forced swim test 
has been associated with depression when mice float more76-78. This test is very 
sensitive to antidepressants, suggesting a depression like phenotype in AS mice. 
Surprisingly however reactivation of the gene does not rescue this phenotype. 
Therefore I would suggest more assessment into his inhibited behavior seen 
in these mice. Testing anti-depressants on both the forced swim test and the 
marble burying test would add greatly to our understanding of the tasks and the 
possibility of reversing this phenotype in the AS mice.
Validating targets
UBE3A, the E3 ligase mutated in Angelman syndrome has been associated 
with many targets as shown in table 1 of the introduction. However, little work 
has been done on independently validating targets. The need for this is illustrated 
by the high-profile reports on ARC (Activity-Regulated-Cytoskeleton associated 
protein). In 2010 Greer et al. found ARC to be tagged and ubiquitinated by the 
UBE3A protein. This resulted in de hypothesis that there would be higher levels 
of ARC protein present in AS.79. This would result in increased internalization of 
AMPA receptors and thus cause weakening of the synapse ultimately resulting 
in leaning deficits in AS. However, Kuhnle et al. in 2013 showed that ARC was 
not a direct substrate of UBE3A80, and they hypothesized that ARC protein 
levels are controlled at the transcriptional level by UBE3A. Like ARC, the PML 
protein described in Chapter 4 proved an equally exciting target protein based 
on the paper by Regad et al. 2009 where PML was shown to be important for 
the development of the neocortex81,82. However we demonstrated in Chapter 4 
that PML is not increased in the AS brain using western blot, questioning the 
relevance of this target in underlying AS. Moreover, loss of PML did not cause any 
behavioral deficits, questioning the importance of PML in brain development. 
In the introduction we report a list of the targets described in literature. Like 
Kuhnle and colleagues, we propose that in addition to in vitro ubiquitination 
studies, additional criteria are needed before calling a protein it a physiologically 
relevant target80. 
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A critical window for rescuing AS phenotypes?
In Chapter 5 we looked into the reversibility of AS phenotypes in mice. A 
previous study from our own lab showed that AS mice have reduced CaMK2A 
activity due to increased phosphorylation at amino acids TT305/306 of the 
CaMK2A protein45. CaMK2A is expressed postnatally reaching its maximal 
expression 2 weeks after birth83.  If changes to a postnatally expressed protein 
can rescue all of the AS phenotypes displayed by the mouse model, then there 
is probably not a large developmental component to the AS phenotype. In 
Chapter  5 we looked into the effects of temporally-controlled Ube3a gene 
reactivation. We showed that motor deficits of the Ube3a mice could be rescued 
by gene reinstatement in adolescent mice, whereas anxiety, repetitive behavior, 
and epilepsy could only be rescued by gene reinstatement very early in life. 
Failure to rescue a majority of the Angelman phenotypes is quite disappointing. 
This would actually indicate that AS is mostly an early-developmental disorder, 
which appears to be at odds with our data obtained with the Camk2a mutation. 
Our lab might have overestimated the rescue seen in the mice with the Camk2a 
counter mutation. The effect we saw might have been in part an effect of the 
Camk2a mutation also seen in WT mice. Homozygous Camk2a-TT305/6VA mice 
were shown to have some deficits in watermaze reversal and LTP as shown 
by Elgersma et al. 2002 84. However Camk2a-TT305/6VA heterozygous mice do 
significantly better in rotarod, show a tendency for lower water maze latencies 
and a tendency for increased fear conditioning as shown by van Woerden et al. 
200768, suggesting that the improvement of the Camk2a mutation may act as a 
general enhancer of these behaviors. This idea is strengthened by our findings in 
Chapter 2, where the Camk2a counter mutation could not rescue the cerebellar 
deficit seen in AS mice. 
There is however a positive note in Chapter 5. We see that LTP phenotype 
has no critical window in which it can be rescued. Since LTP is required for 
normal learning, there is some optimism that cognitive fuction can be improved 
at any time point85. Secondly as we point out in the discussion of Chapter 5, the 
difference between a critical period in humans and mice might be completely 
different. Mice have rapid development and an embryo matures in 21 days while 
this takes 9 months in humans. The same can be said for the brain development 
and the critical window in humans, which might be a lot longer than in mice86,87. 
We might have a bigger window to rescue certain behavioral phenotypes in 
humans than we find in our mice.
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English Summary
The overall objective of this thesis is to try and understand the role of the 
Ubiquitin Proteasome pathway in two neurodevelopmental disorders. The 
Ubiquitin proteasome pathway is known for tagging proteins destined for 
degradation. The ubiquitination of a protein is a three-step process initiated with 
the E1 ubiquitin-activating enzyme. In the second step the activated ubiquitin 
is transferred to the E2 conjugating enzyme. Finally the E2 enzyme ubiquitin 
complex than transfers the activated ubiquitin to an E3 ligase-substrate complex. 
This thesis focuses on the UBE2A and UBE3A protein; both these proteins are 
associated with neurodevelopmental disorders. UBE2A is an E2 conjugating 
enzyme mutation/deletion cause UBE2A deficiency syndrome. UBE3A is an E3 
ubiquitin ligase and mutation/deletion cause Angelman syndrome.
UBE2A deficiency syndrome (also known as X-linked intellectual disability 
type Nascimento) is an intellectual disability syndrome characterized by 
prominent dysmorphic features, impaired speech and often epilepsy. The 
syndrome is caused by Xq24 deletions encompassing the UBE2A (HR6A) gene 
or by intragenic UBE2A mutations. UBE2A encodes an E2 ubiquitin conjugating 
enzyme involved in DNA repair and female fertility. A recent study in Drosophila 
showed that dUBE2A binds to the E3 ligase Parkin, which is required for 
mitochondrial function and responsible for juvenile Parkinson’s disease. 
In addition, these studies showed impairments in synaptic transmission in 
dUBE2A mutant flies. However, a causal role of UBE2A in cognitive deficits 
has not yet been established. In Chapter 2 we show that Ube2a knockout 
mouse has a major deficit in spatial learning tasks, whereas other tested 
phenotypes, including epilepsy and motor coordination, were normal. Results 
from electrophysiological measurements in the hippocampus showed no 
deficits in synaptic transmission nor in the ability to induce long-term synaptic 
potentiation. However, a small but significant deficit was observed in mGLUR-
dependent long-term expression, a pathway previously implied in several other 
mouse models for neurodevelopmental disorders. Our results indicate a causal 
role of UBE2A in learning and mGLUR-dependent long-term depression, and 
further indicate that the Ube2a knockout mouse is a good model to study the 
molecular mechanisms underlying UBE2A deficiency syndrome.
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Angelman syndrome (AS) is a severe neurodevelopmental disorder 
characterized by intellectual disability, happy demeanor, seizures and movement 
and balance disorders. The prominent movement and balance impairments are 
widely considered to be due to defects of cerebellar origin. In Chapter 3 of this 
thesis, using the cerebellar-specific vestibulo-ocular reflex (VOR) phase-reversal 
paradigm, we determined that cerebellar function is only mildly impaired in 
the Ube3am–/p+ mouse model of AS. VOR phase-reversal learning was singularly 
impaired in these animals and correlated with reduced tonic inhibition between 
Golgi cells and granule cells. Purkinje cell physiology, in contrast, was normal in 
AS mice as shown by synaptic plasticity and spontaneous firing properties that 
resembled those of controls. Accordingly, neither VOR phase-reversal learning 
nor locomotion was impaired following selective deletion of Ube3a in Purkinje 
cells. However, genetic normalization of αCaMKII inhibitory phosphorylation 
fully rescued locomotor deficits despite failing to improve cerebellar learning in 
AS mice, suggesting extra cerebellar circuit involvement in locomotor learning. 
We confirmed this hypothesis through cerebellum-specific reinstatement 
of Ube3a, which ameliorated cerebellar learning deficits but did not rescue 
locomotor deficits. This double dissociation of locomotion and cerebellar 
phenotypes strongly suggests that the locomotor deficits of AS mice do not arise 
from impaired cerebellar cortex function. 
Being an E3 ligase UBE3A should bind and tag proteins for degredation. 
Recently Promyelocytic Leukemia (PML) was identified as a target of the ubiquitin 
ligase UBE3A, we hypothesized that either reduced or increased expression 
of PML may result in cognitive deficits. PML is a tumor suppressor gene 
associated with PML nuclear bodies, which can be found in almost all tissues, 
and is deregulated in many cancer types. In addition, PML has been shown to 
be important for normal development of the neocortex. To test this directly, 
in Chapter 5 we assessed spatial learning and memory, reversal learning and 
context discrimination in heterozygous and homozygous Pml mouse mutants. 
In addition we tested the role of PML in synaptic plasticity. We found that 
homozygous or heterozygous loss of PML does not result in spatial learning 
or synaptic plasticity deficits. To test whether PML levels are increased in the 
brain of a mouse model of AS, and whether reducing PML expression in AS mice 
can rescue the behavioral phenotype of AS mice, we crossed heterozygous Pml 
mice with Ube3a mice. However, we did not find increased levels of PML in AS 
mouse brains. Moreover, reducing PML levels did not affect the AS phenotype. 
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In conclusion, our results suggest that PML is not essential for normal spatial 
learning or hippocampal synaptic function in mice, and does not play a 
significant role in the pathophysiological mechanism underlying AS.
AS results from loss of function of the maternal ubiquitin protein ligase E3A 
(UBE3A) allele. Due to neuron-specific imprinting, the paternal Ube3a copy is 
silenced. Previous studies in murine models have demonstrated that strategies 
to activate the paternal Ube3a allele are feasible; however, a recent study showed 
that pharmacological Ube3a gene reactivation in adulthood failed to rescue the 
majority of neurocognitive phenotypes in a murine AS model. In Chapter  6 
of this thesis, we performed a systematic study to investigate the possibility 
that neurocognitive rescue can be achieved by reinstating Ube3a during earlier 
neurodevelopmental windows. We developed an AS model that allows for 
temporally controlled Cre-dependent induction of the maternal Ube3a allele 
and determined that there are distinct neurodevelopmental windows during 
which Ube3a restoration can rescue AS-relevant phenotypes. Motor deficits 
were rescued by Ube3a reinstatement in adolescent mice, whereas anxiety, 
repetitive behavior, and epilepsy were only rescued when Ube3a was reinstated 
during early development. In contrast, hippocampal synaptic plasticity could be 
restored at any age. Together, these findings suggest that Ube3a reinstatement 
early in development may be necessary to prevent or rescue most AS-associated 
phenotypes and should be considered in future clinical trial design.
Taken together these results have provided novel insights into the 
pathophysiology of Angelman syndrome and UBE2A deficiency syndrome, and 
open up new research opportunities to seek treatments for these disorders.
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In dit proefschrift wordt de rol van de ubiquitine-proteasoom route in twee 
erfelijke ontwikkelingsstoornissen beschreven. De ubiquitine-proteasoom 
route identificeert en markeert eiwitten die bestemd zijn voor afbraak. De 
ubiquitinering van een eiwit is drie-staps proces dat start met een E1-ubiquitine-
activerend enzym. In de tweede stap wordt geactiveerde ubiquitine overgebracht 
naar het E2-conjugerende enzym. Tenslotte brengt het E2 enzym complex de 
geactiveerde ubiquitine over op de E3 ligase substraat-complex. Dit proefschrift 
richt zich op het UBE2A en UBE3A eiwit; Beide eiwitten zijn geassocieerd 
met neurologische ontwikkelingsstoornissen. UBE2A is een E2 enzym, en 
inactiverende mutaties in het UBE2A gen veroorzaken UBE2A deficiëntie 
syndroom. UBE3A is een E3 ubiquitine ligase en inactiverende mutaties in het 
UBE3A gen veroorzaken Angelman syndroom.
UBE2A deficiëntie syndroom (ook bekend als Nascimento-type X-gebonden 
verstandelijke handicap) is een syndroom dat gekenmerkt wordt door 
prominente dysmorfie, verstoorde spraak en vaak epilepsie. Het syndroom 
wordt veroorzaakt door Xq24 deleties die het UBE2A (HR6A) gen omvatten of 
door mutaties in het UBE2A gen zelf. UBE2A codeert voor een E2 enzym, dat 
betrokken is bij DNA-herstel en vrouwelijke vruchtbaarheid. Een recente studie 
toonde aan dat in Drosophila dUBE2A bindt aan de E3 ligase Parkin, dat nodig 
is voor mitochondriale functie en verantwoordelijk is voor de juveniele vorm 
van Parkinson. Bovendien toonden deze studie stoornissen in synaptische 
transmissie aan in dUBE2A mutant vliegen. Echter, een causale rol van UBE2A 
in cognitieve dysfunctie is nog niet vastgesteld. In hoofdstuk 2 laten we zien 
dat de Ube2a muismutant een probleem heeft met ruimtelijke leertaken, terwijl 
andere geteste fenotypes, zoals epilepsie en motorische coördinatie, allemaal 
normaal waren. Elektrofysiologische metingen in de hippocampus vertoonden 
geen gebreken in synaptische transmissie of het vermogen om langdurige 
synaptische potentiëring te induceren. Er werd een klein maar significant 
verschil waargenomen in mGluR-afhankelijke synaptische depressie, een 
defect eerder geïmpliceerd in verscheidene andere muismodellen voor 
ontwikkelingsstoornissen. Onze resultaten wijzen op een causale rol van UBE2A 
voor leren en mGluR-afhankelijke synaptische depressie, en daarmee tonen we 
aan dat het Ube2a muismodel een goed model is om de moleculaire mechanismen 
UBE2A deficiëntiesyndroom te bestuderen.
39681 Bruinsma.indd   153 28-03-16   20:31
Appendices
154
Angelman syndroom (AS) is een ernstige neurologische aandoening 
gekenmerkt door een verstandelijke handicap, epileptische aanvallen en 
bewegings- en evenwichtsstoornissen. De geldende opinie is dat de prominente 
bewegingen en evenwichtsstoornissen een cerebellaire oorsprong hebben. In 
hoofdstuk 3 van dit proefschrift, hebben we met behulp van het cerebellum-
specifieke Vestibulo-oculaire reflex (VOR) paradigma vastgesteld dat de 
cerebellaire functie slechts mild verstoord is in het Ube3a muismodel van AS. Het 
leren van de VOR fase verschuiving was echter duidelijk verstoord in deze dieren 
en hangt mogelijk samen met een verminderde tonische remming van de Golgi 
cellen op de Granulaire cellen. Purkinje celfysiologie zoals synaptische plasticiteit 
en spontaan vuurgedrag was normaal in deze muizen. en een selectieve 
verwijdering van Ube3a gen in Purkinje cellen had geen effect op het leren van de 
VOR fase verschuiving noch op de motoriek. Dit geeft aan dat de Purkinje cellen 
geen noemenswaardige rol spelen in de motorische en cerebellaire problemen 
van Ube3a muizen. De motorische problemen konden verholpen worden door 
normalisering van αCaMKII activiteit, maar dit had geen effect op de problemen 
met het leren van de VOR fase verschuiving. Dit suggereert dat een extra-
cerebellair circuit betrokken is bij de motor problematiek. We bevestigden 
deze hypothese door middel van cerebellum-specifiek herstel van UBE3A, die 
de problemen met het cerebellaire leerparadigma (VOR fase verschuiving) 
verbeterde, maar geen effect had op de problemen met het bewegingsapparaat. 
Deze dubbele dissociatie van de motoriek en cerebellaire fenotypes wijst er sterk 
op dat de motorische problemen van AS muizen niet het gevolg zijn van een 
verminderde cerebellaire (cortex) functie.
Omdat UBE3A een E3 ligase is, kan dit enzym ‘target’ eiwitten markeren 
voor afbraak. Onlangs werd Promyelocytic leukemie (PML) geïdentificeerd als 
een ‘target’ van de ubiquitine ligase UBE3A. Hierdoor veronderstelden we dat 
een verminderde afbraak van PML kan leiden tot cognitieve problemen. PML 
is vooral bekend als een tumor-suppressor gen. Het eiwit is geassocieerd met 
PML-bevattende eiwit aggregaten die gebonden zijn aan de nucleaire matrix. 
Deze PML aggregaten zijn aanwezig zijn in bijna alle weefsels en ontregeld zijn 
in vele kankersoorten. Bovendien is aangetoond dat PML van belang is voor 
de normale ontwikkeling van de neocortex. Om dit direct te testen, hebben we 
in hoofdstuk 5 de cognitieve vaardigheden van heterozygote en homozygote 
Pml muismutanten getest. Daarnaast hebben we de rol van PML in synaptische 
plasticiteit getest. We vonden dat homozygoot of heterozygoot verlies van PML 
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niet leidt tot leerproblemen of problemen met  synaptische plasticiteit. Om te 
testen of  vermindering van het PML eiwit in AS muizen de gedragsfenotype 
van AS muizen kan verbeteren, brachten we de  heterozygote Pml mutatie aan in 
Ube3a muizen. Echter, het verminderen van PML eiwit had geen invloed op het AS 
fenotype. Concluderend suggereren onze resultaten dat PML geen belangrijke 
rol speelt in de door ons gebruikte leertesten, en ook geen belangrijke rol speelt 
in het pathofysiologische mechanisme dat ten grondslag ligt aan AS.
AS wordt specifiek veroorzaakt door mutaties in het maternaal overgeërfde 
UBE3A gen. Als gevolg van neuron-specifieke imprinting, is de paternale UBE3A 
kopie niet actief. Eerdere studies in muismodellen hebben aangetoond het 
mogelijk is om het paternaal overgeërfde Ube3a gen te activeren. Echter uit een 
recente studie is gebleken dat farmacologische Ube3a gen activatie op volwassen 
leeftijd de meeste neurocognitieve fenotypes van een AS muismodel niet kan 
herstellen. In hoofdstuk 6 van dit proefschrift hebben we een systematische 
studie gedaan, om te kijken of er neurocognitief herstel kan worden bereikt 
door het Ube3a gen tijdens de ontwikkeling te activeren. We hebben daartoe 
een AS model ontwikkeld waarmee we het Ube3a gen  kunnen activeren op ieder 
gewenst moment. We vonden dat er verschillende periodes zijn waarbij Ube3a 
activatie bepaalde fenotypes kan verbeteren. Het motorische fenotype was het 
langst herstelbaar. Op cellulair nivo vonden we dat hippocampale synaptische 
plasticiteit op iedere geteste leeftijd hersteld kon worden. Tezamen suggereren 
deze bevindingen dat UBE3A activatie idealiter zo vroeg mogelijk moet 
plaatsvinden om een groot effect te sorteren. 
De in dit proefschrift beschreven bevindingen hebben ons meer inzicht 
gegeven in de pathofysiologie van UBE2A deficiëntie syndroom en Angelman 
syndroom, en we hopen dat deze resultaten zullen bijdragen tot het ontwikkelen 
van een therapie voor deze ernstige aandoeningen. 
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List of abbreviations
Abbreviation Description 
ABC Avidin-biotin-immunoperoxidase complex
ACSF Artificial cerebral spinal fluid
AD Alzheimer disease 
ADP Adenosine diphosphate
AKT v-Akt murine thymoma viral oncogene homologue 1
ALS Amyloid lateral sclerosis 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA Analysis of variance
APE1 Apurinic/apyrimidinic endonuclease 1 
APF-1 ATP-dependent proteolysis factor 1
ARC Activity-regulated-cytoskeleton associated protein
AS Angelman syndrome
ASO Anti-sense oligonucleotides
ATF4 Activating transcription factor 4
ATP Adenosine triphosphate
BDNF Brain derived neurotrophic factor
CaMK2A Alpha-calcium/calmodulin-dependent protein kinase 2  
CF Climbing fiber
CREB cAMP response element binding protein
CS Conditioned stimulus 
CV Coefficient of variation
DNA Deoxyribonucleic acid
DUB Deubiquitinating enzyme
E6-AP E6 associated protein
ECL Enhanced chemiluminescence
EDTA Ethylenediaminetetraacetic acid
EEG Electroencephalogram
EGFP Enhanced green fluorescent protein
EMG Electromyography
eNaC Endothelial Na+ channel 
ERK 1/2 Extracellular signal-regulated kinases 
FBXO40 F-box protein 40
FC Fear conditioning
GABA Gamma-aminobutyric acid
GCL Granule cell layer
HD Huntington disease
HECT Homologous to E6AP carboxyl-terminus 
HIF1-α Hypoxia inducible factor 1-α 
HPV Human papilloma virus
HR6A Human homologue to RAD6A
HR6B Human homologue to RAD6B
ID Intellectual disability
IHC Immunohistochemistry
KCC2 Potassium-chloride contransporter
KOS Kaufman oculocerebrofacial syndrome
Limk1 Lysophospholipase 1
L-LTP Late long term potentiation
LTD Long term depression
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LTF Long term facilitation
LTP Long term potentation
Mdm2 Mouse double minute 2 
mGLuR Metabotropic glutamate receptor
ML Molecular layer
MOV10 Moloney leukemia virus 10
mTOR Mechanistic target of rapamycin
NAC1 Nucleus accumbens-associated protein 1 
NEDD4 Neural precursor cell expressed developmentally down-regulated protein 4
NF-kB Nuclear-factor kB
NICHD National institute of child health and human development
NMDA N-Methyl-D-aspartic acid 
OCD Obsessive compulsive disorder
OKR Optokinetic reflex
PARK Parkinsonism associated deglycase
PCL Purkinje cell layer
PCNA Proliferating cell nuclear antigen
PD Parkinson disease
PF Parallel fiber
PKA cAMP-dependent protein kinase A
PML Promyelocytic leukemia
PP1 serine/threonine protein phosphatase
PPF paired-pulse facilitation
PSD Post-synaptic density 
PSD95 Post-synaptic density protein 95
PTEN Phosphatase and tensin homologue
RFWD2 Ring finger and WD repeat domain 2
RING Really interesting new gene
RISC RNA induced silencing complex 
RPT6 Proteasome regulatory particle 
SEM Standard error of the mean
SNRPN Small nuclear ribonucleoprotein N
SNURF SNRPN upstream reading frame
TSC Tuberous sclerosis 1
UBE2A Ubiquitin protein ligase E2A
UBE3A Ubiquitin protein ligase E3A
UBE3A-ATS Ubiquitin ligase E3A antisense transcript 
UBIP Ubiquitous immunopoietic polypeptide
UCH Ubiquitin carboxy-terminal hydrolase
UCH-L3 Ubiquitin C-terminal hydrolase L3
UFD2 Ubiquitin fusion degradation protein 2
UPD Uniparental disomy
UPP Ubiquitin proteasome pathway
US Unconditioned stimulus 
VEGF Vascular endothelial growth factor
VHL Von Hippel-Lindau
VOR Vestibular ocular reflex
VVOR Visually enhanced VOR
WT Wild type
YFP Yellow fluorescent protein
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